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Abstract 
Since the introduction of combination therapy in 1996, Human Immunodeficiency Virus (HIV) 
treatment has changed substantially.  Over twenty new antiretroviral drugs have been licensed for the 
treatment of HIV-infection and HIV has been transformed into a long-term chronic infection for many 
patients.  Yet it remains unclear how improved efficacy of new antiretrovirals reported in clinical 
trials has translated to population-level effectiveness in general clinical care.  Nor is it clear how the 
increasingly chronic nature of HIV-infection, characterised by an ageing HIV-population increasingly 
suffering from age-related non-infectious co-morbidities and drug-drug interactions, will affect HIV 
care.  Such an evaluation is important not just to measure progress, but also to address future 
challenges for clinical care in order to develop evidence-based changes to clinical guidelines and 
ensure continued high-quality care.   
By analysing a dataset that collects data from all HIV-infected patients in clinical care in the 
Netherlands it was shown that the use of combination antiretroviral therapy (cART) regimens in the 
Netherlands closely follows changes in guidelines, to the benefit of patients.  While there was no 
significant improvement in mortality, newer drugs with better tolerability and simpler dosing resulted 
in improved immunological and virological recovery and reduced incidence of switching due to 
toxicity and virological failure.   
An individual-based model of the ageing HIV-population in the Netherlands was constructed 
and used to quantify and evaluate the future challenges posed by an ageing HIV-population.  The 
model showed that the age-structure of HIV-patients in the Netherlands is rapidly shifting to older 
age.  By 2030, almost three quarters of patients will be aged 50 or over.  This will result in an 
increased burden of co-morbidity, polypharmacy and an increasing proportion of patients who will 
experience potential complications with their HIV-treatment.  Cardiovascular disease (CVD) in 
particular will become a major burden of co-morbid disease.  Integrating a smoking cessation 
programme or changing HIV-treatment guidelines to recommend prescribing a polypill for CVD to all 
HIV-patients aged 45 or 55 years and over could improve the burden of CVD, improve patient 
outcome and be cost saving in the long-term.   
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1.1 Background  
The impact of the Human Immunodeficiency Virus (HIV) epidemic is far-reaching; it has become one 
of the world’s leading causes of mortality among both women and men aged 15-59 years old [1–3].  
HIV remains a major global health priority that necessitates effective prevention, treatment, and 
patient management options, in order to reduce the human cost in terms of suffering and lives lost [4].   
Once individuals are infected with HIV, the current treatment option is combination 
antiretroviral therapy (cART).  Since the introduction of cART in 1996, HIV-treatment has improved 
substantially [5–7].  The improved efficacy of cART in suppressing HIV replication has reduced 
mortality of HIV-patients on treatment [8–10], and transformed HIV into a long-term chronic 
infection for many patients [6,11], with mortality rates amongst HIV-infected patients on cART 
approaching those of the general population [10].  There is a growing range of antiretroviral drugs that 
are used to provide life-long therapy.  The pace and scale of development in cART dwarves the 
development of many other medications for other diseases during the same period and in other fields 
of HIV, such as HIV prevention.  But, what have the impacts of these changes been for patients and 
what are the treatment gaps that remain?  It remains unclear how improved efficacy of new 
antiretrovirals reported in clinical trials has translated to population-level effectiveness in general 
clinical care.  Such an evaluation is important not just to document progress, but also to identify 
treatment gaps and future challenges in order to develop frameworks to address these issues.   
This is particularly important in light of the emerging challenges created by the changing 
demographic profile of HIV-patients – that of an ageing HIV-population.  In 2013 UNAIDS 
announced that a substantial proportion of HIV-infected people are 50 years or older [12] and in 2009 
the founder and executive director of National AIDS treatment Advocacy-Project stated that “ageing 
is the No.1 problem in HIV today” [13].  Public health experts say that health services will need to 
expand to address the unique health problems of the world’s ageing HIV-patients.  Ageing HIV-
patients are suffering increasingly from age-related non-infectious co-morbidities that they previously 
did not live long enough to experience.  Studies have found that HIV-infected people in high-income 
countries develop more co-morbidities and do so at an earlier age than in the age-matched uninfected 
Summary 
This Chapter provides background information on the research presented in this thesis.  HIV-
treatment will be discussed in detail, including drug classes, targets and mechanisms, clinical 
management of patients, and the changes in treatment guidelines since 1996.  The Dutch national 
ATHENA cohort, which is the main dataset used in this PhD, will be described, together with the 
epidemic in the Netherlands.  The potential effects of a demographic shift towards an ageing 
population will be explained.  Finally, examples of mathematical models of treatment are presented 
and discussed.   
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population [5].  Management of these patients will put new demands on the health care system and 
create several important implications for health services.  Co-morbidity will increase the need for 
polypharmacy, defined as the co-administration of multiple medications and HIV-medication.  This 
will lead to higher pill burdens and increase the risk of drug-drug interactions and drug toxicity, loss 
of efficacy of co-administrated medications, and virological breakthrough [14].  Until recently, this 
population has been relatively ignored, with most studies of HIV-treatment excluding patients of 
advanced age and those with co-morbid disease [15].  Consequently, current guidelines do not provide 
a working framework for dealing with the growing number of older HIV-patients with multiple co-
morbidities.  In light of the shifting demographic profiles of HIV-patients, there is a need for more 
research on the factors affecting the successful management of older HIV-infected patients, as well as 
the formulation of frameworks to deal with this growing problem.   
This Chapter provides background information on this research.  HIV-treatment will be 
discussed in detail, including clinical drug classes, targets and mechanisms, management of patients, 
and the changes in treatment guidelines since 1996.  The Dutch national ATHENA cohort, which is 
the main dataset used in this PhD, will be described, together with the epidemic in the Netherlands.  
The potential effects of a demographic shift towards an ageing population will be described in detail.  
Finally, examples of mathematical models of treatment are presented and discussed.   
 
 
1.2 Natural History and Disease Progression of HIV 
Clinical management of HIV-patients, including treatment initiation and clinical treatment decisions, 
rely on an understanding of the natural history and disease progression of HIV as well as the factors 
affecting them.  Disease progression of HIV is defined by depletion of a subset of immune cells, 
called T4 helper cells, or CD4 cells and an increase in VL over time (Figure 1.1).  It is the depletion 
of CD4 cells that makes the HIV-patient susceptible to a large variety of infections that would not 
cause disease in individuals with a functioning immune system.  The use of CD4 cell counts (Cluster 
of Differentiation Antigen 4) and plasma viral load (VL) is crucial for the evaluation of patients’ 
disease stage and progression assessment [16].  In patients with a CD4 count of less than 200 
cells/mm
3
 cellular immunity is considered to be lost [17].  The VL is not only associated with disease 
outcome, but also with the transmission of HIV [18,19].  Viral loads that are >10,000 copies/mL in 
patients on treatment are associated with poor clinical outcome [16].   
The rate of clinical disease progression can vary considerably between patients [16].  There 
are a number of factors that can affect disease progression: co-infection (e.g. tuberculosis) may 
increase disease progression [20], certain HIV subtypes can result in faster disease progression 
[21,22], genetic inheritance also plays an important role in disease progression (e.g. patients who are 
homozygous CCR5-Δ32 strain of HIV have slower disease progression) [23], and the patient’s 
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immune system can affect disease progression, with older patients experiencing higher risk of rapid 
disease progression [24].   
While the pattern of natural history varies from patient to patient, a general pattern can be 
presented as in Figure 1.1.  The first ‘stage’ of HIV-infection starts upon HIV-acquisition and is 
associated with high infectivity and high VL, and is generally accompanied by flu-like symptoms.  
This stage generally lasts for a short period and is followed by clinical latency.  During this latent 
period, the virus is thought to lie “dormant” in CD4 cells.  This stage of infection is followed by the 
development of symptomatic illness.  AIDS is the most severe stage of HIV-infection.  A study by 
Morgan and colleagues in 2002 found that the median time of progression from HIV to AIDS, in the 
absence of cART, was nine to ten years.  Once a patient has developed AIDS, median survival time 
was only 9.2 months, although the group also found that rates of clinical progression vary widely 
between individuals [25].  A more recent study by Lodi and colleagues found that median time from 
seroconversion to CD4 <200 cells/mm
3 
in the absence of cART is 7.93 years (95% CI 7.76-8.09) [26].   
 
 
 
Figure 1.1.  Natural history of HIV.  Graph shows progression of plasma HIV RNA and CD4 count over 
time from the time of HIV acquisition until AIDS-related death.   
Source: adapted from Mylonakis et al. 2001 [27].   
 
 
 
 
 
 
 
 
 
 
 
 
Pre-AIDS 
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1.3 HIV Treatment 
1.3.1 HIV Life Cycle 
Antiretrovirals (ARVs) work using various mechanisms, intended to interfere with different stages of 
the virus’ life cycle.  They slow down the progress of the HIV-infection and the damage the virus 
does to the patient’s immune system.  HIV-treatment aims to ensure maximum and prolonged control 
over the patient’s viral load, reducing plasma and seminal viral load, thus slowing disease 
progression, preventing falls in CD4 count [16,18,19,28,29].  This reduces HIV-related illnesses and 
risk of death, ultimately improving the patient’s quality of life [4,30,31].  However, ARVs only target 
replicating virions, and as some viruses remain dormant in cells, current HIV-treatment is unable to 
eliminate HIV-infection [30,31].   
As infectivity has been shown to be strongly correlated with viral load [18,19,28], with ARVs 
reducing the risk of HIV transmission, it has been argued that widespread use of ARVs could, in the 
long-term, also reduce incidence of HIV at a population level [32,33].  Observational studies 
documented a reduction in transmission from patients on HIV-treatment [33], a trend which was 
confirmed in a randomized controlled trial [34].  However, these drugs are expensive and regular 
access to ARVs is not possible in all countries or for all HIV-infected individuals. 
In order to understand how ARVs work one has to look at the HIV-life cycle.  Figure 1.2 
illustrates the HIV-life cycle as well as the target sites of ARVs.  As HIV can only replicate inside the 
human cell, the viral cycle begins with cell entry (Figure 1.3).  This process involves the attachment 
of the virion to the CD4 cell surface receptor (Figure 1.3A).  Attachment is mediated by the HIV 
glycoprotein 120 (or gp120) envelope protein binding to the cellular CD4 receptor (Figure 1.3B).  
This is followed by the binding of the first viral heptad-repeat (HR1) region of the envelope gp41 
protein to the T-cell co-receptor via a conformational change of the gp120 (Figure 1.3C).  This in turn 
triggers a conformational change in the viral gp41 envelope protein HR1 and HR2 region (Figure 
1.3D) [30,35,36].  It is this conformational change that results in the fusion of the viral and cellular 
membranes and allows the viral core of the HIV-particle, two HIV-RNA and HIV-enzymes (including 
reverse transcriptase (RT) and integrase) to be released into the cell (Figure 1.3D) [30,35,36].   
Once inside the cell, the HIV RT enzyme attaches to the HIV RNA, converting it to DNA 
(Figure 1.4A).  The DNA is then transported to the cell nucleus and integrated into the human DNA 
(Figure 1.5A) [30].  This action is mediated by viral integrase which attaches to the viral DNA and 
mediates the transport of the DNA into the nucleus through the nuclear pores as well as the integration 
into the human DNA [31].  Once integrated the HIV DNA is called a provirus and it can lie 
“dormant” within the cell for a long time [30].  When the cell becomes activated the DNA is 
converted to messenger RNA (mRNA) and transported outside of the nucleus where some are cleaved 
by HIV protease enzyme (Figure 1.6B) [30].  The smaller cleaved mRNA comes together with HIV 
RNA and a new virus is assembled and buds out of the CD4 cell [30,31].   
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Figure 1.2.  HIV life-cycle and drug target sites.  
Source: http://www.elsevier.es/ [Accessed 21 July 2010].   
 
 
Figure 1.3.  Entry and fusion stage of the HIV life cycle and drug targets.  A to D show the stages of viral 
fusion and entry.   E and F show the mechanism of action of entry and fusion inhibitors, respectively.   
Source: created with information by Moore & Doms and Moyle & colleagues [30,35,36].  
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Figure 1.4.  Reverse transcription stage of the HIV life cycle and drug  
targets.  A shows the stage of reverse transcription.  B and C show the 
mechanism of action of NRTI and NNRTI ART, respectively.   
Source: created using information from Stine [30,31].   
 
 
 
 
 
 
Figure 1.5.  Integration stage of the HIV life cycle and drug targets.  A shows 
the stage of viral DNA integration.  B shows the mechanism of action of 
integrase inhibitors.   
Source: adapted from immune.paedia.org and using information from The 
Molecular Biology of HIV/AIDS [30].   
A.Viral DNA is transported through the nuclear pore and integrated into host chromosomal 
DNA  by the action of virus-encoded integrase.  Nuclear DNA repair enzymes are also 
required to complete the insertion process. The inserted virus genome is known as a 
provirus. 
 
 
B.  The integrase inhibitors binds to viral integrase and prevents the DNA transfer function 
that inserts the viral DNA into the host chromosome DNA 
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Figure 1.6.  Protease stage of the HIV life cycle and drug targets.  A to C show the protease stage of the 
life cycle.  D shows the mechanisms of action of protease inhibitors.   
Source: adapted from Stine [31].   
 
1.3.2 Antiretroviral Drugs  
Over the past three decades six subclasses of ARVs have been developed.  Table 1.1 lists these 
subclasses, their mode of functioning and the date they were first approved for HIV treatment.  As of 
2013, there were 37 anti-HIV medications licensed and approved for the treatment of HIV.  Table 1.2 
shows the full list of FDA (Federal Drug Administration) approved ARVs, with the brand and 
chemical name, manufacturer and the date they were first approved for HIV treatment.  Most of the 
drugs are nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs) and non-
nucleoside reverse transcriptase inhibitors (NNRTI), while fusion, entry and integrase inhibitors are 
fewer in number.  Each of the ARV classes has their specific mechanism of action, which will be 
discussed in more detail below.   
 
Table 1.1.  Subclasses of ARVs, date they were first approved for HIV treatment by the Federal Drug 
Administration (FDA) and their mode of functioning.  *Date first approved 
ART class Abbreviation DFA* Mechanism 
Nucleoside Reverse 
Transcriptase Inhibitors 
NRTI 1987 Inhibit reverse transcriptase enzyme, preventing HIV 
from making copies of itself 
Non-Nucleoside Reverse 
Transcriptase Inhibitors 
NNRTI 1995 Inhibit reverse transcriptase, stopping HIV replication 
Protease Inhibitors PI 1996 Inhibit protease enzyme, stopping HIV replication 
process 
Entry Inhibitors  2003 Preventing HIV from entering human target cells 
Fusion Inhibitors  2007 Prevent co-receptor binding 
Integrase Inhibitors  2007 Interfere with the integrase enzyme, utilized by the virus 
to insert itself into the human DNA  
Source: created with information from AIDS Update 2009 [31].   
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1.3.2.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
The NRTI subclass contains the first ARV, zidovudine, to be marketed for the treatment of HIV in 
1987 [37].  Since the marketing of zidovudine, a further twelve NRTIs have been developed [37].  
Currently, NRTIs serve as the backbone of the cART combination [31], with two NRTIs generally 
combined with at least one other ARV from another class for combination therapy.  All NRTIs work 
by being converted intracellularly to active metabolites, competing with the natural substrate for 
incorporation into the viral DNA that is being translated from viral RNA (Figure 1.4B) [31].  As the 
metabolites lack a 3’-hydroxyl group the NRTI prevents the formation of the 5’ to 3’ phophodiester 
linkage necessary for DNA chain elongation, thus terminating the DNA chain growth [31,38–40].   
 
 
1.3.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
The first NNRTI to be marketed was nevirapine, which was approved for HIV-treatment by the FDA 
in 1996 [37].  Since then, five more NNRTI have been marketed for HIV-treatment [37].  They have a 
mechanism of action that involves binding directly to the active site of RT, thus blocking the DNA 
polymerase active site (Figure 1.4C).  This binding causes a disruption of the enzyme's catalytic site, 
resulting in the termination of DNA chain elongation [31].   
 
 
1.3.2.3 Protease Inhibitors (PIs) 
In 1988, PIs were identified in cell culture as possible candidates for antiretroviral agents [31].  
However, at the time their rapid liver metabolism, poor oral absorption and insolubility made them 
unsuitable for marketing [31].  In 1992, a suitable therapeutic PI was developed, and on December 6
th
 
1995, saquinavir, the first PI, was marketed by Hoffman-La Roche [31].  Since then, a further 10 PIs 
have been developed for therapeutic use in HIV-patients [37].  All PIs have the same mechanism of 
action; they work by selectively binding the catalytic site of virus-specific protease enzymes (Figure 
1.6).  This prevents cleavage of viral poly-protein, preventing the formation of a mature virus [31].   
 
 
1.3.2.4 Fusion Inhibitors 
Enfuvirtide is the first of the fusion inhibitors.  Enfuvirtide interferes with the entry of HIV into cells 
by inhibiting fusion of viral and CD4 cellular membranes.  Enfuvirtide binds to the first heptad-repeat 
(HR1) of the gp41 subunit of the HIV envelope glycoprotein and prevents the conformational changes 
required for the fusion of viral and cellular membranes (Figure 3 F) [35,36].  Enfuvirtide is currently 
the only fusion inhibitor marketed for HIV treatment [37].   
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Table 1.2.  FDA approved anti-HIV medication.   
Brand name Generic name (Chemical name) Manufacturer FAD** 
1. Multi-class combination products 
Atripla Efavirenz (EFV), emtricitabine (FTC), and 
tenofovir disoproxil fumarate (TDF) 
Bristol-Myers Squibb and Gilead 
Sciences 
12 July 2006 
Complera Emtricitabine (FTC), rilpivirine (TMC278), and 
tenofovir disoproxil fumarate (TDF) 
Gilead Sciences 10 Aug 2011 
Stribild Elvitegravir, cobicistat, FTC, TDF Gilead Science 27 Aug 2012 
1. NRTIs 
Combivir Lamivudine (3TC) and zidovudine (AZT) GlaxoSmithKline 27 Sep 1997 
Emtriva Emtricitabine (FTC) Gilead Sciences 02 Jul 2003 
Epivir Lamivudine (3TC) GlaxoSmithKline 17 Nov 1995 
Epzicom Abacavir (ABC) and lamivudine (3TC) GlaxoSmithKline 02 Aug 2004 
Hivid Zalcitabine/dideoxycytidine (ddC)*  Hoffmann-La Roche 19 Jun 1992 
Retrovir Zidovudine (AZT), azidothymidine (ZDV) GlaxoSmithKline 19 Mar 1987 
Trizivir Abacavir (ABC), zidovudine (AZT), and 
lamivudine (3TC) 
GlaxoSmithKline 14 Nov 2000 
Truvada tenofovir disoproxil fumarate (TDF) and 
emtricitabine (FTC) 
Gilead Sciences, Inc. 02 Aug 2004 
Videx EC enteric coated didanosine (ddI EC) Bristol Myers-Squibb 31 Oct 2000 
Videx didanosine, dideoxyinosine (ddI) Bristol Myers-Squibb 09 Oct 1991 
Viread tenofovir disoproxil fumarate (TDF) Gilead 26 Oct 2001 
Zerit Stavudine (d4T) Bristol Myers-Squibb 24 Jun 1994 
Ziagen abacavir sulphate (ABC) GlaxoSmithKline 17 Dec 1998 
2. NNRTIs 
Endurant Rilpivirine (TMC278) Tibotec Therapeutics 20 May 2011 
Intelence Etravirine (TMC125) Tibotec Therapeutics 18 Jan 2008 
Rescriptor Delavirdine (DLV) Pfizer 04 Apr 1997 
Sustiva Efavirenz (EFV) Bristol Myers-Squibb 17 Sep 1998 
Viramune Nevirapine (NVP) Boehringer Ingelheim 21 Jun 1996 
Viramune XR Nevirapine (NVP) Boehringer Ingelheim 25 Mar 2011 
3. PIs 
Agenerase Amprenavir (APV) GlaxoSmithKline 15 Apr 1999 
Aptivus Tipranavir (TPV) Boehringer Ingelheim 22 Jun 2005 
Crixivan Indinavir (IDV, MK-639) Merck 13 Mar 1996 
Fortovase Saquinavir (SQV)* Hoffmann-La Roche 07 Nov 1997 
Invirase saquinavir mesylate (SQV) Hoffmann-La Roche 06 Dec 1995 
Kaletra lopinavir and ritonavir (LPV/RTV) Abbott Laboratories 15 Sep 2000 
Lexiva Fosamprenavir Calcium (FOS-APV) GlaxoSmithKline 20 Oct 2003 
Norvir Ritonavir (RTV) Abbott Laboratories 01 Mar 1996 
Prezista Darunavir (TMC114) Tibotec, Inc. 23 Jun 2006 
Reyataz atazanavir sulphate (ATV) Bristol-Myers Squibb 20 Jun 2003 
Viracept nelfinavir mesylate (NFV) Agouron Pharmaceuticals 14 Mar 1997 
4. Fusion inhibitors 
Fuzeon Enfuvirtide (T-20) Hoffmann-La Roche & Trimeris 13 Mar 2003 
5. Entry Inhibitors – CCR5 co-receptor antagonist 
Selzentry Maraviroc (MVC) Pfizer 06 Aug 2007 
6. HIV integrase stand transfer inhibitors 
Isentress Raltegravir (RGV) Merck & Co., Inc. 12 Oct 2007 
Tivicay Dolutegravir GlaxoSmithKline 13 Aug 2013 
*available as once-daily **available as once-daily in treatment-naive ***no longer marketed ****FDA 
approval date *****In US called Complera 
Source: adapted from U.S.  Food and Drug Administration’s Drugs Used in the Treatment of HIV-
infection (available at http://www.fda.gov/oashi/aids/virals.html [Accessed 4th Nov 2013].   
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1.3.2.5 Entry Inhibitors 
Maraviroc is the first entry inhibitor to be marketed and is a member of a drug class called CCR5 co-
receptor antagonists.  It is currently the only entry inhibitor for HIV treatment [37].  Maraviroc works 
by selectively binding to and blocking the human chemokine receptor, CCR5, which is present on the 
cell membrane of CD4 cells [35,36].  This prevents the interaction of gp120, the HIV surface protein 
that mediates binding, and the CD4 receptor CCR5 necessary for HIV to enter CD4 cells (Figure 3 E) 
[35,36].  As maraviroc only binds CCR5, CXCR4-tropic (refers to HIV use of co-receptors for cell 
entry) and dual-tropic HIV entry is not inhibited by this drug.   
 
1.3.2.6 Integrase Strand Transfer Inhibitors 
Raltegravir and dolutegravir are integrase strand transfer inhibitors.  They works by interfering with 
the catalytic activity of HIV-1 integrase, inhibiting the integrase enzyme thus preventing the 
integration of the linear viral DNA into the host cell genome, and thus preventing the formation of the 
provirus (Figure 1.5B) [31,41].  The provirus is required for the production of progeny virus.  
Therefore, inhibiting integration prevents propagation of the viral infection [31,41].   
 
 
1.4 Progress in HIV Treatment 
1.4.1 From Mono- to Triple Therapy and its Impact on HIV Survival 
After the first antiretroviral (ARV), zidovudine, was approved for treatment of HIV in 1987 [37], it 
took nearly a decade, the availability of PIs and NNRTIs and the advent of combination therapy 
before a marked change in the epidemic of HIV was observed, with HIV-related morbidity and 
mortality rates declining dramatically in countries with high treatment coverage [8,42–44].   
Prior to 1996, HIV-treatment consisted mostly of mono-therapy, the prescription of one ARV 
for the treatment of HIV-infection.  In 1996 the Delta study, a randomised double-blind controlled 
trial, showed that treatment with dual-therapy of zidovudine and didanosine or zalcitabine delayed 
disease progression and prolonged life compared with mono-therapy with zidovudine alone [45,46].  
Three other studies also found that combination of two NRTIs was beneficial for patients [46–48].  
This was followed by trials showing that the treatment with a combination of three ARVs controlled 
HIV infection better [42,49].   
In 1996, ARVs started being given in a combination of at least three drugs from at least two 
different drug classes.  Combination therapy substantially improved patient prognosis and reduced 
morbidity and mortality [8,42,44].  Today combination therapy remains the most appropriate method 
for treating HIV.  From this point on, this combination of at least three ARVs will be referred to as 
combination antiretroviral therapy or cART.   
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CART generally works on at least two different viral target sites, resulting in less drug 
resistance compared to mono-or dual-therapy [31].  cART given to those beginning treatment, or 
‘first-line treatment’, generally consists of a ‘backbone’ of two NRTIs combined with either a NNRTI 
or a ritonavir-boosted PI [31].  Patients on cART can experience treatment failure, which can drive 
the need for switching to second-line treatment regimens where at least one of the drugs is changed.   
Since the introduction of cART, success of HIV-treatment has improved significantly [5–7]; 
treatment regimens have become more effective, with more convenient dosing and better tolerability 
than the original cART regimens [6].  The clinical treatment outcomes of HIV-infected patients have 
improved dramatically, especially in industrialized, high-income countries, where most patients have 
access to health care and cART [8,44,50,51].   
In countries where effective treatment is widely available, cART has transformed HIV into a 
survivable chronic infection for many patients [6,11].  Extensive epidemiological studies have shown 
that cART can significantly reduce morbidity and mortality in infected individuals [10].  Evidence is 
showing that improved access to cART is helping to drive declines in HIV-related mortality [4].   
In low- and middle-income countries, several studies have demonstrated the beneficial effect 
of cART.  In Brazil, where free cART has been available since 1996, average survival following 
AIDS diagnosis in the state of São Paulo rose from four months in 1992-1995 to fifty months in 1998-
2001[52].  In Uganda, of cART has reduced mortality by 95% compared with no intervention [53], 
while in Botswana 79% of adults on cART were alive five years after treatment initiation [54].  
Finally, a 35% population-level reduction in mortality was observed in the first eight months of cART 
scale-up in northern Malawi [55].   
In high-income countries, similar findings were reported at the population level [5,10,56,57].  
Bhaskaran and colleagues, for example, carried out a large multi-centre study of data from 12 high-
income countries to evaluate the changes in the mortality gap between HIV-infected individuals and 
uninfected individuals.  They found that since the introduction of cART, death rates for HIV-infected 
individuals have become closer to that of the general population, particularly within the first 5 years 
following infection [10].   
The Antiretroviral Therapy Cohort collaboration carried out a retrospective study among a 
cohort of patients enrolled in 13 European and North American countries.  The study found that cART 
dramatically improved life expectancy for HIV–infected patients and that AIDS-related deaths 
decreased with increased cART use [57].   
Despite this reduction in mortality and morbidity, HIV-infected patients still have a life 
expectancy that is lower than that of the general population.  Van Sighem and colleagues (2005) 
investigated progression to death in a population of cART-naïve patients from the Dutch ATHENA 
observational cohort, comparing mortality in that group with that of the general population in the 
Netherlands.  They found that mortality, matched by sex and age, in non-injecting drug using HIV-
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infected individuals who respond well to cART (as reflected by high CD4 cell counts and low plasma 
viral load (VL) after 24 weeks of cART) is still higher than in the general population [58].   
More recently, two studies by the Antiretroviral Therapy Cohort Collaboration compared life 
expectancy of HIV-infected patients to that of the general population using data from countries in 
Europe and North America.  In one study the Antiretroviral Therapy Cohort Collaboration found that 
while life expectancy in HIV-infected individuals treated with cART increased between 1996 and 
2005, the average life-expectancy of HIV-patients at the age 20 was about two-thirds that of the 
general population.  The group, however, stressed that considerable variability between subgroups of 
patients existed [5].  In their second study the group reported that in industrialized countries, the life-
expectancy of HIV-infected patients who started cART and survived the first 6 months continued to 
be lower than in the general population.  However, the group also reported that for many patients 
excess mortality was moderate and comparable to excess mortality of patients with other chronic 
conditions.  They also argued that this gap could be reduced by earlier diagnosis of HIV followed by 
timely initiation of cART [56].   
 
1.4.2 Changes of cART Regimens and Guidelines 
National guidelines for the management and treatment of HIV-infection exist in a number of countries 
in Europe for example, as well as in the USA, and Australia [59–63].  These guidelines aim to 
promote a high standard of HIV care at a national level, by reviewing HIV clinical trial and research 
data and providing guidance for treating physicians.  Since the introduction of cART in 1996 the 
guidelines on first-line regimens have changed considerably, as new evidence has emerged, and new 
more potent antiretroviral drugs have been introduced, paralleling a change in the treatment of HIV-
infected treatment-naïve patients.  The guideline changes will be discussed in detail below, using the 
USA and the United States’ Department of Health and Human Service (DHHS) guidelines as an 
example of the general changes in cART in developed countries.   
When combination therapy was first introduced, most cART regimens consisted of a 
backbone of 2 NRTIs and a PI, with 1998 U.S. guidelines recommending this combination for first-
line therapy [64].  Between 1996 and 2003 the U.S. recommended either stavudine (d4T) or 
zidovudine (AZT) for use in the NRTI backbones (Table 1.3) [64–72].  These recommendations were 
based on  a number of studies into the safety and efficacy of d4T [73–79] and AZT [47,74,80–83], 
alone and as part of combination therapy.   
In the early years following the introduction of cART, d4T was thought to have a relatively 
good tolerability, efficacy, and virological and immunological response compared to AZT [74,84–86].  
This began to change after September 1997, when Combivir (CBV) was approved by the FDA for 
treatment of HIV-infected patients [37].  It was introduced in Europe in March 1998 [84].  CBV was 
the first twice-daily fixed-dose combination tablet available for HIV-treatment, containing AZT and 
lamivudine (3TC) [84].  Clinical trials showed that it in addition to simpler dosing, CBV had a good 
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efficacy and tolerability [84].  In the ACTG 384 trial the advantages of CBV-based regimens over 
d4T-based regimens were demonstrated [87].  By then, d4T had been associated with the development 
of mitochondrial toxicity, including lipoatrophy (localized fat loss), lipid elevations, and lactic 
acidosis (condition characterized by low pH in body tissues and build-up of lactose) [88,88–92].  As a 
result, d4T prescription in Europe and North America decreased and CBV became the ‘gold standard’ 
and most frequently prescribed NRTI backbone [84].  In October 2004, d4T was removed from the 
“preferred regimens” in U.S. guidelines (Table 1.3) [93].  More recently, however, long-term use of 
AZT has been associated with the development of lipoatrophy [94–96] and in January 2008 CBV was 
also removed from the list of “preferred regimens” by the DHHS [97].   
In September 1998, efavirenz (EFV) was licensed for HIV-treatment by the FDA [37].  A 
large body of evidence rapidly emerged, demonstrating its efficacy in combination therapy [98–104].  
In December 1998 the DHHS updated U.S. guidelines, recommending first-line cART based on two 
NRTIs combined with either a PI or with efavirenz (Table 1.3) [65].  At around the same time, the use 
of the PI ritonavir (RTV) as a “booster” was rapidly evolving.  RTV was approved for HIV-treatment 
by the FDA on March 1996 [37,105,106].  It was the first PI to demonstrate prolonged survival in 
advanced HIV disease [105] although studies established that RTV as a sole dose was associated with 
high toxicity [107].  However, further studies found that RTV had good bioavailability and could 
increase that of other PIs [108–113].  Consequently, RTV was introduced in clinical care as a 
‘booster’ of other PIs.  As guidelines evolved, recommendations introduced more RTV-boosted 
regimens as “preferred PI-based regimens” (Table 1.3) [69].   
Tenofovir (TDF) was approved by the FDA in 2001 for the treatment of HIV-infected 
patients [37].  Early studies demonstrated a comparable efficacy to d4T with a better lipid profile and 
less lipoatrophy compared to d4T [88,114].  A later study comparing TDF to CBV demonstrated that 
TDF was superior in terms of virological suppression, and was better tolerated, with significantly less 
lipoatrophy than the CBV arm [95,115,116].  In addition, TDF was found to have a favourable 
resistance profile [88,95] and to be effective in treating some treatment-experienced patients who had 
experienced virological failure [117–119].  This was particularly important, as at the time that TDF 
was introduced, cross-resistance within the NRTI class had become an increasing problem [120,121].   
In July 2003, the DHHS added TDF to its “preferred regimens” (Table 1.3).  Over the last 
decade TDF has significantly changed the treatment of HIV-infected patients.  As well as its potent 
antiviral activity, TDF has a long half-life, that allows for once-daily dosing as well as a level of 
‘forgiveness’ regarding timely intake [120,122].  Since its introduction two once-daily fixed-dose 
combination tablets containing TDF and other ARVs with long half-lives have been introduced, 
further reducing pill burden and dose complications.  In 2003, a dual combination tablet of TDF and 
emtricitabine (FTC), called Truvada, was introduced and in 2006 a single-tablet, triple antiretroviral 
combination of TDF, FTC and EFV, called Atripla, was introduced [37].  Atripla was the first once-
daily, fixed-dose triple combination tablet to be made available for HIV-treatment [123] and it has 
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demonstrated the reality of a once-daily tablet for HIV-treatment.  TDF-based regimens are now the 
“preferred regimens” in European and North American guidelines (Table 1.3) [60,62].   
 
Table 1.3.  Timeline of U.S. HIV-treatment guideline changes.   
Source: created using information from DHHS guidelines for the use of antiretroviral agents in HIV-1-
infected adults and adolescents [64,65,69,93,97,124,125].   
 Changes in guidelines cART recommendations 
1996 Introduction of cART use of combination therapy 
Early 1998 U.S. guidelines recommend the use of 2 NRTIs + 1 PI as 
"preferred regimen" 
2 NNRTIs + 1 PI 
Backbone is AZT- or d4T-based with 3TC 
Late 1998 U.S. guidelines add EFV to list of "preferred regimens".   
 
2 NRTIs + PI  
or  
2 NRTIs + EFV 
Backbone is AZT- or d4T-based 
Early 2001 Use of ritonavir as booster rapidly evolves.  U.S. 
guidelines add other ritonavir-booster PI-regimens to list 
of "preferred regimens".   
2 NRTIs + boosted-PI  
or  
2 NRTIs + EFV 
Backbone is AZT- or d4T-based 
Mid 2003 DHHS/CDC cuts down recommendations to one 
NNRTI-based and one PI-based regimen.  
 
Tenofovir is added to list of "preferred regimens" in U.S. 
guidelines.   
 
Guidelines express caution for the use of d4T.   
EFV + 3TC + (AZT or d4T* + TDF)  
or  
LPV/RTV + 3TC + (AZT or d4T) 
*higher incidence of lipoathrophy and lipid 
abnormalities 
Late 2004 d4T is removed from list of "preferred regimens" 
 
FTC is added to both NNRTI and PI-based regimens as 
"preferred" 
EFV + (3TC or FTC) + (AZT or TDF) 
or 
LPV/RTV + (3TC or FTC) + AZT 
Late 2006 U.S. guidelines add other ritonavir-booster PIs to list of 
“preferred regimens” 
EFV + (3TC or FTC) + (AZT or TDF) 
or 
RTV-boosted PIs + (3TC or FTC) + AZT 
Early 2008 Combivir is removed from "preferred" regimens.   (EFV or RTV-boosted PIs) + TDF/FTC 
Late 2009 U.S. guidelines  add RAL to preferred regimens (EFV or ATV/r or DRV/r or RAL) + 
TDF/FTC 
 
 
1.5 Clinical Care of HIV Patients 
1.5.1 Treatment Initiation 
Another aspect of HIV care that has changed since 1996 is the timing of treatment initiation.  The 
point within the natural history at which treatment is initiated is an important determinant of a 
patient’s survival and response to future therapy [51,126,127].  The CD4 cell count in particular has 
up to now been a central measure in guiding decisions on treatment initiation.  Patients who begin 
treatment at the pre-AIDS stage (Figure 1.1) tend to experience better prognosis compared with 
patients who initiate treatment at the AIDS stage [127].  Early treatment results in preservation of 
immune function, earlier control of viral replication and prolongation of disease-free survival [128].   
Patients who start treatment below a CD4 count of 200 cells/mm
3
, on the other hand, have an 
increased risk of treatment failure and incomplete viral suppression as well as a greater frequency of 
side effects [51].  Recent studies have also shown that delaying treatment may be associated with 
adverse cardiovascular consequences and increased bone loss on treatment [129,130].  Starting 
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treatment too early is not always financially feasible and could also lead to earlier evolution of 
resistance and subsequent treatment failure or increased toxicity, and drug-drug interactions [131].  As 
a consequence, any beneficial effect of cART on immune restoration must be balanced against the 
risks.   
Recently there has been a shift towards earlier treatment initiation [132].  The first WHO 
treatment initiation guidelines recommended cART initiation at a CD4 count ≤200 cells/mm3.  
However, when treatment programmes began in Africa, people with the lowest CD4 counts were 
initiated first.  A study by the When to Start Consortium in 2009 found that 350 cells/mm
3 
should be 
the minimum CD4 threshold for initiation of cART, and should help to guide physicians in deciding 
when to start treatment [127].  In 2010, WHO treatment initiation guidelines were revised, in an effort 
to better align global standards [133], recommending cART be initiated in patients with a CD4 count 
≤350 cells/mm3.  In 2013 the WHO revised the guidelines again, stating that cART should be initiated 
in all individuals with a CD4 cell count of 500 cells/mm
3 
or less and giving priority to individuals 
with severe or advanced HIV disease and those with a CD4 cell count of 350 cells/mm
3
 or less [132].  
In contrast US guidelines recommend cART initiation immediately, regardless of CD4 count
 
[134].   
 
1.5.2 Monitoring HIV-infection 
Monitoring of HIV-infection using VL and CD4 count was introduced in the 1990s [27,135].  New 
technologies, namely the quantitative polymerase chain reaction assay, the branched DNA assay and 
the nucleic acid sequence-based amplification assay, allowed clinicians to carry out accurate 
quantitative measurements and monitoring of VL [27].  VL levels have been shown to be a predictor 
of disease progression [136,137].  CD4 cell counts, on the other hand, are not a direct measure of HIV 
but a useful tool to monitor immune system function in HIV-patients [31].  Epidemiological studies 
have shown that, in clinical settings, the combined use of VL and CD4 cell count tests provides a 
more accurate prediction of patient prognosis then either test alone [138].   
In high-income and industrialized countries, monitoring of CD4 cell count and VL has 
become central to cART delivery strategies and evaluating the effectiveness of cART.  However, 
globally, monitoring of CD4 count and VL in relation to cART delivery and evaluation is strongly 
influenced by cost and resource availability [27].  The US DHHS and International AIDS Society-US 
panel guidelines recommend frequent VL and CD4 count testing at three to four months intervals 
during the first one to two years following cART initiation.  The International AIDS Society-USA 
suggest monitoring intervals should be extended to six months in patients with good adherence, whose 
VL has been suppressed for a year and CD4 cell counts are stable at 350 cells/mm
3
 or greater [139].  
The continued monitoring of patients, not only allows improved patient prognosis by identifying 
treatment failure in a timely manner, but also decreases the use of cART regimens that are no longer 
effective, thus limiting the emergence of drug-resistance HIV strains [27].   
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1.5.3 Challenges to cART Durability 
Since the introduction of cART in 1996, the success of HIV-treatment has improved significantly [5–
7]; treatment regimens have become more effective, often with more convenient dosing and better 
tolerability than the original cART regimens [6].  As discussed before, there is a growing range of 
antiretroviral drugs that are used to provide life-long therapy, and some of them are now available as 
once-daily regimens (Table 1.2).  While the most limiting factors of HIV-treatment have shifted over 
time [6], there are still a number of problems associated with cART that challenge regimen durability, 
such as considerable cross-resistance within drug-classes [140], and potential, sometime serious, 
adverse effects which can make adherence to regimens difficult or necessitate changing to another 
regimen [141–143].   
Prolonging the durability of first-line cART is particularly important for treatment success.  
First-line cART has been shown to have the greatest success in achieving effective and long-lived 
CD4 increase and viral load suppression [144,145].  Patients who achieve undetectable levels of viral 
load on first-line cART have a greater chance of long-term success on HIV-treatment [6,145–147].   
In high-income and industrialized countries, patients generally start treatment soon after being 
diagnosed with HIV, and will either be on successful treatment or experience problems with their 
cART regimen.  When the latter occurs, a change of treatment to second-line is needed, which is 
called switching.  The reasons for switching that are central to this thesis will be discussed in more 
detail below.   
 
1.5.3.1 Toxicity 
HIV-treatment is associated with an array of common and sometimes severe side effects, which can 
make it difficult for patients to adhere to their cART regimens [141,148].  Side effects can lead to 
switching when side effects become too serious or debilitating.  The management of side effects 
associated with cART is becoming increasingly important; toxicity is increasingly reported as the 
most common reason for switching cART regimens [149–152] and the benefits of cART rely on near-
perfect life-long adherence [148].   
Every drug is associated with its own range of side effects.  Toxicity of HIV-treatment can 
vary from patient to patient, drug to drug and drug class to drug class [141].  Toxicities can be 
common and can be classified as mild to moderate, for example headache, nausea and vomiting, but 
can sometimes be significant clinical adverse effects, such as Stevens-Johnson syndrome (toxic 
epidermal necrolysis), hepatic impairment and new onset diabetes.  According to the FDA report on 
“Managing the risk from medical product use”, a drug does not have to be risk-free but “has 
reasonable risks given the magnitude of the benefit expected and the alternatives available” [153].  
The high risk of morbidity associated with HIV-infection, explains the greater permitted “reasonable 
risk” of toxicity [148].   
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It can be difficult to establish an association between specific HIV drugs, patient 
characteristics, and specific toxicities.  Post-marketing surveillance of drugs has limited reporting 
standards, often lacking power, with poor consensus on method and definition regarding the collection 
of information on toxicity [148].  Given the impact and reported risk of toxicity-driven switching 
[149–152], and thus the success of cART, the study, analysis and reporting of toxicity is important 
[148].   
There exists some understanding of the association between some drugs and subclasses and 
the mechanisms underlying some toxicities [141,148,154].  NNRTIs and NRTIs have commonly been 
associated with toxicities related to mitochondrial impairment, such as lactic acidosis, hepatic 
steatosis (fatty liver), and hyperlactatemia (increased of lactic acid in the blood) and even peripheral 
neuropathy (damage to the peripheral nervous system), lipomatosis (abnormal localized accumulation 
of fat) and pancreatitis [141,148,154].  These toxicities are thought to be the result of the inhibition of 
mitochondrial polymerase γ by NRTIs and NNRTIs, as these drug classes can theoretically function 
as substrates for enzymes [141,148,154].  The result is the impairment of synthesis of mitochondrial 
enzymes, reflected by elevated plasma lactate in patients [141,148,154].  Similarly, lipodistrophy 
which is mainly associated with PIs, could be due to the inhibition of lipid and adipocyte regulatory 
proteins, which have partial homology to the catalytic site of HIV protease [148].   
 
1.5.3.2 Resistance 
The success of cART can be compromised by the emergence of resistance [155].  Resistance is of 
particular concern due to its transmitability and cross resistance [155].  Resistance refers to a mutation 
in the genetic code of the virus that renders one or more drugs less effective at targeting HIV [155].  
Resistance occurs as the virus does not possess a genetic proofreading mechanism.  This, together 
with HIV’s high viral replicative rate, means that, errors are continuously introduced into the viral 
genome during the replication process [155].  This mutation accumulation can sometimes be to the 
advantage of the pathogen, as certain mutations may confer resistance to ARVs [156] and 
subsequently take over the population of other viruses, following simple Darwinian selection [155].  
Most HIV-infected patients have a complex and diverse viral population [155].  HIV strains began to 
acquire resistance in 1987 when mono-therapy was introduced as treatment for HIV-infected 
individuals.  Despite the adoption of triple combinations in cART in 1996, resistance remains a 
serious problem for many patients and is causing serious clinical and public health problems 
throughout the United States and Europe [157,158].   
There are two types of resistance: that which is transmitted between individuals, and that 
which evolves within the infected individual, sometimes referred to as primary and secondary 
resistance, respectively.  The majority of resistance is secondary [159].  Different ARVs and HIV 
subtypes have different genetic barriers [160].  The genetic barrier can be defined as the number of 
transitions and/or transversions (types of mutations) that need to occur to result in a resistance 
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mutation [160].  The use of first-generation NNRTIs, such as nevirapine and efavirenz has been found 
to have a low genetic barrier compared with second-generation NNRTIs such as etravirine and 
rilpivirine [161,162].  Most concerning, however, is the development of multi-drug resistant HIV 
[31].  As a consequence, there is continued demand for drug development.   
Non-adherence is an important factor in drug-resistance and treatment failure.  Adherence 
below 95%, or missing more than one dose per month (for once-daily ART), has been associated with 
increased resistance [163].  In fact, a modelling study has highlighted that non-adherence could in part 
explain poor response in second-line treatment [164].   
In 2004 Bezemer and colleagues found that the transmission of resistant HIV strains in 
Amsterdam had decreased over time [165].  Similar results have been demonstrated in the UK [166].  
Resistance testing is important in assisting decisions about switching.  Although, some modelling 
studies have suggested that the roll-out of pre-exposure prophylaxis (PrEP) could increase the 
transmission of resistance, posing a threat to global public health by compromising cART 
effectiveness [167,168], a recent study found that PrEP is predicted to have a limited impact on 
resistance [169].  In any case, resistance monitoring should continue to track changes in trends.   
 
1.5.3.3 Other Adverse Outcomes 
Other than resistance and toxicity, patients on cART can switch or stop treatment regimens for a 
number of other reasons.  For example, some ARVs can interact with co-medications, so that a patient 
on cART, who requires prescription of other medications, aside from cART, might have to switch 
their current cART regimen.  In the case that a patient is started on another drug as a consequence of a 
new condition, the physicians may also decide to alter the patient’s cART regimen out of caution, in 
case the combination of side effects may be too much for the patient.  CART regimens can also be 
changed due to contra-indications.  In this case, an underlying disease, such as family history of CVD, 
or the discovery of a new contra-indication necessitates a change in current cART regimen.  CART 
regimens can have a high pill-burden and complicated dosing.  As a consequence, patients are often 
unable to adhere to the prescribed cART regimen.  In these cases physicians might elect to switch the 
patient onto another cART regimen with reduced pill-burden and/or simplified dosing, for example a 
once-daily regimen.  Poor compliance can be another reason for changing cART regimen, a result of 
patients not taking their medication as prescribed.  A marker for poor compliance could be drug 
plasma concentration and is commonly followed by simplification of regimen.  However, sometimes 
cART is simply switched because a new regimen has become available that is thought to be better for 
the patient, despite the absence of a specific clinical problem with the current regimen.   
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1.6 The National Dutch ATHENA Cohort 
In 1997, a large study, called AIDS Therapy Evaluation in the Netherlands (ATHENA), was 
established with the aim of evaluating the, at that time, new treatment possibilities for HIV in the 
Netherlands, their side effects and the development of resistance among HIV-patients.  In 2001, 
ATHENA was converted into a permanent facility, the Stichting HIV Monitoring (SHM), the Dutch 
HIV Monitoring Foundation, in order to continue to evaluate the long-term effects and effectiveness 
of cART in the treatment of Dutch HIV-infected patients.  SHM was officially appointed by the Dutch 
Minister of Health, Welfare and Sports (Ministerie van Volksgezondheid, Welzijn en Sport) in 2002 
as the national executive foundation for the monitoring of HIV-infected adults in follow-up in all 26 
HIV-treatment centres in the Netherlands (Figure 1.7).  SHM also includes the monitoring of HIV-
infected children and adolescents in four institutes that are recognized paediatric HIV-treatment 
centres (Figure 1.7).  SHM’s mission is to further contribute to the knowledge and understanding of 
the epidemiology, course of infection and clinical outcome of HIV-infected patients.   
ARVs are exclusively prescribed by physicians at one of the 26 treatment centres around the 
country that are registered with the SHM.  Currently, patients are being treated in accordance with the 
European AIDS Clinical Society guidelines [60].  Clinical, biological and immunological data for 
HIV-infected patients are collected upon entry and at each follow-up visit (Table 1.4).   
 
1.7 The HIV Epidemic 
1.7.1 Three Decades of HIV Pandemic 
June 5, 2011 marked the 30
th
 anniversary of the first documented cases of what would eventually 
become known as Acquired Immune Deficiency Syndrome (AIDS); in the United States a 31-year-old 
patient called Thomas, was admitted to hospital with weight loss and fever [170].  While this new 
disease was first recognized on 5
th
 June 1981, it was only in 1983, after AIDS cases had been reported 
in 28 nations, that the causative agent was determined to be a virus [171] 
.  Since the 1980s, the epidemic has grown rapidly; around 75 million people have become infected 
with the virus, 36 million people have died of HIV-related causes [1] and more than 14 million 
children have been orphaned [172].  In 2012 35.3 million people were living with HIV and 1.6 million 
people died from AIDS-related causes worldwide [1].   
On the cusp of the fourth decade since the first HIV case it seems the world has managed to 
turn a corner and not just halt but also reverse the epidemic.  According to UNAIDS the year 1999 
marked the peak of the HIV epidemic, in terms of new infections, and since then the number of new 
infections annually has fallen by 19% [173].  Since 2001 new infections fell by 33% and AIDS-
related deaths have fallen by 30% since their peak in 2005 [1].  Considerable geographic variation in 
the HIV epidemic exist (see Table 1.5) and sub-Saharan Africa remains the most affected region with 
67% of HIV-infected individuals living in this region [172].   
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Figure 1.7.  Map of the Netherlands with the locations of the 26 Health institutions involved as 
(sub)centres for adult HIV care and of the four paediatric centres (in alphabetical order by location).   
Source:  SHM report [174].   
 
Centre name Location  Centre name Location 
1 Medisch Centrum Alkmaar  Alkmaar 17 Leids Universitair Medisch 
Centrum 
Leiden 
2 Flevoziekenhuis Almere 18 MC Zuiderzee Lelystad 
3 Academic Medical Centre of the 
University of Amsterdam 
Amsterdam 19 Academisch Ziekenhuis 
Maastricht 
Maastricht 
4 Onze Lieve Vrouwe Gasthuis Amsterdam 20 Universitair Medisch Centrum 
Sint Radboud 
Nijmegen 
5 Sint Lucas Andreas Ziekenhuis Amsterdam 21 Erasmus Medisch Centrum Rotterdam 
6 Slotervaart Ziekenhuis Amsterdam 22 Maasstad Ziekenhuis Rotterdam 
7 Medisch Centrum Jan van 
Goyen 
Amsterdam 23 St Elisabeth Ziekenhuis Tilburg 
8 VU Medisch Centrum Amsterdam 24 Universitair Medisch Centrum 
Utrecht 
Utrecht 
9 Ziekenhuis Rijnstate Arnhem 25 Admiraal De Ruyter Ziekenhuis Vlissingen 
10 HagaZiekenhuis  Den Haag 26 Isala Klinieken (location Sophia) Zwolle 
11 Medisch Centrum Haaglanden  Den Haag    
12 Catharina Ziekenhuis Eindhoven Centres for the treatment and monitoring of 
paediatric HIV  
13 Medisch Spectrum Twente Enschede A Emma Kinderziekenhuis, AMC-
UvA 
Amsterda
m 
14 Universitair Medisch Centrum 
Groningen 
Groningen B Beatrix Kinderkliniek, UMCG Groningen 
15 Kennemer Gasthuis Haarlem C Sophia Kinderziekenhuis, EMC Rotterdam 
16 Medisch Centrum Leeuwarden Leeuwarden D Wilhelmina Kinderziekenhuis, 
UMCU 
Utrecht 
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Table 1.4.  Information collected from HIV-patients by the ATHENA cohort at entry and follow-up.   
Demographic data  Date and Country of birth 
 Sex 
 First and second nationality 
 Height 
 Location of testing and health care body that referred patient to specialist 
History of HIV 
infection 
 Date of the last negative HIV-1 and HIV-2 test 
 Date of the first positive HIV-1 and HIV-2 test 
 Diagnosed with primary HIV infection (yes, no, most likely)? 
HIV transmission  Most likely route of transmission (blood and blood products, breastfeeding, during 
pregnancy/partum, heterosexual, homosexual (for men only), injecting drug use, other, unknown) 
 Contact type if most likely route of transmission is sexual (steady sexual partners or multiple 
sexual contacts) 
 Country where the patient became infected 
Intoxication  Alcohol consumption 
 Drug Intake 
 Smoking 
Additional data for HIV-infected children  
Demographic data  Country of birth and nationality of patient’s parents 
Family data  HIV status of patient’s mother, father and siblings 
Perinatal data  Antenatal complications  
 Apgar scores  
 Birth weight 
  Congenital defects 
 Duration of pregnancy 
 Perinatal exposure to ARV and co-
medication 
 Type of delivery   
Additional data for HIV-infected pregnant women  
Demographic data  Country of birth and nationality of patient’s parents 
Screening  HIV-positivity established at the national pregnancy screening (yes or no) 
Visit to the 
gynaecologist 
 Blood pressure  Visit date 
Obstetric data  Apgar scores after 1 minute/5minutes 
 Birth weight of the baby 
 Breast-feeding  
 Date of delivery/abortion 
 Duration of dilation  
 Duration of ruptured membranes 
 Duration of stay in the incubator 
 Duration of the pregnancy 
 Episiotomy or rupture 
 Foetal scalp electrode 
 Has there been a delivery/abortion 
 Intra-uterine infection 
 Other children and how many? 
 Prophylactic antibiotic 
 Type of delivery 
 Sex of the baby 
Complications 
during pregnancy 
 Abdominal trauma and weeks into pregnancy of 
trauma event 
 Blood loss during the first half of pregnancy 
 Blood loss during the second half of pregnancy 
 Complications during and/or after birth 
 Intercurrent infection 
 Intra-uterine retardation of growth 
(sonography <p5%) 
 PPROM (preterm premature rapture of 
outer membranes) at how many weeks 
 Pre-eclampsia 
 Version (attempt) with breech 
presentation 
Clinical 
examination 
  Blood pressure 
  Weight 
CDC events 
 
 Definition of diagnosis (possible, presumptive 
or definitive)  
 Start and stop date 
 Status at current visit (ongoing: yes or no) 
Adverse events 
Any event leading to 
changes in cART 
are recorded in 
addition to types of 
events  
 Start and stop date 
 Status at current visit (ongoing: yes or no) 
 Type of event (abacavir hypersensitivity, anal dysplasia, arrhythmia, cardiomyopathy, carotid 
endarterectomy, coronary artery by-pass grafting, coronary angioplasty/stenting, diabetes 
mellitus, heart failure, hepatic encephalopathy, hepatic fibrosis/cirrhosis, hepatic steatosis, 
hepatorenal syndrome, hospital admission, hypertension, kidney dialysis, kidney transplantation, 
lactic acidosis, lipodistrophy, fat loss in extremities, lipodistrophy, central fat accumulation, 
liver transplantation, myocardial infarction, myopathy, nephrolithiasis, non-AIDS malignancies, 
oesophagus varices, osteopenia/osteoporosis, pancreatitis, pregnancy, peripheral neuropathy, 
rash, renal insufficiency and failure, sexual dysfunction stroke) 
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Table 1.4. Information collected for HIV-patients [continued].   
Antiretroviral 
therapy 
 
 Dosage, unit and route of admission 
 Reason for stopping (as a precaution, compliance 
problems, end of pregnancy, immunological failure, 
interaction with co-medication, new CDC-B/ CDC-
C events, newly available medication, other, 
patient’s decision, pregnancy, pregnancy wish, 
related to blood  
concentration of ARV, simplification 
of the regimen, structured treatment 
interruption, unknown, toxicity, 
virological failure) 
 Start and stop date 
 Status of medication at current visit 
(ongoing: yes or no) 
Co-medication 
 
 Start and stop date 
 Status at current visit  
 Type of medication (incl. anabolic steroids and 
appetite stimulants, anti-arrhythmic agents, anti-
coagulant agents, anti-diabetic agents, anti-epileptic 
agents, anti- 
hypertensive agents, CDC events, 
prophylaxis, Hepatitis B and/or C 
treatment, insulin and its derivatives, 
lipid lowering agents, medication that 
interacts with cART, miscellaneous, 
platelet aggregation inhibitors) 
Laboratory 
results 
 HIV virology/RNA (cut-off, laboratory, sample date, sample material,  undetectable (yes or no), 
value (copies/ml), and VL assay type) 
 Immunology/T-cell count (laboratory, sample date for CD4 count, CD8 count, CD4 percentage, 
CD8 percentage, CD4/CD8 ratio units, and value) 
 Chemistry (laboratory, sample date for ALAT/SGPT>3xN*, alkaline phosphatase >3xN*,  amylase 
>250mmol/l, cholesterol**, cholesterol HDL**, creatine**, gamma GT >3xN*, glucose>N*, 
lactate>N*, triglycerines**, value) 
 Haematology (laboratory, sample date  for haemoglobin <5.5 mmol/l, leukocytes <2.0 10e9/l, 
thrombocytes <150 10e9/l, units, and value) 
 Other viral infections (laboratory, sample date for CMV-IgG, CMV-IgM, HBcAb, HBeAb, HBeAg, 
HBsAb, HBsAg, HBV-DNA***, HCV-Ab, HCV-RNA***,  values (positive or negative))  
 Sexually transmitted diseases (laboratory, sample date for chlamydia, condylomata accuminata, 
gonorrhoea, Human Papilloma virus, syphilis, units, and value) 
 ART drug concentrations (dosage and units of the medication, laboratory, plasma concentration, 
sample date, time after drug intake) 
Additional data for HIV-infected children  
Clinical 
examination 
 Skull circumference 
 Puberty stage 
 
CDC events 
 
 Start and stop date 
 Status at current visit 
 Type of CDC event as classified by 
CDC 
Adverse events  Abnormalities of locomotive development 
 Abnormalities of puberty development 
 Abnormalities of psychological 
development 
 Pathologic and traumatic fractures 
Additional 
treatment 
 
 Start and stop date 
 Status at current visit  
 Type of treatment (incl. pedagogue, physiotherapist, 
psychiatrist , psychologist, 
rehabilitation worker, social worker, 
speech therapist) 
Care and 
education 
 Cared by: Mother, father, parents, family, foster family, care institute, other and unknown 
 Education: nursery school, playground, primary school, secondary school, other and unknown 
Vaccinations 
date 
 BCG 
 BMR 
 DKTP1, DKTP2, DKTP3, and DKTP4 
 HIB1, HIB2, HIB3, and HIB4 
 Influenza 
 Meningitis C  
 Other 
 PNCV 
 Pneumovax 
Laboratory 
results 
 Chemistry (glucose, amylase, ALAT/SGPT, ASAT/SGOT, alkaline phosphatase, gamma GT, 
lactate, triglycerides, cholesterol, cholesterol HBA1c) 
 Haematology (haemoglobin, leukocytes, thrombocytes, MCV) 
 HIV virology/DNA (laboratory, sample date for HIV-1 DNA, HIV-2 DNA, HIV-1 antibodies, 
HIV-2 antibodies, and values (positive or negative)) 
 Other viral infections (laboratory, sample date for Hepatitis,  CMV, toxoplasmosis and Varicella 
Zoster Virus, and values (positive or negative))   
Source: table constructed using information from the SHM annual reports [174] 
* N are normal values, can vary for different laboratories 
** Always collected 
*** Qualitative and quantitative values 
 
Chapter 1 - Introduction 
43 
 
Table 1.5. Regional HIV statistics.  The square brackets indicate the range of uncertainty in the data.   
Source: UNAIDS 2013 and 2009  [1,172].   
Region People living with 
HIV 
New infections 
2012 
AIDS-related 
deaths 2012 
 HIV prevalence 
2008 (%) 
Sub-Saharan 
Africa 
25.0 million  
[23.5-26.6 million] 
1.6 million  
[1.4–1.8 million]  
1.2 million  
[1.1 -1.3 million] 
5.2%  
[4.9-5.4%] 
South and 
South-East Asia 
3.9 million 
[2.9-5.2 million] 
270,000  
[160,000-440,000]  
220,000  
[150,000-310,000]  
0.3% 
[0.2-0.3%] 
East Asia 880,000 
[650,000-1.2 
million] 
81,000  
[34,000-160,000]  
41,000  
[25,000-64,000]  
<0.1% 
[<0.1%] 
Latin America 1.5 million  
[1.2 -1.9 million]  
86,000  
[57,000-150,000]  
52,000  
[35,000-75,000]  
0.6% 
[0.5-0.6%] 
Western and 
Central Europe 
860,000  
[800,000-930,000  
29,000  
[25,000-35,000] 
7,600  
[6,900-8,300]  
0.3% 
[0.2-0.3%] 
North America 1.3 million  
[980,000-1.9 
million]  
48,000  
[15,000-100,000] 
20,000  
[16,000-27,000]  
0.4% 
[0.3-0.5%] 
Eastern Europe 
and Central Asia 
1.3 million  
[1.0 -1.7 million] 
130,000  
[89,000-190,000]  
91,000  
[66,000-120,000]   
0.7% 
[0.6-0.8%] 
Caribbean 250,000  
[220,000-280,000]  
12,000  
[9,400-14,000]  
11,000  
[9,400-14,000]  
1.0% 
[0.9-1.1%] 
Middle East and 
North Africa 
260,000  
[200,000-380,000]  
32,000  
[22,000-47,000] 
17,000  
[12,000-26,000]  
0.2% 
[<0.2-0.3%] 
Oceania 51,000  
[43,000-59,000]  
2,100  
[1,500-2,700]  
1,200  
[<1,000-1,800]  
0.3% 
[<0.3-0.4%] 
Global 35.3 million  
[32.2 - 38.8 million]  
2.3 million  
[1.9 - 2.7 million]  
1.6 million 
[1.4 - 1.9 million] 
0.8% 
[<0.8-0.8%] 
 
 
1.7.2 The Epidemic and cART in the Netherlands 
As of 31
st
 December 2012, 21,012 patients were registered with the SHM in one of the 26 HIV-
treatment centres in the Netherlands [175].  This is up by 1,260 patients (6%) compared to 2011.  
Clinical data had been collected for 20,676 (98.4%) of the registered patients, with 336 (1.6%) people 
opposed to the collection of data.  In 2012, 4,359 (21%) registered patients had no data collected; 
1,937 (9.2%) people were deceased prior to 2012, 831 (4.0%) had moved abroad and 1,591 (7.5%) 
had been lost to follow-up for unknown reasons [175].   
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Out of 20,676 people registered in 2012, 20,315 (98%) were adults at the time of registration; 
16,261 (80%) men and 4,054 (20%) women.  Of the total patient population registered with the SHM 
in 2011, 14,874 started cART between January 1995 and December 2010.  The remaining 3,861 had 
started on mono- or dual-therapy [175].   
On the eve of the 10
th
 anniversary of the SHM, the annual report described the main trends of 
the epidemic in the Netherlands in 2011 as “cautiously optimistic” [176].  On the one hand, the data 
show that as of mid-2011, a larger number of patients in the Netherlands were on treatment and that 
there were no further increases in the annual number of new diagnoses, including in the MSM (men-
who-have-sex-with-men) population [176].  In addition, viral load levels were reported below assay 
threshold for longer periods, and CD4 counts levels were higher than in previous years [176].  On the 
other hand, annual mortality rates amongst HIV-patients on cART are still not similar to those of age- 
and gender-matched uninfected individuals, physicians are still diagnosing AIDS, and clinical 
management of HIV-infected patients is challenged by the increasingly frequency of serious non-
AIDS related diseases [176].   
Yet, national monitoring data have shown a decline in AIDS, HIV/AIDS-related deaths, and 
HIV-related illnesses.  The overall mortality rate in the cohort had declined to 8.9 (CI 95%, 7.3-10.6) 
in 2010 [176].  Although patients still experience an excess mortality rate compared with gender- and 
age-matched uninfected individuals, the SHM reports that this observation can in part be explained by 
late patient diagnosis, who already had AIDS at the time of diagnosis.  They found that a group of 
recently diagnosed individuals, effectively treated patients had a life expectancy similar to HIV-
negative people in the Netherlands [176].  This suggests that effective cART management can enable 
patients to achieve mortality levels similar to those of the general population [176].   
Despite the increasing number of HIV-infected patients increasing yearly, in 2011 the SHM 
reported no further increase in the annual number of new diagnoses in 2011 [176].  Between 2003 and 
2008 the SHM had reported a steady increase in the registered number of new infections [174].  These 
increases paralleled reported increases in risk behaviour amongst men who have sex with men (MSM) 
and reflect increases in the number of individuals tested following the introduction of new HIV testing 
policies [176].  2004 marked the peak in the yearly number of diagnoses amongst heterosexuals, since 
when the number has declined to approximately 300 new infections per year [176].  Among MSM, 
the annual number of diagnoses has been steadily increasing since the 1990s, reaching a maximum of 
just above 800 in 2008 [176].  It seems this trend has started to decline since, with approximately 750 
new registered diagnoses among MSM in 2009 and 2010 [176].   
Furthermore, trends in viral load appear to have changed over the years.  In 2011 the SHM 
reports that 58% of patients experience viral load suppression below detection thresholds within 6 
months after cART initiation, 72% within 9 months and 80% within 12 months [176].  Trends over 
calendar time have shown that suppression of viral load to below 50 copies/ml at 9 months after 
cART initiation has increased.  The percentage of patients who achieved viral load suppression below 
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50 copies/ml within 9 months of starting cART increased from 68% in 1999-2001, to 73% in 2002-
2004, to 75% for those who started treatment in 2005-2007 to 83% in 2008-2010.  Between 2008 and 
2010 the virological response to cART response seemed to have declined from 75% to 72%.  
However, when results were recalculated excluding the new laboratory assay for HIV RNA 
determination, levels were actually 83% [176].   
 
 
1.8 Ageing and HIV Treatment 
The global HIV epidemic is experiencing a shift in its demographic, the prevalence of middle aged 
and elderly HIV-patients increasing [177–183].  In its 2006 report UNAIDS announced that “it is now 
evident that a substantial proportion of people living with HIV are 50 years or older” [184].  In the 
Netherlands, the HIV Monitoring Foundation projects that by 2015, 41% of the HIV-patients 
registered in the HIV-treatment centres in the Netherlands will be aged over 50 [185,186].  UNAIDS 
reported in 2013 that approximately 30% of all adults living with HIV are aged 50 years and over 
[12].  This demographic shift is in part because of the increased survival of patients on successful 
cART, and in part due to the increasing number of new infections that occur in older patients 
[12,187].  In 2006, the Centres for Disease Control (CDC) and Prevention in the United States 
reported that 16% of new infections were diagnosed in HIV-infected patients aged over 50 years old, 
up 10% from 2006 [188,189].   
The ageing HIV-population will put new demands on the health care system and create 
several important implications for the health of HIV-infected patients in clinical care [14,15,190,191].  
Treatment services established in response to the HIV epidemic will need to expand to address the 
unique health problems of the world’s ageing HIV population, discussed below.  Older patients are 
often diagnosed at a later stage of HIV-infection compared to younger patients [192–194].  This may 
be because health care providers are less likely to suspect HIV in elder patients and ask about their 
exposure risk [192,195].  In addition, older patients suffer from medical co-morbidities that they 
previously did not live long enough to endure.   
Co-morbid disease is becoming an increasing problem among the ageing HIV-population 
[15].  Several studies have found that a number of age-related non-infectious co-morbidities were 
more common among HIV-infected patients than in the age-matched uninfected population 
[5,9,10,196,197].  This has been shown for a number for co-morbidities, including CVD [198–202], 
non-AIDS malignancies [203–205], liver and kidney disease [206–208], and osteoporosis [209–211].  
A study by Goulet and colleagues compared co-morbidity between HIV-infected and non-infected 
veterans.  The group found that the HIV-infected individuals had higher odds of patients with multiple 
morbidities compared to non-infected individuals [196].  Furthermore, a study by Guaraldi and 
colleagues found that the onset of co-morbid disease occurred earlier than in the non-HIV–infected 
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population.  They found that the prevalence of co-morbid disease was similar in HIV-patients aged 40 
years to that in control subjects aged 55 years, revealing a 15-year earlier onset [197,212].  Other 
studies have found similar results [190,213,214].   
The mechanism for this increased prevalence and early onset is thought to be multi-factorial 
[213].  It may be in part due to residual immunodeficiency and consequent persistent  inflammation, 
or a result of long-term antiretroviral drug toxicity [215–217].  HIV-treatment is associated with 
numerous toxicities of virtually all organ systems.  Reported toxicities include diabetes, 
hepatotoxicity, renal insufficiency, dyslipidaemia, pancreatitis, neuropathy and lactic aciodosis 
[89,218–223].  Abavcavir and some PIs, for example, have been associated with cardiovascular 
toxicity [224,225].  HIV-infection itself is associated with chronic inflammation and immune 
activation, with HIV-treatment decreasing most markers of immune activation and inflammation 
[226].  The SMART study, comparing continuous cART to structured treatment aimed at reducing 
treatment-related toxicity, found that the structured treatment interruption arm had 1.7 times as many 
major CVD, renal or liver events [227–229].  These findings suggested that HIV-infection could be 
associated with the development of co-morbidities, through residual inflammation and immune 
activation.   
Residual inflammation is closely linked to cell senescence (biological ageing).  At the 
molecular and cellular levels, senescence is induced by an accumulation of damages, including 
genetic and epigenetic alterations but mainly mitochondrial dysfunction resulting in increased 
oxidative stress [212].  Oxidative stress reflects an imbalance between the systemic manifestation 
of reactive oxygen species (chemically reactive molecules containing oxygen) and a biological 
system's ability to readily detoxify the reactive intermediates or to repair the resulting damage.  Cells 
stop dividing, change their phenotype, and secrete a number of factors, including pro-inflammatory 
cytokines that contribute to systemic low-grade inflammation [212].   
Whether a particular HIV-related co-morbidity is causally related to HIV, for example due to 
chronic inflammation or a consequence of long-term cART use seems to depend on the condition in 
question [191].  For example, increased risk of osteoporosis seems to be closely linked to BMI (body 
mass index) and the use of PIs [211,230].  In contrast, increased risk of myocardial infraction (MI) 
appears to remain even after adjustment for established risk factors [231].  Finally, it is important to 
point out that lifestyle factors such as smoking can often be a more important risk factor for 
developing CVD and lung cancer than HIV-infection or HIV-treatment [232–234].   
As the prevalence of co-morbidity increases, the care of HIV-patients will be complicated 
[14,15].  Co-morbid disease causes problems with polypharmacy, the co-administration of multiple 
co-medications with HIV-medication, leading to higher pill burden [14,15].  A further problem is that 
of drug-drug interaction.  In an analysis of the Swiss HIV cohort study, the combination of cART with 
polypharmacy increased significantly the chance of potentially serious drug-drug interactions [235], 
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which can lead to drug toxicity, loss of efficacy of the co-administrated medication and virological 
breakthrough.   
Until recently, this aging HIV-population has been relatively ignored.  Most studies of HIV-
treatment have excluded patients of advanced age and those with co-morbid disease [15].  Little data 
exist on the long-term toxicity of cART, on dosing or the pharmacokinetics of HIV and co-morbid 
drugs in older HIV-patients, or on the ideal cART regimen type in older patients.   
The issue of ageing and multi-morbidity also calls into question the ‘one-size-fits-all’ 
approach to care suggested by care guidelines [191].  Current guidelines do not provide a working 
framework for dealing with the growing number of older HIV-patients with multiple co-morbidities.  
In light of the shifting demographic profile in HIV-patients, there is a need for more data on the 
factors affecting the successful management of older HIV-infected patients, as well as the formulation 
of frameworks to deal with this growing problem.  In July 2012 a special issue in the AIDS journal, 
“The ageing of the HIV epidemic” was published, aimed at marking the beginning of a shift in the 
global response to HIV with regards to research, funding and policy [236].  It emphasised the need to 
address the impact future demographic trends may have on the impact of the HIV response [236].   
 
 
1.9 Mathematical Modelling of HIV Treatment  
Evaluation of treatment strategies for HIV-infected patients would, ideally, employ randomised 
controlled trials (RCTs) [237].  While there are many RCTs evaluating the efficacy of drugs and drug 
regimens, such studies are often associated with a high cost, long follow-up time.  For some aspects of 
clinical care RCTs are not ideal as HIV-patients need treatment now, and not “at the conclusion of 
long-term prospective trials” [237].  Mathematical modelling provides a powerful synthesizing tool.  
They provide a quantitative tool to carry out formal evaluation of the impact of different treatment 
strategies and the future of an epidemic [237].  Infections such as HIV involve complex interactions; 
mathematical models allow the integration of important biological and demographic variables and 
thus allow us to investigate factors affecting these dynamics.  They also allow the studying of the 
population effect of varying various parameters of treatment, by providing a practical framework for 
carrying out sensitivity analysis.  Models allow scientists and policy makers to understand the likely 
benefits and possible risk of various strategies.  Models can be used to investigate treatment 
optimization, by evaluating the impact of treatment variables, such as late entry into care, adherence 
and cART regimens on life expectancy and clinical outcome [237].   
There are different types of models, deterministic and stochastic, population-level and 
individual-based [238].  Deterministic models describe what occurs on average in a population, and 
patients are not subject to chance [238,239].  Consequently, two realisations of the model using the 
same parameters and starting conditions will yield the exact same output [239].  In stochastic models, 
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chance variation is incorporated [238,239].  Sets of possible events, are assigned a probability and a 
random number generator is used to calculate which event will occur next and when [238,239].  
Individual-based models track every individual within the population, allowing chance to determine 
whether or not an event occurs at each time step [238,239].  Population-modelling on the other hand 
looks at population-level outcomes.   
There are many mathematical models of HIV, evaluating a plethora of questions.  Fung and 
colleagues constructed a model of the immune system and HIV-infected to investigate different 
research questions [240,241].  Gomez and colleagues carried out a systematic review of cost-
effectiveness modelling studies of PrEP [242].  Other groups have developed transmission models 
[243,244], or models of microbiological processes such as those by Nampala and colleagues [245] or 
co-infection models like those constructed by Mushayabasa and colleagues [246].  While these have 
contributed greatly to the knowledge of HIV-infection and clinical care, we are going to focus in this 
section on some of the key models of treatment and clinical care.   
Several models of HIV-treatment and patient management exist.  Paltiel and colleagues 
developed a Monte Carlo Simulation model of HIV disease.  The model is a “state-transition” model, 
simulating a cohort of individual patients whose clinical course is tracked from model entry until 
death.  The model is characterized by a sequence of monthly probabilities of transitions from one 
health state to another that describe the patients’ underlying health.  A random number generator is 
used to determine the sequence of clinical pathways that a given patient follows, using CD4 count and 
HIV RNA level as predictors for disease progression and opportunistic infection.  A running tally of 
the events, time and cost is maintained allowing the calculation of various outcome measures, 
including life expectancy, and lifetime direct medical costs [247,248].  This model has been adapted 
to a number of different settings and used to address a number of questions related to the cost-
effectiveness of treatment strategies [247,249–260].   
Freedberg and colleagues, for example, used it as a health economic model of HIV disease to 
investigate the clinical impact and cost-effectiveness of combination ART in 2001.  They concluded 
that treatment of HIV with a combination of three antiretroviral drugs is a cost-effective use of 
resources [251].  Their analysis was limited by a number of assumptions, including assumptions 
surrounding the benefits of three-drug regimens and the complex relationship between VL and CD4.  
The model does not include the long-term effects of early start of cART, thus predicting that early 
cART initiation is reasonable [251].   
Overall, the Monte Carlo model developed by Paltiel and colleagues provides a flexible and 
powerful framework with which to evaluate strategies of patient management as well as investigate 
their cost-effectiveness.  The model includes limited details on disease and treatment, such as 
different cART regimens [133,247,248].  It also assumes homogenous patient populations, including 
treatment history, and underlying health status [247,248].  Adaptations of the model are also 
sometimes limited by the availability of data for parameter estimation [261].   
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Hallett and colleagues developed a stochastic mathematical model representing disease 
progression, diagnosis, clinical monitoring and survival in a cohort of 1,000 hypothetical HIV-
infected individuals in Africa.  Each individual is assigned demographic and clinical characteristics 
using random parameter distribution.  The aim was to use this model to evaluate the impact of patient 
monitoring in resource-limited settings, where laboratory facilities are limited and the WHO’s 
recommendation, that CD4 counts should be used to decide when HIV-treatment should be initiated, 
cannot be followed.  The group investigated the impact of alternative patient management for cART 
initiation on treatment roll-out in Sub-Saharan Africa.  It concluded that the impact would be greater 
using CD4 cell count information versus WHO staging criteria to determine when to start treatment 
[262].  The analysis was limited by the lack of information on the relationship between CD4 count 
and WHO staging criteria and its inability to replicate clinical judgement [262].   
Estill and colleagues and Smit and colleagues both adapted the model from Hallett and 
colleagues to address further research questions.  Estill and colleagues aimed to investigate the impact 
of routine VL monitoring on HIV transmission [263].  They found that routine viral load testing while 
on cART could reduce transmission and that [263].  The group, however, also highlighted the 
necessity to evaluate its cost-effectiveness in the light of an increasing need for access to treatment..  
In 2013, Estill and colleagues published a cost-effectiveness study based on this work [264].  They 
examined the cost-effectiveness of qualitative point-of care viral load tests in Sub-Saharan Africa, and 
found that that viral load monitoring could be an important factor in the reduction of mortality[264].  
The analysis is limited by a number of factors.  It only models the treated population, and one 
limitation of the model is that it does not take into account increased risk behaviour after treatment 
initiation [263].   
In the Netherlands, Smit and colleagues adapted the model by Hallett and colleagues to find 
possible explanation for the different survival rates in the first three years of cART between HIV 
treatment centres.  Their model investigated three scenarios, including varying age distribution, 
monitoring rates and CD4 counts of patients entering care.  The group found that the latter was the 
main source of variation [265].   
In 2009 Granich and colleagues used mathematical modelling to explore the effect of ‘test 
and treat’ in a generalised heterosexual epidemic.  ‘Test and treat’ consists of universal voluntary 
testing and immediate initiation of cART upon diagnosis.  The group aimed to evaluate the conditions 
under which the epidemic could be driven to elimination.  The group found that the strategy of 
universal ‘test and treat’ together with current prevention methods could have a major impact on 
generalised epidemics.  Their model predicted that HIV prevalence could be reduced to less than 1% 
within 50 years of implementation [266].  Some of the limitations of the work centre on the quality of 
data and the lack of full economic analysis of costing [267].  The limitations of the interpretation of 
the results focus on the feasibility of implementing universal test and treat.   
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Phillips and colleagues constructed a stochastic simulation model of HIV in the UK [268].  
The model simulates the course of HIV-infection and the impact of cART for patients in clinical care 
in the UK.  The model was then used to investigate the potential consequences of WHO 
recommendations on monitoring strategies for low-income countries.  The model of HIV-infection 
was based on viral load, CD4 cell count or clinical observation alone for determining switching from 
first-line to second-line [164].  The group found that viral load or CD4 cell count monitoring had 
modest benefits compared with clinical monitoring alone [164].  The model manages to incorporate 
many underlying processes of HIV-treatment and disease success, and consequently one possible 
disadvantage is its complexity.  Due to the complexity of the model extensive informal manual fitting 
procedures were carried out on the model, meaning that not the entire parameter space had been 
investigated [268].   
In 2012 Smit and colleagues from Imperial College and the Netherlands constructed a 
deterministic model of HIV-infection and treatment in the Netherlands using ATHENA cohort data.  
The model simulated how new drug regimens that had either an improved virological failure profile or 
toxicity profile could impact on the clinical outcome of patients on treatment.  The group found that 
new regimens with better tolerability could have the greatest impact on patient outcomes and would as 
simplify management of HIV-infection in the Netherlands [269].   
All of these models of HIV-treatment and/or clinical care and other aim to answer a specific 
set of questions.  The models differ however, in their approaches in many aspects.  Their structure can 
differ from stochastic to deterministic, for example, and their focus can vary from focusing on 
different setting, modelling various interventions or making assumptions about epidemic dynamics.   
This Chapter has provided the background information on the research presented in this 
thesis.  HIV-treatment was be discussed in detail, including drug classes, targets and mechanisms, 
clinical management of patients, and the changes in treatment guidelines since 1996.  The Dutch 
national ATHENA cohort, which is the main dataset used in this PhD, were described, together with 
the epidemic in the Netherlands.  The potential effects of a demographic shift towards an ageing 
population were be explained.  Finally, examples of mathematical models of treatment were presented 
and discussed.  In the below section the key questions central to this thesis will be presented in detail 
as well as the layout of the thesis, with a description of the organisation of the chapter.   
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1.10 Outline and Structure of Thesis 
1.10.1 Key Research Questions 
The overall aims of this thesis are to evaluate the progress achieved in clinical care since the 
introduction of cART in 1996 using data-analysis and to evaluate future challenges posed by an 
ageing HIV-population using a mathematical modelling approach.  The work will focus on the 
Netherlands as a case study.  It has a large national observational cohort called ATHENA that 
includes all HIV-patients followed in 26 designated HIV treatment centres in the Netherlands since 
1996.  The work was guided by the following key questions which fall into the following two broad 
categories: 
 
(i) Evaluating progress 
 
a. What were the commonly used cART regimens between 1996 and 2010 and how 
have these regimens changed over this period, 
 
b. What effects have these changes had on short-term clinical effects, namely mortality, 
CD4 recovery, VL suppression and switching of cART regimens.   
 
 These questions are addressed in Chapter 2.   
  
(ii) Future challenges 
 
a. To develop a model to simulate the impact of the ageing HIV-population 
 
b. To predicted the age-structure, burden of age-related co-morbidity and polypharmacy 
over the next 20 years 
 
c. To evaluate the impact of interventions targeting the primary prevention of key co-
morbid diseases 
 
 These questions are addressed in Chapter 3, Chapter 4 and Chapter 5.   
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1.10.2 Organisation of Chapters 
 
Chapter 2: An analysis of the progress in HIV-treatment is presented in Chapter 2 with an in-depth 
review of changes in first-line, second-line and third-line cART since 1996 and an evaluation of the 
effect of these changes on patient clinical outcomes using the Dutch ATHENA national observational 
cohort.   
 
Chapter 3: The development and construction of an individual-based model of an ageing HIV-
population in the Netherlands is described in Chapter 3.  The first part of the chapter presents the 
model structure and parameters and the second half discusses a number of model checks and 
calibration.   
 
Chapter 4: In Chapter 4 this model is used to predict the future age structure of HIV-patients in the 
Netherlands, quantify the future burden of co-morbidity and polypharmacy and describe the main 
types of co-morbidity and co-medication by 2030.  Finally, the model is used to quantify the burden 
of drug-drug interactions and long-term restrictions of recommended cART regimens.   
 
Chapter 5: Chapter 5 uses an individual-based model constructed in Chapter 3 to compare the impact 
of two interventions for the primary prevention of CVD in an ageing HIV-population to standard care.  
More specifically it evaluates the impact of a smoking cessation programme and the prescription of a 
polypill for cardiovascular disease to all patients aged 55 or 45 years old on the burden of co-
morbidity, the number of drug-drug interactions, the number of disability-adjusted life years averted, 
and average cost per DALY averted as a measure of programme success and cost comparison.   
 
Chapter 6: The findings of the thesis are summarized in Chapter 6.  The limitations of the work are 
discussed, as well as the public health implications.  Finally the directions for future work are outlined 
in Chapter 6.   
 
Appendices: Appendix A contains a list of publications and presentations from the author.  Appendix 
B provides additional information for the work carried out in Chapter 2.  Appendix C and D contain 
additional results for Chapter 2 and 4, respectively.   
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Chapter 2 - Reporting Progress: cART 
Regimens and Short-Term Clinical Outcomes 
in the Netherlands between 1996 and 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A modified version of this chapter has been published: Smit M; Smit C; Geerlings S, Gras L, 
Brinkman K, Hallett TB, De Wolf F.  Changes in first-line cART regimens and short-term clinical 
outcome between 1996 and 2010 in the Netherlands.  PLoS One 2013;8(9): e76071. 
doi:10.1371/journal.pone.0076071.   
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Abstract 
 
Background Since the introduction of cART in 1996, treatment of HIV-infected patients has changed 
considerably.   
 
Aims The aims of this chapter are to document progress in HIV-treatment in the Netherlands since 
1996 by reviewing changing patterns of cART use and relating those to trends in short-term patient 
clinical outcomes between 1996 and 2010.   
 
Method Data from 10,278 patients in the Dutch ATHENA national observational cohort between 
1996 and 2010 were analysed. The annual number of patients starting a type of first-, second-, and 
third-line regimen was quantified. Regimen types were classified by NRTI backbone: i) lamivudine 
(3TC) and stavudine (d4T); ii) 3TC and zidovudine (AZT); and iii) Tenofovir (TDF) with 3TC or 
emtricitabine (FTC).  The analysis was further stratified into regimens combined with either: i) 
NNRTI; ii) non-boosted PI; or iii) (ritonavir)-boosted-PIs.  Trends in the following outcomes were 
described, i) recovery of 150 CD4 cells/mm
3 
within 12 months of starting cART, ii) achieving viral 
load (VL) suppression ≤ 1,000 copies/ml within 12 months of starting cART, iii) switching from first-
line to second-line regimen within three years of starting treatment, and iv) all-cause mortality rate per 
100 person-years within three years of starting treatment.   
 
Results Between 1996 and 2010, first-line regimens changed from 3TC/AZT-based or d4T/3TC-
based regimens with PIs to TDF/3TC or TDF/FTC with NNRTIs.  Mortality rates did not change 
significantly over time.  CD4 recovery on first-line and third-line and VL suppression on all cART 
lines improved over time.  While the incidence of switching due to virological failure and toxicity 
more than halved between 1996 and 2010, toxicity remains the main reason patients in clinical care in 
the Netherlands switch cART-line.  These improvements in patient clinical outcomes appear to be 
related to the use of new regimens rather than the improvements in clinical care.   
 
Conclusion The use of cART regimens in the Netherlands closely follows changes in guidelines, to 
the benefit of patients.  While there was no significant improvement in mortality, newer drugs with 
better tolerability and simpler dosing resulted in improved immunological and virological recovery 
and reduced incidence of switching due to toxicity and virological failure.   
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2.1. Background 
Combination therapy was first introduced more than 15 years ago.  Since 1996, over twenty new 
antiretroviral drugs have been licensed for the treatment of HIV-infection [37].  A number of clinical 
trials and studies have compared specific antiretroviral drugs or regimen types with respect to selected 
clinical outcomes [87,88,90,92,95,96,109,112,114–116].  Early cART regimens were often 
complicated, consisting of multiple drugs with different administration frequencies [122,270].  In the 
last several years, more convenient dosing and improved tolerability have improved the treatment of 
HIV-infected patients [6].  The introduction of fixed-dose combination tablets, such as Combivir 
(AZT/3TC) in 1997 [271] has simplified dosing requirements, and once-daily combination tablets like 
Truvada (TDF/FTC) in 2004 [272] or Atripla (TDF/FTC/EFV) in 2006 [273], have reduced daily pill 
burden and improved tolerability [84,87,88,95,114–116].  However, it remains unclear how the 
improved efficacy of new antiretroviral drugs reported in trials has translated to population-level 
effectiveness in general clinical care.   
Evaluating how clinical care of HIV-treatment has changed over time, and how the changes in 
ARVs have affected patient clinical outcomes is vital to record progress and identify treatment gaps 
and future challenges.  A non-selective database that collects data from all HIV-infected patients in 
clinical care in the Netherlands provides a unique opportunity to record the progress of cART since 
1996 with reference to a variety of clinical and non-clinical markers.  The aims of this chapter are to 
use this dataset to document progress in HIV-treatment by, i) reviewing the changing patterns of first-
line cART regimens between 1996 and 2010 in the Netherlands, ii) to describe time trends in a variety 
of short-term clinical and non-clinical markers and iii) to relate new regimens to trends in short-term 
patient clinical outcomes as a measure of population-level effectiveness.   
 
 
2.2. Method 
2.2.1 Data and Patient Population 
ATHENA is a national observational cohort that includes all HIV-patients followed in 26 designated 
HIV-treatment centres in the Netherlands since 1996.  The design of this cohort has been described 
previously (see Section 1.6 The National Dutch ATHENA Cohort, page 39 and SHM Monitoring 
Report 2008 [274]).  Clinical, biological and immunological data on HIV-infected patients are 
collected upon entry and at each follow-up visit.  Anonymised patient data are available on request 
and for scientific research purposes only (Ref: www.hiv-monitoring.nl).   
Patients from the ATHENA cohort were included in this analysis if they were aged 18 or 
over, infected with HIV-1, and diagnosed with HIV after 1
st
 January 1996.  All patients included in 
this analysis were antiretroviral drug-naïve prior to entering the study and started cART during 
follow-up.  Women known to have been pregnant during follow-up were excluded entirely, due to the 
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treatment changes that occur during pregnancy.  Data was analysed up to and including 31
st
 December 
2010.  The number of patients in the analysis was 10,278.  ` 
Combination therapy was defined as regimens containing three or more antiretroviral drugs.  
Regimen types were classified by NRTI backbone: i) lamivudine (3TC) and stavudine (d4T); ii) 3TC 
and zidovudine (AZT); and iii) TDF with 3TC or emtricitabine (FTC).  The analysis was further 
stratified into regimens combined with either: i) NNRTI; ii) PI; or iii) (ritonavir)-boosted-PIs.  
Regimens other than those described above were classified as ‘other’ in further analysis.  The choice 
of regimen classification reflects the main regimen types used between 1996 and 2010 in the 
Netherlands.   
Clinical outcome was measured using: i) hazard rate (HR) of recovering ≥150 CD4 cells/mm3 
within 12 months of starting cART; ii) HR of achieving viral load (VL) suppression ≤ 1,000 copies/ml 
within 12 months of starting cART; iii) the incidence of switching from first-line to second-line 
regimen within three years of starting treatment; and iv) all-cause mortality rate per 100 person-years 
within three years of starting treatment.  A threshold of 1,000 copies/ml for VL suppression was 
chosen to allow for comparison across the years, due to the changing detection threshold for VL 
suppression, from 1,000 copies/ml in 1996 to 20 copies/ml in 2010.   
A switch was defined as a change in regimen that included at least one new antiretroviral 
drug.  Reasons for switching were classified as: i) toxicity, ii) simplification/new medication 
becoming available, iii) virological failure, and iv) other reasons [269].  ‘Toxicity’ is defined as the 
need to change regimen due to side effects.  ‘Simplification/new medication becomes available’ is 
defined as patients switching regimen for a simpler cART regimen, for example a once-daily regimen, 
or because a new cART regimen has become available, in the absence of a clinical need for a switch.  
‘Virological failure’ refers to a switch due to poor virological response, including resistance.  ‘Other 
reasons’ included pharmacological reasons, caution, ‘other’ and ‘unknown’ reasons as classified by 
the ATHENA cohort.  ‘Pharmacologic reason’ refers to an interaction with co-medication/other drug 
and ‘caution’ refers to the situation where patients are starting an additional treatment, for example 
chemotherapy, and the physician decides to stop or change a regimen as the combination of side 
effects may be too severe.  Apart from toxicity, simplification/new medication becoming available, 
virological failure, and other reasons, there were other drug-related reasons for switching treatment 
(compliance (0.66%), and contra-indication (0.04%)), which were excluded as they accounted for less 
than 1% of switches.  Date and reasons for switching are recorded by physicians at the follow-up visit 
at which a patient is prescribed a change in cART regimen.   
The detailed analysis into toxicity classified toxicity into short-term, medium-term and long-
term toxicity, where short-term refers to toxicity that occurs within the first year after the start of 
treatment, medium-term refers to toxicity that occurs one to two years after starting treatment and 
long-term refers to toxicity occurring two to three years after cART initiation.  Side effects that 
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caused a change in regimens are recorded by treating physicians.  The list of side effects recorded by 
the ATHENA cohort is presented in Appendix B.   
 
 
2.2.2 Statistical Analysis 
Time-dependent Cox proportional hazard model and Kaplan-Meier curves were used as in a time-to-
event analysis.  Cox regression analyses were carried out on all four clinical outcomes i-iv defined 
above.  When analysing switching, Cox analysis was limited to virological failure and toxicity.  
Follow-up time was defined as months from the start of treatment until the end date of follow-up time, 
closure of the database (31
st
 December 2010), or the outcome of interest, whichever occurred first.  
Follow-up was divided into three time periods, 1996-2000, 2001-2005, and 2006-2010, designated as 
the early cART, medium cART and late cART periods.  Mortality was treated as a censored event in 
analyses in which mortality was not the outcome of interest.  Wald statistics were used to determine 
significance of this analysis using a significance level of 0.05 throughout.   
Cox Proportional Hazard analysis were adjusted by sex, age (divided into 5-year 
categories,18-22, 23-27 years, etc., the latest category being 78-82 years), CD4 and VL at the start of 
treatment, route of HIV transmission [i) men-who-have-sex-with-men (MSM), ii) heterosexual, iii) 
injecting drug use (IDU), and iv) vertical infection, blood infusion, or unknown], and region of origin.  
Categories of regions of origin were i) Netherlands, ii) Europe (excluding the Netherlands), iii) Sub-
Saharan Africa, and iv) other. CD4 count categories were <200, 201-350, 351-500, and 
>501cells/mm
3
, and VL categories were <100,000, 100,000-1,000,000, and >1,000,000 copies/ml.  
Analysis of mortality was further controlled for smoking and cumulative number of AIDS-defining 
events, as a proxy for lifestyle and advanced disease.  Dutch-born MSM with a CD4 count between 
350 and 500 cells/mm
3 
and RNA below 100,000 copies/ml when starting cART were used as the 
reference categories in the Cox model.  The reference regimen type was TDF/3TC or TDF/FTC with a 
NNRTI.  These references were chosen, as this constitutes the majority of patients in the cohort.  The 
CD4 count range reflects current European guidelines for treatment initiation [60].  All data-analyses 
were carried out in SAS v.9.3 (SAS Institute, Cary, North Carolina, USA).   
 
 
2.2.3 Aims 
The aim of this research chapter is to review changes in first-, second-, and third-line cART regimens 
between 1996 and 2010 in the Netherlands and evaluate their effect on patient clinical outcomes using 
the Dutch ATHENA national observational cohort.   
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More specifically the aims are to review: 
a) What the commonly used cART regimens were between 1996 and 2010 and how these 
regimens changed over this period, 
b) What the effects of these changes were on short-term patient clinical outcome, namely: 
i) Hazard rate (HR) of recovering ≥150 CD4 cells/mm3 within 12 months of starting cART,  
ii) HR of achieving VL suppression ≤1,000 copies/ml within 12 months of starting cART, 
iii) The time-to-event of switching from first-line to second-line, second-line to third-line 
and third-line to fourth-line regimen within three years of starting treatment, and  
iv) All-cause mortality per 100 person-years within three years of starting treatment.   
 
 
2.3. Results 
2.3.1 Population Description 
Baseline demographic characteristics of the patients are summarized in Table 2.1.  Overall, of the 
10,278 patients 84% were male, 59% were MSM, and 58% were Dutch-born.  44% of patients had 
spent a cumulative time of five to ten years on cART, and the mean age was 40 at the start of 
treatment. 391 patients died within three years of starting treatment.   
The primary route of HIV acquisition among the male patients was homosexual contact 
(70%) or heterosexual contact (21%).  In female patients, acquisition occurred primarily via 
heterosexual contact (91%), with only a small fraction of patients of both sexes acquiring HIV 
through other/unknown routes (7%), and injecting drug use (2%).  The majority of male patients were 
Dutch-born (64%), while female patients were frequently from Sub-Saharan Africa (44%).  Trends in 
region of origin and route of acquisition were relatively constant over the entire period (Table 2.1).   
 
 
2.3.2 Analysis of cART Regimens between 1996 and 2010 
2.3.2.1 First-line cART Regimens between 1996 and 2010 
The first-line cART regimen types used between 1996 and 2010 are presented in Figure 2.1A.  The 
most frequently prescribed first-line cART regimen was based on a backbone of TDF/FTC or 
TDF/3TC, with half the patients (n=4,949, 48%) during this period receiving a first-line cART 
regimen containing this backbone.  TDF/3TC or TDF/FTC was mostly combined with NNRTIs 
(n=3,882, 78%), or a boosted-PI (18%).  Due to the low number of patients prescribed first-line 
TDF/FTC or TDF/3TC with a non-boosted PI, these patients were excluded from further analyses.   
The second most prescribed first-line regimen was based on a backbone of 3TC/AZT, with 
more than a third of patients receiving first-line cART based on this backbone (n=3,392, 33%).  
3TC/AZT was most frequently combined with a boosted-PI (n=1,272, 38%) or a NNRTI (n=1,175, 
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35%).  6% of the patients received first-line regimens based on either 3TC/d4T, most commonly 
combined with boosted-PIs (n=248, 39%) or PIs (n=225, 35%).  16.4% of patients started on regimen 
types with other backbones or third components.   
Between 1996 and 2010, the annual number of patients who were started on treatment 
increased.  In 1996, 156 patients (2% of all patients) were started on therapy per year, increasing to 
around 1,000 patients (10% of all patients) per year after 2007.  Overall during this period, first-line 
therapy evolved considerably over time (Figure 2.1B and C).   
 
 
Table 2.1. Demographic and clinical characteristics of the 10,278 patients by period of treatment 
initiation.   
Source: Smit et al 2013 [275].   
 1996-2000 
(N=1,997, 19%) 
2001-2005 
(N=3,190, 31%) 
2006-2010 
(N=5,091, 50%) 
Total 
(N=10,278) 
Sex 
Men 
Women 
 
1,721 
276 
 
86% 
14% 
 
2,543 
647 
 
80% 
20% 
 
4,322 
769 
 
85% 
15% 
 
8,586 
1,692 
 
84% 
16% 
Mean age (years) at treatment 
initiation 
 
39 (IQR, 32-44) 
 
39 (IQR, 33-46) 
 
41 (IQR, 34-48) 
 
40 (IQR, 33-47) 
Transmission route 
MSM 
Heterosexual 
IDU 
Other/unknown 
 
1,186 
605 
70 
136 
 
59% 
30% 
4% 
7% 
 
1,575 
1,247 
75 
293 
 
49% 
39% 
2% 
9% 
 
3,279 
1,448 
63 
301 
 
64% 
28% 
1% 
6% 
 
6,040 
3,300 
208 
730 
 
59% 
32% 
25% 
7% 
Region of origin 
The Netherlands 
Sub-Saharan Africa 
Europe 
Other 
 
1,188 
264 
188 
357 
 
59% 
13% 
9% 
18% 
 
1,643 
717 
230 
600 
 
52% 
22% 
7% 
19% 
 
3,136 
647 
437 
871 
 
62% 
13% 
9% 
17% 
 
5,967 
1,628 
855 
1,828 
 
58% 
16% 
8% 
18% 
Cumulative years on treatment 
<1 
1-2 
3-4 
5-10 
>10 
 
29 
41 
29 
392 
1,506 
 
1% 
2% 
1% 
20% 
75% 
 
76 
51 
43 
2,774 
246 
 
2% 
2% 
1% 
87% 
8% 
 
513 
1,495 
1,633 
1,331 
119 
 
10% 
29% 
32% 
26% 
2% 
 
618 
1,587 
1,705 
4,497 
1,871 
 
6% 
15% 
17% 
44% 
18% 
Number of deaths within three 
years of treatment initiation 
 
75 
 
4% 
 
154 
 
5% 
 
162 
 
3% 
 
391 
 
4% 
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From 1996 to 2004 the majority of patients were started on a backbone of 3TC/AZT, 
accounting for 52-82% of regimen types yearly.  After 2001, the use of 3TC/AZT in first-line cART 
declined steadily, accounting for less than 10% of NRTI backbones from 2008.  The use of 3TC/d4T 
ranged from 7% to 36% between 1996 and 2002. From 2003 onwards, 3TC/d4T was used in less than 
10% of new prescriptions.  Other backbones were most commonly prescribed between 2001 and 
2004, accounting for up to 35.3% of first-line regimes.  Since the introduction of TDF in Europe in 
2001, its use as a first-line regimen NRTI backbone increased steadily.  After 2004, TDF/3TC or 
TDF/FTC-based regimens constituted the majority of NRTI-backbones for first-line therapy in the 
Netherlands accounting for over 85% of first-line backbones from 2007 on.   
The third component that formed the combination therapy of first-line has also changed 
between 1996 and 2010 (Figure 2.1C).  The most frequently used third component from 1996 to 2000 
was a PI (45-81% non-boosted PI, 9-48% boosted-PI), and from 2000-2010 was a NNRTI (45-81%).   
 
 
A.  
B. C.  
Figure 2.1. A. First-line cART regimens commonly prescribed in the Netherlands between 1996 and 2010.  
Incidence measure of patients starting on first-line regimens by B. NRTI backbone and C. third 
component between 1996 and 2010.   
Source: Smit et al 2013 [275].   
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2.3.2.2 Second-line and Third-line cART Regimens between 1996 and 2010 
The overall pattern observed in second-line and third-line regimens is comparable to that of first-line 
(Figure 2.2A and B).  Around a third of patients switched to a second-line and third-line consisting of 
TDF/FTC or TDF/3TC-based regimens (n=2,255, 33% for second-line and n=1,699, 35% for third-
line), the majority of which received a regimen including a NNRTI (n=1,491, 66% for second-line 
and n=1,095, 64% for third-line) or a boosted-PI (n=602, 27% for second-line and n=508, 30% for 
third-line).  Due to the low number of patients prescribed second and third-line TDF/FTC or 
TDF/3TC with a non-boosted PI, these patients were excluded from future analysis.   
As with first-line, 3TC/AZT-based regimens were the second most common regimen 
(n=1,301, 19% for second-line and n=983, 20% for third-line), and were most frequently combined 
with a NNRTI (n=568, 44% for second-line and n=440, 45% for third-line), or a boosted-PI (n=404, 
31% and n=293, 30%).  Equally, few patients were prescribed second-line or third-line regimens 
containing 3TC/d4T (n=411, 6% and n=323, 7%).  One observed difference compared to first-line 
was an increased use of ‘other combinations’ in second-line and third-line (40% in second-line and 
37% in third-line versus 6% in first-line), based on regimens containing backbones other than 
3TC/d4T, 3TC/AZT or TDF/FTC or TDF/3TC.  This may in part be driven by the reason for 
switching first-line including resistance contra-indication and caution.   
Changes in second-line and third-line cART over time were similar to those observed with 
first-line (Figure 2.2C and D).  As with first-line, 3TC/d4T and 3TC/AZT were most commonly 
prescribed in the years following the introduction of cART in 1996.  From 2006 TDF/FTC or 
TDF/3TC-based regimens became the most commonly prescribed backbone among the patients in the 
Netherlands.   
The third component that formed the combination therapy of second-line and third-line has 
also changed between 1996 and 2010 (Figure 2.2E and F).  As with first-line regimens, the use of a 
non-boosted PI was most common in the years following the introduction of cART.  As with first-
line, the use of boosted-PIs was relatively steady throughout this period.  A difference compared to 
first-line is the increase in ‘other’ regimen types, containing ‘other’ backbones or third components.  
32.3-54.5% of second-line and 22.2-50.5% of third-line consisted of regimens based on ‘other’ 
backbones, and 3.3-21.2% of second-line and 0.0-12.2% of third-line consist of third components 
other than non-boosted PI, boosted-PI or NNRTI, higher compared to first-line.  As mentioned above, 
this may in part be driven by the reasons patients’ switched from first-line.   
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A.       B.  
       
 
 
C.        D. 
     
 
E.        F. 
       
Figure 2.2. A. Second-line cART regimens commonly used in the Netherlands between 1996 and 2010.  B. 
Third-line cART regimens commonly used in the Netherlands between 1996 and 2010.  Incidence 
measure of the backbones used by patients starting on C. second-line regimens and D. third-line 
regimens.  Incidence measure of the third cART component used by patients starting on E. second-line 
regimens and F. third-line regimens.   
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2.3.3 Analysis of Clinical Effects cART Regimens 
2.3.3.1 Mortality  
The Kaplan-Meier estimate of the percentage of deaths at three years was 6.4% (95% CI 5.9-6.9).  
The short-term all-cause mortality rate of patients on cART between 1996 and 2010 is presented in 
Figure 2.3.  Hazards for mortality did not differ significantly between 1996 and 2010 (Table 2.2) (p-
value=0.44 for 1996-2000 and p-value=0.16 for 2001-2005 compared to 2006-2010).   
All-cause mortality was significantly increased in older patients (HR=1.27 per 5-year increase 
in age, 95% CI 1.21-1.33, p-value<.0001), in patients who had acquired HIV via injecting drug use 
compared to MSM (HR=2.90, 95%CI 1.81-4.64, p-value<0.0001), in smokers (HR=1.70, 95% CI 
1.11-2.60, p-value=0.01), and with increasing cumulative AIDS-defining events (p-value<0.0001) 
(Table 2.2).  Patients on regimens of TDF/3TC or TDF/FTC with boosted-PIs may experience 
increased risk of mortality compared to patients on TDF/3TC or TDF/FTC with NNRTIs (HR=1.49, 
95% CI 1.03-2.15, p-value=0.04) (Table 2.2).    
 
 
 
Figure 2.3.  Mortality rate per 100 person-years.  The black dotted line is the mortality rate; the grey 
shaded area represents the 95% confidence-intervals.   
Source: Smit et al 2013 [275].   
 
2.3.3.2 CD4 Recovery 
Between 1996 and 2010 70.4% (95% CI 69.5-71.3) patients reached a CD4 increase of ≥150 
cells/mm
3
 within 12 months of treatment initiation.  The probability of an increase in CD4 counts of 
≥150 cells/mm3 or more following treatment initiation was significantly lower in 2001-2005 
compared to 2006-2010 (HR=0.94, 95% CI 0.88-0.99, p-value=0.03) (Figure 2.4A, Appendix C Table 
1).  The difference between periods was not significant when models were adjusted for cART regimen 
(p-value=0.46).   
 
 
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
M
o
rt
a
li
ty
 p
e
r 
1
0
0
 p
e
rs
o
n
-y
e
a
rs
 
Chapter 2 – Reporting Progress 
64 
Table 2.2.  Adjusted hazard ratio (95% confidence intervals) of 3-year mortality.   
Source: Smit et al 2013 [275].   
 
Variables Model 1: Calendar Time Model 2: Calendar Time and Regimen Type 
 Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 0.88 (0.63-1.21) 0.42 0.84 (0.54-1.31) 0.44 
2001-2005 1.25 (1.00-1.57) 0.051 1.22 (0.92-1.61) 0.16 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 1.27 (1.21-1.33) <.0001 1.27 (1.21-1.33) <.0001 
Sex     
Male [Reference]  [Reference]  
Female 0.85 (0.61-1.18) 0.33 0.85 (0.61-1.18) 0.32 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 0.75 (0.49-1.15) 0.19 0.74 (0.48-1.13) 0.16 
Sub-Saharan Africa 0.62 (0.41-0.92) 0.02 0.62 (0.41-0.92) 0.02 
Other 0.77 (0.57-1.04) 0.08 0.77 (0.57-1.04) 0.08 
Route of transmission     
Heterosexual 1.14 (0.86-1.52) 0.36 1.14 (0.86-1.52) 0.36 
MSM [Reference]  [Reference]  
Injecting Drug Use 2.96 (1.85-4.74) <.0001 2.90 (1.81-4.64) <.0001 
Other 1.46 (1.05-2.02) 0.02 1.44 (1.04-2.00) 0.0281 
Smoking     
Never Smoked [Reference]  [Reference}  
Ever smoke 1.69 (1.11-2.59) 0.02 1.70 (1.11-2.60) 0.01 
Unknown 3.57 (2.37-5.39) <.0001 3.57 (2.37-5.39) <.0001 
Clinical     
CD4 cell count at start of cART     
CD4 ≤200  1.07 (0.67-1.18) 0.77 1.06 (0.67-1.70) 0.80 
CD4 201-350  0.86 (0.53-1.41) 0.55 0.87 (0.53-1.43) 0.58 
CD4 351-500  [Reference]  [Reference]  
CD4 >500 0.50 (0.19-1.32)  0.16 0.48 (0.18-1.29) 0.15 
RNA at start of cART     
RNA ≤100 000 [Reference]  [Reference]  
RNA 100 000-1 000 000 0.91 (0.71-1.18) 0.49 0.92 (0.71-1.19) 0.51 
RNA >1 000 000  0.89 (0.56-1.40) 0.60 0.85 (0.54-1.35) 0.49 
Cumulative AIDS-defining event     
No events [Reference]  [Reference]  
1 event 3.59 (2.72-4.75) <.0001 3.53 (2.67-4.67) <.0001 
2 events 6.19 (4.53-8.46) <.0001 6.05 (4.42-8.29) <.0001 
3 events 10.40 (7.04-15.37) <.0001 10.14 (6.85-15.02) <.0001 
4 events 8.95 (5.19-15.46) <.0001 8.78 (5.07-15.18) <.0001 
5 events 24.81 (11.81-52.12) <.0001 24.88 (11.83-52.32) <.0001 
6 events 22.32 (6.92-71.99) <.0001 21.15 (6.54-68.41) <.0001 
7 events 49.03 (11.84-203.07) <.0001 50.73 (12.20-210.95) <.0001 
cART Type     
3TC/d4T + PI   1.41 (0.72-2.76) 0.32 
3TC/d4T + Boosted-PI   0.94 (0.46-1.92) 0.86 
3TC/d4T + NNRTI   1.49 (0.72-3.11) 0.28 
3TC/AZT+ PI   1.18 (0.70-1.98) 0.54 
3TC/AZT + Boosted-PI   1.16 (0.80-1.68) 0.43 
3TC/AZT + NNRTI   1.26 (0.84-1.89) 0.27 
TDF/FTC or TDF/3TC + Boosted-PI   1.49 (1.03-2.15) 0.04 
TDF/FTC or TDF/3TC + NNRTI   [Reference]  
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The time to CD4 recovery of ≥150 cells/mm3 on first-line was improved in women (HR=1.26, 
95% CI 1.14-1.38, p-value<0.0001 for women), and worse in older patients (HR=0.97 per 5-year 
increase in age, 95% CI 0.96-0.99, p-value=0.0001), in patients from Sub-Saharan Africa compared to 
Dutch-born (HR=0.71, 95% CI 0.64-0.78, p-value<0.0001), and patients who had acquired HIV 
through heterosexual contact or injecting drug use compared to MSM (HR=0.80, 95% CI 0.74-0.87, 
p-value<0.0001 and HR=0.51, 95% CI 0.39-0.67, p-value<0.0001, respectively) (Appendix C Table 
1).  CD4 recovery was also worse in patients who had a CD4 count below 200 cell/mm
3
 or above 500 
cells/mm
3
 at the start of treatment (HR=0.84, 95% CI 0.77-0.92, p-value=0.0003) and in patients with 
VL below 100 000 copies/ml at the start of treatment (HR=0.76, 95% CI 0.65-0.89, p-value=0.0004).  
Patients on regimens of 3TC/d4T or TDF/3TC or TDF/FTC with boosted-PIs may experience 
improved rates of immunological recovery, compared to patients on TDF/3TC or TDF/FTC with 
NNRTIs (HR=1.30, 95% CI 1.08-1.57, p-value=0.01 and HR=1.18, 95% CI 1.07-1.29, p-
value=0.0006) (Appendix C Table 1).   
Time to reaching CD4 increase of ≥150 cells/mm3 was not found to have changed 
significantly between 1996 and 2010 amongst patients on second-line (HR=1.08, 95% CI 0.97-1.21, 
p-value=0.16 and 0.98, 95% CI 0.89-1.07, p-value=0.6) (Figure 2.4C, Appendix C Table 2).  
However, time to CD4 recovery of ≥150 cells/mm3 following initiation of third-line was significantly 
lower in 2006-2010 compared to 1996-2000 (HR=1.17, 95% CI 1.02-1.35, p-value=0.02) (Figure 
2.4E, Appendix C Table 3).  For both second-line and third-line treatment the difference between 
periods was not significant when models were adjusted for cART regimen.  As with first-line cART 
patients on second-line and third-line regimens of 3TC/d4T or TDF/3TC or TDF/FTC with boosted-
PIs may experience faster immunological recovery compared to patients on TDF/3TC or TDF/FTC 
with NNRTIs (HR=1.43, 95% CI 1.07-1.92, p-value=0.02 and HR=1.41, 95% CI 1.21-1.65, p-
value<0.0001) (Appendix C Table 2 and Table 3).   
 
2.3.3.3 Viral Load Suppression 
The Kaplan-Meier estimate of the percentage of patients achieving VL suppression <1,000 copies/ml 
by 12 months was 94.7% (95% CI 94.2-95.1).  VL suppression following the start of cART improved 
in recent years (HR=0.79, 95% CI 0.75-0.84, p-value<0.0001 for 1996-2000 and HR=0.90, 95% CI 
0.86-0.95, p-value<0.0001 for 2001-2005) (Figure 2.4B and Appendix C Table 4).  The difference 
between periods became non-significant when models were adjusted for cART regimen type (p-
value=0.07 and p-value=0.12).   
In adjusted analysis, VL suppression on first-line was worse in non-Dutch, European patients 
(HR=0.90, 95% CI 0.82-0.98, p-value=0.02), for those who had acquired HIV either via heterosexual 
contact or injecting drug use (HR=0.88, 95% CI 0.82-0.95, p-value=0.0004 and HR=0.78, 95% CI 
0.64-0.94, p-value=0.01), and in patients with a VL above 100,000 copies/ml at the start of treatment 
(p-value<0.0001).  Regimens of 3TC/AZT with non-boosted or boosted-PIs, and TDF/3TC or 
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TDF/FTC with boosted-PIs may be associated with worse rates of VL suppression (HR=0.71, 95%CI 
0.63-0.81, p-value<0.0001, HR=0.82, 95% CI 0.75-0.89, p-value<.0001, and HR=0.87, 95% CI 0.81-
0.95, p-value=.001) (Appendix C Table 4).   
Rates of virological suppression following the start of cART were also improved in recent 
years on second-line and third-line cART (Figure 2.4D and F Appendix C Table 5 and Table 6).  
Amongst patients on second-line, VL suppression to <1,000 copies/ml was improved in 2006-2010 
compared to 1996-2005 (HR=0.72, 95% CI 0.63-0.84, p-value<0.0001 for 1996-2000 and HR=0.84, 
95% CI 0.74-0.95, p-value=0.004 for 2001-2005).  For patients on third-line cART, VL suppression 
was improved in 2006-2010 compared to 2001-2005 (HR=0.86, 95% CI 0.75-0.99, p-value=0.04).  
The difference between periods became non-significant when models were adjusted for cART 
regimen type (p-value=0.95 and p-value=0.61 for second-line and p-value=0.61 for third-line).  As 
with first-line, patients on a second-line or third-line regimen of 3TC/AZT with non-boosted or 
boosted-PIs, and TDF/3TC or TDF/FTC with boosted-PIs may be associated with worse rates of VL 
suppression (HR=0.50, 95%CI 0.34-0.74, p-value=0.0004, HR=0.76, 95%CI 0.59-0.98, p-value=0.03, 
and HR=0.77, 95% CI 0.62-0.95, p-value=0.02 for second-line and HR=0.50, 95% CI 0.34-0.74, p-
value=0.0004, HR=0.76, 95% CI 0.59-0.98, p-value=0.03, and HR=0.77, 95% CI 0.62-0.95, p-
value=0.02) (Appendix C Table 5 and Table 6).   
 
2.3.3.4 Incidence of Switching cART 
During follow-up, 4,481 patients (44%) switched to second-line treatment.  The short-term incidence 
of switching (within three years of starting treatment), due to virological failure or toxicity, from first-
line regimens has declined between 1996 and 2010 (Figure 2.5A), suggesting that the duration 
patients spend on a cART-line before switching regimens has improved considerably over time.  The 
incidence of switching due to virological failure, toxicity, and ‘other’ reasons between 2006 and 2010 
was approximately half that of 1996 to 2000.  The incidence of switching due to virological failure 
decreased from 4.7 events (95% CI 3.8-5.8) in 1996-2000 to 2.3 events per 100 person-years (95% CI 
2.0-2.7) in 2006-2010.  The incidence of toxicity-related switching decreased from 26.3 events (95% 
CI 24.1-28.7) in 1996-2000 to 13.5 events per 100 person-years (95% CI 12.7-14.4) in 2006-2010.  In 
contrast, the incidence of switching due to simplification/new medication becoming available 
increased between 1996 and 2010 from 2.2 events per 100 person-years (95% CI 1.6-2.95) in 1996-
2000 to 5.26 events per 100 person-years (95% CI 4.75-5.81) in 2006-2010.   
In models adjusted for cART regimen type, differences between time periods were not 
significant (Table 2.3 and Table 2.4).  The only exception was the increased hazard of switching due 
to virological failure within three years of starting cART amongst patient who started first-line cART 
in 2001-2005 compared to 2006-2010, which could partly, but not fully, be attributed to the newer 
regimens (Table 2.4).   
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A.              B.   
 
C.           D.  
 
E.            F.  
Figure 2.4. Unadjusted Kaplan-Meier curves for rates of CD4 recovery of ≥150 cells/mm3 by 12 months 
for A. first-line, C. second-line and E. third-line cART and rates of VL suppression to below 1,000 
copies/ml by 12 months for B. first-line, D. second-line, and F. third-line cART.   
Source for A and B: Smit et al 2013 [275].   
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Older patients and women had an increased hazard of toxicity-driven switch, while patients 
who acquired HIV via heterosexual sex had a reduced hazard of toxicity-driven switch compared to 
MSM.  Patients on backbones of 3TC with either d4T or AZT had an increased risk of toxicity-driven 
switch compared to patients on TDF/3TC or TDF/FTC with boosted-PIs.  The incidence of switching 
due to virological failure was higher in patients from Sub-Saharan Africa, and with a CD4 count 
below 200 cells/mm
3
 and VL above 100,000 copies/ml at the start of treatment.  Patients on regimens 
of 3TC/d4T or 3TC/AZT with unboosted-PIs had an increased risk of virological failure, while 
patients on 3TC/AZT or TDF/3TC or TDF/FTC with boosted-PIs had a decreased risk of virological 
failure.   
 
 
 
A.  
 
B.           C.  
 
Figure 2.5.  Rate of switching per 100 person-years for A. first-line cART, B. second-line and C. third-line 
cART according to ATHENA data.  Calendar time refers to time of switching.   
Source for A: Source: Smit et al 2013 [275].   
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Table 2.3.   Adjusted hazard ratio (95% confidence intervals) for covariates associated with time between 
start of first-line cART and switching to second-line due to toxicity.   
Source: Smit et al 2013 [275].   
 
Variables Model 1: Calendar time Model 2: Calendar time and regimen type 
 Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 1.53 (1.37-1.71) <.0001 1.02 (0.84-1.24) 0.83 
2001-2005 1.40 (1.27-1.54) <.0001 1.00 (0.86-1.16) 0.99 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 1.04 (1.02-1.06) 0.0007 1.04 (1.02-1.07) 0.001 
Sex     
Male [Reference]  [Reference]  
Female 1.36 (1.18-1.56) <.0001 1.39 (1.19-1.62) <.0001 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 0.86 (0.73-1.02) 0.09 0.87 (0.72-1.04) 0.12 
Sub-Saharan Africa 1.04 (0.90-1.21) 0.57 1.02 (0.86-1.19) 0.85 
Other 1.01 (0.90-1.13) 0.90 0.99 (0.87-1.12) 0.82 
Route of transmission     
Heterosexual 1.21 (1.07-1.37) 0.003 0.80 (0.70-0.92) 0.002 
MSM [Reference]  [Reference]  
Injecting Drug Use 0.93 (0.64-1.34) 0.69 0.75 (0.49-1.13) 0.17 
Other 1.03 (0.86-1.23) 0.78 0.87 (0.72-1.05) 0.14 
Clinical     
CD4 cell count at start of cART     
CD4 <200  0.99 (0.86-1.14) 0.90 0.96 (0.82-1.12) 0.61 
CD4 201-350  0.93 (0.81-1.07) 0.30 0.96 (0.82-1.12) 0.57 
CD4 351-500  [Reference]  [Reference]  
CD4 >501 1.44 (1.19-1.75) 0.0002 1.24 (0.99-1.56) 0.06 
RNA at start of cART     
RNA <100,000 [Reference]  [Reference]  
RNA 100,000-1,000,000 1.05 (0.96-1.15) 0.32 0.97 (0.87-1.07) 0.50 
RNA >1,000,000  1.08 (0.88-1.32) 0.47 0.88 (0.69-1.12) 0.29 
cART Type     
3TC/d4T + PI   2.16 (1.63-2.86) <.0001 
3TC/d4T + Boosted-PI   3.34 (2.59-4.31) <.0001 
3TC/d4T + NNRTI   2.21 (1.50-3.26) <.0001 
3TC/AZT + PI   1.38 (1.08-1.75) 0.01 
3TC/AZT + Boosted-PI   2.31 (1.97-2.70) <.0001 
3TC/AZT + NNRTI   1.55 (1.30-1.86) <.0001 
TDF/FTC or TDF/3TC + Boosted-PI   1.16 (0.97-1.39) 0.10 
TDF/FTC or TDF/3TC + NNRTI   [Reference]  
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Table 2.4.  Adjusted hazard ratio (95% confidence intervals) for covariates associated with time between 
start of first-line cART and switching to second-line due to virological failure.   
Source: Smit et al 2013 [275].   
 
Variables Model 1: Calendar time  Model 2: Calendar time and regimen type 
 Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 1.69 (1.30-2.23) 0.0002 0.83 (0.50-1.35) 0.45 
2001-2005 1.81 (1.46-2.25) <.0001 1.86 (1.31-2.62) 0.001 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 0.95 (0.91-1.01) 0.07 0.98 (0.93-1.04) 0.47 
Sex     
Male [Reference]  [Reference]  
Female 0.91 (0.67-1.23) 0.53 0.74 (0.52-1.04) 0.08 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 0.91 (0.61-1.35) 0.63 0.94 (0.61-1.45) 0.79 
Sub-Saharan Africa 1.28 (0.94-1.75) 0.11 1.48 (1.06-2.08) 0.02 
Other 1.03 (0.78-1.35) 0.85 1.08 (0.80-1.45) 0.61 
Route of transmission     
Heterosexual 0.90 (0.69-1.17) 0.42 1.10 (0.82-1.46) 0.54 
MSM [Reference]  [Reference]  
Injecting Drug Use 0.85 (0.37-1.96) 0.71 0.82 (0.30-2.23) 0.69 
Other 0.84 (0.57-1.24) 0.37 0.77 (0.49-1.21) 0.25 
Clinical     
CD4 cell count at start of cART     
CD4 <200  2.92 (1.83-4.67) <.0001 3.16 (1.83-5.46) <.0001 
CD4 201-350  1.50 (0.92-2.44) 0.11 1.64 (0.93-2.89) 0.09 
CD4 351-500  [Reference]  [Reference]  
CD4 >501 1.36 (0.66-2.81) 0.40 1.20 (0.50-2.86) 0.69 
RNA at start of cART     
RNA <100,000 [Reference]  [Reference]  
RNA 100,000-1,000,000 1.60 (1.27-2.01) <.0001 1.87 (1.44-2.43) <.0001 
RNA >1,000,000  2.46 (1.68-3.60) <.0001 3.3 (2.16-5.13) <.0001 
cART Type     
3TC/d4T + PI   3.05 (1.79-5.19) <.0001 
3TC/d4T + Boosted-PI   0.87 (0.40-1.90) 0.72 
3TC/d4T + NNRTI   1.03 (0.43-2.44) 0.95 
3TC/AZT + PI   2.65 (1.65-4.24) <.0001 
3TC/AZT + Boosted-PI   0.60 (0.40-0.92) 0.02 
3TC/AZT + NNRTI   0.69 (0.45-1.04) 0.08 
TDF/FTC or TDF/3TC + Boosted-PI   0.51 (0.30-0.87) 0.01 
TDF/FTC or TDF/3TC + NNRTI   [Reference]  
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The short-term incidence of switching to second-line and third-line, due to virological failure 
or toxicity, has declined between 1996 and 2010 (Figure 2.5B and C), suggesting that second-line and 
third-line cART regimens have also improved considerably over the course of the last decade.  The 
incidence of switching from second and third-line due to virological failure, toxicity and ‘other’ 
reasons decreased by a factor of three between 1996-200 and 2006-2010.  The incidence of switching 
due to virological failure decreased from 6.3 events (95% CI 4.8-8.2) for second-line and 9.0 events 
(95% CI 6.6-12.0) for third-line in 1996-2000 to 1.3 events (95% CI 2.0-2.7) for second-line and 2.4 
events (95% CI 1.9-2.9) per 100 person-years for third-line in 2006-2010.  The incidence of toxicity-
related switching decreased from 32.8 events (95% CI 29.1-36.8) for second-line and 37.9 events 
(95% CI 32.7-43.6) for third-line in 1996-2000 to 9.7 events (95% CI 8.8-10.6) for second-line and 
10.4 events (95% CI 9.31-11.5) events per 100 person-years for third-line in 2006-2010.  In contrast 
to first-line cART, the incidence of switching from second and third-line due to simplification/new 
medication becoming available didn’t change significantly between 1996 and 2010.  In models 
adjusted for cART regimen type, differences between time periods were not significant (Appendix C 
Table 7 to Table 8).   
 
2.3.4 A Closer Look at Toxicity 
An analysis of toxicity as reason for switching was carried out.  Between 1996 and 2010 there were 
2,665 patients who switched their first-line cART regimen due to toxicity.  Analysis of the side effects 
that caused switching could link 2,236 patients to specific reason for switching.  The remaining 429 
patients experienced multiple side effects.  Due to the difficulty of accounting for which side effect 
ultimately cause patients to switch regimens these were excluded from the subsequent analysis of 
toxicity.  Between 1996 and 2010 more than half switched due to short-term toxicity (54%).  The 
remaining patients switched due to medium-term or long-term toxicity (24% and 22%, respectively).   
Out of 1,317 patients who switched second-line regimen due to toxicity, 876 patients could be 
matched to a single side effect causing this switch.  Among 996 third-line patients who switched 
third-line due to toxicity, 581 were matched.  The majority of patients switched due to short-term 
toxicity (41% and 55%, respectively).   
Across all lines, gastrointestinal side effects was consistently amongst the top three reasons 
for switching treatment (Figure 2.6 A, C and E).  Switching due to hepatological reasons was only a 
major reason for switching first-line between 1996 and 2000.  In contrast, amongst patients on 
second-line and third-line, hepatological toxicity remained a major cause of switches throughout 1996 
to 2010 (Figure 2.6 A, C and E).  Switching due to haematological reasons was only a major issue 
amongst patients on first-line between 1996-2005.  Amongst patients on first-line, reasons for 
switching changed from hepatological and haematological to dermatological and 
neurological/psychological over time (Figure 2.6A).  In contrast amongst patients on second-line and 
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third-line, a shift from neurological/psychological side effects to dermatological side effects resulting 
in switching of regimens (Figure 2.6C and E).   
 
 
A. B.  
 
C. D.  
 
E. F.  
 
Figure 2.6.  Three toxicity categories that are the causes of most regimen switches over calendar time for 
A. first-line, C. second-line, E.  third-line.  Three side effects that cause the most regimen switches over 
calendar time for B. first-line, D. second-line, and F.  third-line.   
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Amongst patients who started first-line, second-line or third-line treatment between 1996 and 
2000, one of the main side effects that resulted in switching was diarrhoea (Figure 2.6 B, D and F).  
Amongst patients on first-line a shift was observed from nausea and anaemia driving a large number 
of switches in the period 1996 to 2005 to depression and rashes in the period 2006-2010 (Figure 
2.6B).  A similar pattern was observed in amongst patients on second-line, with a shift from nausea 
and anaemia to depression and rash (Figure 2.6D).  Among patients on third-line the major side 
effects changed from nausea and rash in 1996-2000, to rash and fatigue in 2001-2005 and rash and 
anaemia in 2006-2010.    
Analysis further found that some side effects appear to be associated with specific drugs or 
drug classes.  The data suggest that d4T/3TC-based regimens are associated with gastrointestinal side 
effects (17-35%, depending on the specific regimen), neurological side effects, in particular peripheral 
neuropathy (8-14%), systemic side effects (8-10%), and lipodystrophy (5-17%).  3TC/AZT-based 
regimens are associated with gastrointestinal, in particular nausea (10-18%), liver toxicity (5-15%), 
and haematological side effects, in particular anaemia (10-18%).  TDF-based regimens appear to be 
associated with gastrointestinal (6-41%), rash (6-14%), and liver toxicity (10-23%).  Similarly, ARV 
classes were found to be associated with specific side effects; non-boosted PI and boosted PIs are 
associated with gastrointestinal side effects, including diarrhoea, nausea, vomiting, and abdominal 
pain.  NNRTI appear to be associated with the development of a rash.   
 
 
 
2.4. Discussion  
Between 1996 and 2010, cART regimens changed from mainly 3TC/AZT-based or d4T/3TC-based 
regimens with PIs to TDF/3TC or TDF/FTC with NNRTIs.  There was no significant reduction in 
short-term mortality between 1996 and 2010 when controlling for clinical and demographic factors, 
such as age and CD4 at start of cART, likely because the greatest impact on short-term mortality 
occurred before this, as a consequence of the introduction of combination therapy [4,5,10,52,53,55–
58].  However, there were improvements in CD4 recovery on first-line and third-line and VL 
suppression on all cART lines.  In addition, there is strong evidence showing that the short-term 
incidence of switching has decreased significantly since 1996 on all cART lines, suggesting that the 
duration patients spend on a cART-line before switching has lengthened considerably over time.  The 
incidence of switching to simpler or newer medication in the absence of virological failure or toxicity 
has increased between 1996 and 2010.  As far as we can tell these changes in outcomes are related to 
new drugs rather than improvements in other aspects of clinical care.  This suggests that the changing 
pattern of first-line cART use over time in the Netherlands, which closely follows changes in 
guidelines, has done so to the benefit of patients in care.  However, toxicity remains the main reason 
for switching cART, accounting for 50% of switches of all lines in 2006-2010.  In the Netherlands, 
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the main problem is short-term toxicity, occurring within three months of cART initiation, in 
particular short-term toxicity such as rashes, nausea, diarrhoea and anaemia.   
The pattern of changes in first-line cART regimens in the Netherlands between 1996 and 
2010 parallels changes in Dutch national treatment guidelines and publications of a number of clinical 
studies [60,276], as outlined in section 1.4.2 Changes of cART Regimens and Guidelines, page 32 and 
summarized in Table 1.3 of Chapter 1.  Second-line and third-line regimens show similar patterns as 
first-line cART.  Although guidelines have specific recommendations regarding first-line regimens, 
clinical trials and studies into efficacy also drive changes in second-line and third-line regimens.  
However, prescribing behaviour of second-line and third-line is also strongly driven by the reasons 
patients stopped previous regimens as well as by their clinical status.  A patient who has suffered from 
the toxic side effects of a regimen, may be changed to a less toxic regimen, while a patient who 
switched due to virological failure, will either be put on a regimen that has a higher genetic barrier to 
resistance, or to a simpler regimen, if the reason for the development of virological failure is 
suspected to be poor adherence.  This may account for the increased number of ‘other’ regimens 
prescribed, that are not based on a backbone of 3TC/d4T, 3TC/AZT, TDF/FTC or TDF/3TC or are 
not combined with only an NNRTI, a non-boosted PI or a boosted-PI.   
The changes in clinical outcomes are consistent with findings from international studies.  A 
study by the Swiss HIV cohort study showed that adherence to the national recommendation on cART 
regimens was associated with better treatment outcomes between 1998 and 2007 [277].  International 
cohort collaborations in developed countries have looked at time trends of certain clinical outcomes. 
The ART cohort collaboration found that while more patients achieved VL suppression to below 500 
copies/ml by 6 months this did not result in a reduction in one-year mortality between 1995 and 2003.  
The Swiss HIV cohort study found that while the one-year incidence of switching did not improve 
between 2000 and 2005, the proportion of patients that were virologically suppressed did improve and 
CD4 cell count after start of cART showed greater increases over calendar time.  Mocroft and 
colleagues also found no significant change in mortality rates between the early and late cART era in 
developed settings [278].  As reported in other countries, toxicity remains the main reason for 
switching [149,150,152,279], although newer regimens are associated with improved tolerability 
[6,88,116].  The changes in common side effects resulting in switching coincide with changes in 
prescribed regimen types between 1996 and 2010 [37].   
Studies into different clinical outcomes have identified similar risk factors.  Studies into 
mortality have reported age, injecting drug use, smoking and AIDS-defining events as risk factors for 
mortality [10,51,234].  Studies into toxicity found the risk to be increased in women, and older 
patients, and amongst patients on older regimens, in accordance with previous work [84,88–92,94–
96,150,235,280–282].  Drug exposure is thought to be influenced by pharmacokinetic differences 
between women and men [150], while polypharmacy in older patients has been shown to significantly 
increase the chance of serious drug-drug interactions [150,235,280–282].  As with other studies, our 
Chapter 2 – Reporting Progress 
75 
results showed that baseline CD4 count and VL can be predictors for virological failure, CD4 
recovery and VL suppression [283–285].  There is no clear explanation why some of the other risk 
factors identified affect the risk of certain clinical outcomes.  For example, our results suggested that 
MSM have higher risk of toxicity-driven switch compared to heterosexual patients, in accordance 
with work by Prosperi and colleagues [286].  This may be due to different perceptions of side effects 
[287].   
Despite the improvement in cART and patient clinical outcomes since 1996, patients still 
have to deal with a lifetime of treatment that is often associated with a plethora of issues.  Toxicity in 
particular remains the main reason for patients to switch cART regimens [149,150,152,279].  With the 
improvement of HIV therapy and the decline in the incidence of switching, toxicity has in fact 
become an even more dominant reason patients switch, relatively.  This means that as HIV is 
becoming a chronic disease, with a substantial decline in opportunistic infections, physicians will 
have to spend a lot of time assisting patients with the wide array of side effects associated with cART 
regimens.  Toxicity can affect adherence.  A meta-analysis by Al-Dakkak and colleagues found that 
adherence to cART was significantly lower in patients with non-specific adverse events than in 
patients who did not experience toxicity (OR=0.62, 95% CI 0.47-0.83) [288].  This will become even 
more important in the face of an ageing HIV-population.  Co-morbid disease is becoming an 
increasing problem among the ageing HIV-population [15].  As the prevalence of co-morbidity 
increases, the management of HIV-patients will be complicated by polypharmacy, with the co-
administration of multiple co-medications with HIV-medication and drug-drug interactions, leading to 
more toxicity [14,15].   
Toxicity can compromise the near-perfect adherence needed to maintain treatment efficacy 
[148].  Given the importance of side effects of HIV-treatment both as a reason for switching but also 
for adherence, it is disappointing that they are studied so poorly [148].  For regulatory approval, only 
side effects affecting major organ systems, such as central nervous system, cardiovascular and 
respiratory, have to be reported [148].  Although side effects related to blood, liver or kidney are also 
reported, these side effects are often analysed chemically instead of clinically [148].  Some side 
effects can only be analysed chemically in the short-term, such as changes in creatine levels.  Pre-
license studies are often small, underrepresenting and sometimes excluding sub-populations, and short 
in duration, meaning that side effects that are rare, delayed in onset or limited to specific sub-
populations are often underreported [148].  In terms of post-marketing data collection, the reporting of 
side effects occurs passively, with little consensus on the definition of side effects or method of 
collection [148].  All of these factors can make it difficult to run a full analysis on side effects of HIV-
treatment.   
Furthermore, it can be difficult to analyse side effects in patients on HIV-treatment.  With the 
number of ARVs that patients are prescribed, it can often be difficult to disentangle what side effect is 
associated with a particular drug within the regimen.  In addition, some malaises, such as headache, 
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diarrhoea, or nausea commonly occur in people who are not on HIV therapy.  Depending on the 
patient, some will attribute it to the treatment, while others may not even mention it to their treating 
physician.  Furthermore, the reason for switching due to toxicity may be multi-factorial, so that the 
sum of side effects brought about a switch in regimen.  Finally, there are known to be long-term 
toxicities associated with cART, such as cardiovascular events [289].  However, it may take some 
time for these to occur [289,290] and this analysis was unable to capture these long-term toxicities 
adequately.   
The results of this and other studies suggest that given the high rate of patients discontinuing 
regimens due to toxicity, and the emerging problems related to an ageing HIV-population, managing 
toxicity must remain key to the effective management of HIV-infection.  Staying on cART regimens 
longer can increase the beneficial effect of cART, slow disease progression, and reduce clinical 
disease and virological failure [290].  Prolonging the durability of first-line cART is particularly 
important for treatment success.  First-line cART has been shown to have the greatest success in 
achieving effective and long-lived CD4 increase and viral load suppression [144,145].  Patients who 
achieve undetectable levels of viral load on first-line have a greater chance of long-term success on 
HIV-treatment [147], and survival times on of successive lines are progressively of shorter duration 
[6,145,146].   
To my knowledge this is the first attempt to document progress in population-level 
effectiveness of HIV-treatment in the Netherlands since 1996 across a large number of clinical and 
non-clinical markers.  By using a unique, non-selective dataset to review the changing patterns of 
cART use coupled with trends in short-term patient clinical outcomes, it provides a valuable insight 
into how HIV-treatment has changed and the impact this has had on treatment success.  The analysis 
is limited by factors typical of cohort data.  Comparison of rates of VL suppression is limited by our 
use of the cut-off of 1,000 copies/ml in the definition of VL suppression.  However, we used it in 
order to compare trends in VL suppression from 1996 to 2010.  Analysis of CD4 recovery and VL 
suppression is restricted by the varying monitoring intervals amongst patients in clinical care.  Further 
work could include carrying out an interval-censored analysis, for example.  However, as these 
intervals have lengthened since 1996 and most patients will have a CD4 count and VL test by 12 
months; this should not significantly affect the results.   
The analysis of mortality is limited by the cohort effect, and the fact that the risk of mortality 
may also depend on a number of factors, such as lifestyle, general health, and co-morbidities, which 
are not all routinely collected in the dataset.  In the analysis we could not control for adherence as 
adherence data is not routinely collected in ATHENA.  Adherence may have improved over time as 
drugs have become more tolerable [6] and regimens simpler [272,273].  This and the grouping of 
regimens into regimen types, makes it inappropriate to associate specific clinical outcomes, such as 
mortality, to specific regimen types.  Consequently, associations observed, such as the increased 
mortality hazard in patients on TDF/3TC or TDF/FTC with boosted-PIs compared to NNRTI, should 
Chapter 2 – Reporting Progress 
77 
be interpreted with caution.  The use of marginal structural models may be better suited to carry out 
this kind of evaluation.  Marginal structural models are a type of statistical model used for causal 
inference and can handle time-dependant confounding [291].  However, even then analyses are 
difficult and dependant on the assumption that there are no unmeasured confounders.  The short 
follow-up available for patients who started treatment in later years means that the long-term effect of 
cART regimen on mortality and toxicity could not be evaluated.  The evaluation of the effect of long-
term cART use on long-term toxicity and mortality are important questions to address in the future to 
ensure the continued high quality standard of care.  This will require the establishment of an 
international consensus on the definition of adverse events, along with improved systematic study of 
side-effects.   
The use of first-line cART in the Netherlands closely follows changes in guidelines, to the 
benefit of patients.  While there was no significant improvement in mortality, newer drugs with better 
tolerability and simpler dosing resulted in improved immunological and virological recovery and 
reduced the incidence of switching due to toxicity and virological failure.   
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3.1 Summary 
The aims of this chapter are to provide a detailed description of the construction of an individual-
based model of the ageing HIV-population in the Netherlands.  The model follows HIV-patients from 
the start of treatment, as they age, develop co-morbidities, namely diabetes, hypertension, 
hypercholesterol, osteoporosis and renal insufficiency or experience strokes, and MIs or malignancies, 
and are prescribed co-administered treatment for these conditions.  This individual-based model 
provides a framework with which to quantify the future challenges posed by an ageing HIV-
population, by predicting trends in age-structure, burden of age-related co-morbidity and 
polypharmacy on HIV-clinical care.  It is a means of quantifying the problem that HIV care will face 
in light of a growing number of drug-drug interactions and contra-indications.  Finally, the model 
provides a tool with which to evaluate interventions aimed at tackling these issues, such as the 
introduction of a polypill for cardiovascular disease.   
 
 
3.2 Background  
Mathematical models are powerful synthesizing tools.  They provide a practical means of projecting 
the future of an epidemic and a quantitative tool to carry out formal evaluation of the impact of 
different treatment strategies [237].  HIV-treatment is dynamic and involves complex interactions; 
mathematical models allow the integration of important biological and demographic variables and the 
investigation factors affecting these dynamics.  Models can be used by scientists and policy makers to 
understand the likely benefits and possible risks of various interventions and carry out projections of 
the behaviour of a disease in the future [237], such as the impact of an ageing HIV-population on 
prognosis and burden of co-morbidity and polypharmacy.   
After evaluating how cART regimens have changed since their introduction in 1996 and the 
impact these changes have had on clinical outcomes of patients in care (Chapter 2), the next step is to 
explore the future challenges of HIV clinical care.  A model of the ageing HIV-infected population in 
the Netherlands is the natural next step to achieving these goals.  Such a model will provide the means 
to carry out a thorough evaluation of the future of HIV-treatment and patient care in the Netherlands 
and the means to formulate strategies that can best address new challenges as they arise.   
Effective treatment has resulted in HIV-patients suffering increasingly from age-related non-
infectious co-morbidities that they previously did not live long enough to endure [15].  As the 
prevalence of co-morbidity increases, the management of HIV-patients will be complicated [14,15].  
Comorbid disease causes problems with polypharmacy, the co-administration of multiple co-
medications with HIV-medication, leading to higher pill burden [14,15], drug-drug interactions and 
drug toxicity, loss of efficacy of the HIV- and co-administrated medication and virological 
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breakthrough.  With these patients becoming increasingly complex to manage it is important to 
quantify the scale of the problem facing the Netherlands in the future, using a modelling approach.   
In public health one can differentiate between population-level and individual-based models.  
Population-level models provide schematic representation of population health and factors that affect 
them, measuring the average health status in the population [292].  Individual-based models are a type 
of stochastic model, where every individual within the population is tracked [238,239].  In health 
science, individual-based models allow greater flexibility.  Given the complexity of multi-morbid 
HIV-patients, an individual-level approach to modelling can be particularly valuable.  Its flexibility 
provides the means to model the heterogeneity of patients, individual physiological interactions that 
influence the development of co-morbidities, and the medical consequences, such as the prescription 
of specific co-medication.   
 
 
3.3. Method 
3.3.1 Model Structure 
A simple schematic of the model is presented in Figure 3.1.  The model will follow HIV-patients from 
the start of treatment (Part B).  It will simulate how HIV-patients age over time (Part C), how they 
develop co-morbidities, namely diabetes, hypertension, hypercholesterol, osteoporosis and renal 
insufficiency or experience a stroke, MI or malignancy, and start co-medication for these conditions 
(Part A).  Furthermore, it will model the entry of increasingly older patients to follow-up.   
The basic model structure of the individual-based model is illustrated in Figure 3.2.  Part A 
shows the demographic and clinical characteristics of the patient population within the model, which 
include age, sex, co-morbidities, and co-medication.  Part B of Figure 3.2 illustrated the events that 
patients can experience, including developing a new co-morbidity, starting new co-medication or 
death.  The risk factors for these events are listed in the corresponding boxes, with the probability of 
events occurring evaluated at one monthly time steps in the model.  The particulars of the model 
structure are outlined in details below.   
 
3.3.2 Data and Patient Population 
The same ATHENA patient population was used as in Chapter 2 (see Chapter 2 section 2.2.1 Data 
and patient population for more details).  That is, we included all patients with HIV-1 only, who were 
treatment-naïve prior to entering the study, and who initiated cART during follow-up.  Women who 
were known to have been pregnant during follow-up were excluded from this study, due to the 
treatment changes that occur during pregnancy.  Data were analysed up to and including 31
st
 
December 2010.   
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Figure 3.1.  Schematic of the model of an ageing HIV-population.  The model follows HIV-patients from 
the start of treatment until death or closing year of model (2030) (Part B).  The model simulates how 
HIV-patients age over time (Part C), develop co-morbidities over time, start co-medication for these 
conditions, and how these co-medications affect HIV-treatment (Part A).   
 
 
3.3.3 Model Parameters 
3.3.3.1 Demographic Factors 
At the start of the model and as new patients enter clinical follow-up, the model assigns each patient 
key demographic factors such as age and sex.  Sex is assigned using a random number generator and 
the observed proportion of men and women (84% men and 16% women) entering care in the 
Netherlands as calculated from the ATHENA data.   
Age at the start of the model is assigned from a distribution using a random number generator.  
Several distributions were tested to establish which best described the observed age distribution at the 
start of treatment in the ATHENA cohort, namely normal, Weibull and gamma distribution.  The age 
distribution at the start of treatment was found to best be described using a gamma distribution (p-
value<0.001 Kolmogorov-Smirnov, Cramer-von Mises and Anderson-Darling test), with the scale and 
shape in Table 3.1.  Figure 3.3A illustrates the gamma distribution for men and women used in the 
model.     
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Properties Details Comments 
Demographic   
Alive Yes/No If ‘no’ record date of death 
Age Age Picked from a distribution at entry, increasing 
linearly each year 
Sex F/M  
Co-morbidity   
Diabetes Yes/No If ‘yes’ record date developed co-morbidity 
Hypercholesterol Yes/No If ‘yes’ record date developed co-morbidity 
Hypertension Yes/No If ‘yes’ record date developed co-morbidity 
Malignancy Yes/No If ‘yes’ record date developed co-morbidity 
MI Yes/No If ‘yes’ record date developed co-morbidity 
Osteoporosis Yes/No If ‘yes’ record date developed co-morbidity 
Renal insufficiency Yes/No If ‘yes’ record date developed co-morbidity 
      Stroke Yes/No If ‘yes’ record date developed co-morbidity 
Co-medication   
Metformin Yes/No If ‘yes’ record date start co-medication 
Insulin Yes/No If ‘yes’ record date start co-medication 
Sulphonylurea Derivates Yes/No If ‘yes’ record date start co-medication 
ACE Inhibitors Yes/No If ‘yes’ record date start co-medication 
Beta Blockers Yes/No If ‘yes’ record date start co-medication 
Calcium Channel Blockers Yes/No If ‘yes’ record date start co-medication 
Diuretics Yes/No If ‘yes’ record date start co-medication 
Statins Yes/No If ‘yes’ record date start co-medication 
Alendronic Acid Yes/No If ‘yes’ record date start co-medication 
 
Figure 3.2.  Model structure for an ageing HIV-patient population in the Netherlands.  Part A shows the 
patient properties and Part B shows the events that can occur during follow-up.  
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Table 3.1.  Parameters defining age at treatment initiation.  The age distribution is defined using a 
gamma distribution and the increase in mean age per year is defined by a linear equation, f(x)=a*year-b.   
Age distribution 
Sex Shape Scale 
Men 2.50541 16.7205 
Women 2.88265 13.1475 
Increase in mean age per year 
Sex ai bi 
Men (i=1)               
Women (i=2)               
 
 
Figure 3.3.  A. Age distribution at cART initiation in 2010, using a gamma distribution fitted to observed 
age distribution in the ATHENA cohort.  B and C. annual mean age at start of treatment of the 
observational ATHENA data and linear model fit for B. men and C. women.   
A.  
B. C.  
 
The ATHENA cohort data showed that the mean age of patients who start treatment each year 
has increased over time.  By 2010 the mean age of patients in the ATHENA data had increased to 39 
for women and 42 for men.  Consequently the model will assume that age at treatment initiation will 
increase over calendar time.  After looking at the data, a linear relationship between year of cART 
initiation and mean age was assumed.  Microsoft Excel Solver 2010 and a least square method were 
used to fit a linear function to the ATHENA data of 1996-2010, for men and women separately.  The 
fit of this function to the data is shown in Figure 3.3B and C.  The parameters describing this 
increasing relationship in mean age are presented in Table 3.1 with the following linear equation, 
where i stands for sex and t stands for the year: 
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In the individual-based model, the age distribution at the start of cART will change over time 
as a function of mean age.  The gamma distribution will shift by keeping the same shape and shifting 
the scale as follows, such that the mean age at start increases at the same rate a: 
 
       
   ̅̅ ̅̅ ̅   
      
 
 
3.3.3.2 Incidence of Starting Treatment 
An important component of the individual model and its potential to predict future trends is the 
simulation of the annual number of HIV-infected people who will initiate treatment.  In order to 
determine this, a simple deterministic model of the HIV cascade was constructed from infection to 
start of treatment, including the incidence of HIV-infection.  The incidence model contains four 
compartments, susceptible, infected, diagnosed and treated.  Figure 3.4 illustrates the flow diagram of 
this compartmental model, where λt stands for the incidence rate, δ stands for the rate of HIV-
diagnosis and ψ stands for rate of treatment initiation.  The rates of diagnosis and treatment initiation 
were obtained from the ATHENA data, and were time-dependent.  Birth rates were taken from Dutch 
national birth statistics, and death rate was assumed to be equal to birth rate to maintain a constant 
population size.  It was assumed that the age at infection was independent of the age at the start of 
treatment and of the incidence rate.  The model simulated infection, and diagnosis from 1980, and 
starting cART from 1996 onwards.  The incidence rate was calculated using a non-parametric 
approach, with the following equation, where A stands for the starting year of the epidemic (1980), B 
and C are scaling parameter and α, β and γ are parameters defining the incidence rate:  
 
   
     ( ((       )     )
 ))
(   ) 
    
 
In order to project future trends in the HIV cascade the model was fit simultaneously to the 
number of patients diagnosed and starting treatment per year between 1996 and 2010 from the 
ATHENA data.  The model fit was carried out using Excel 2010 Solver and a least square method, by 
changing the parameters defining the incidence rate (alpha, beta and gamma).  When running the 
model forward in time, three scenarios were assumed; high, medium and low incidence rate (Figure 
3.5).  Rate of diagnosis and of starting treatment were assumed to be constant from 2010 onwards.  
The fit of the model output to the data and future trends are illustrated in Figure 3.5.   The number of 
people starting treatment between 2010 and 2030, as computed by the model, are presented in Table 
3.2.   
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Figure 3.4.  Flow diagram of deterministic model to simulate predictions of the incidence of starting 
treatment.  Parameter λt stands for the incidence rate, δ stands for the rate of diagnosis and ψ stands for 
rate of treatment.   
 
A.  
B. C.  
Figure 3.5.  Model projection of A. incidence of HIV-infection, B. number of people starting HIV-
treatment, and C. number of people diagnosed with HIV which is fed into the ageing model.   
 
3.3.3.3 Clinical Factors 
A combination of analysis of the ATHENA cohort data, literature review and consultation with 
treating physicians in the Netherlands was carried out to determine and parameterize the key clinical 
factors that change with age.  These include mortality, co-morbidities and co-medication, and will be 
discussed in more detail below.   
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Table 3.2.  Projected number of people starting treatment as predicted by the deterministic model of 
HIV-infection using three scenarios for the epidemic; minimum, medium and maximum.   
 Number of new treatment initiations 
Year Min 
scenario 
Mid 
scenario 
Max 
scenario 
2010 1009 1009 1009 
2011 897 897 897 
2012 805 805 805 
2013 730 728 734 
2014 667 661 681 
2015 612 602 642 
2016 563 549 614 
2017 518 501 594 
2018 476 461 580 
2019 436 429 570 
2020 397 405 564 
2021 359 387 559 
2022 322 374 556 
2023 285 365 554 
2024 252 358 552 
2025 225 354 551 
2026 204 351 550 
2027 189 348 550 
2028 177 347 550 
2029 169 346 549 
2030 163 345 549 
 
3.3.3.3.1 Co-morbidities 
The model includes the following age-related co-morbidities; diabetes mellitus, hypercholesterol, 
hypertension, non-AIDS malignancy, myocardial infarction (MI), osteoporosis, renal insufficiency, 
and stroke.  Henceforth non-AIDS malignancy will be referred to as malignancy and diabetes mellitus 
as diabetes.  In the model it is assumed that once a patient has developed a co-morbidity, they have it 
for life.  The exceptions are MI, stroke and malignancies where a patient will be attributed ‘ever had’ 
an MI, stroke or malignancy, to account for their need for co-medication and their increased risk of 
death.  Co-morbidities were defined using clinical and laboratory guidelines for diagnosing co-
morbidities, according to the European AIDS Clinical Society [60].  Non-AIDS-defining 
malignancies excluded precancerous stages of anal and cervical cancer, basal-cell carcinoma, and 
squamous cell carcinoma of the skin [293].  In the Netherlands histological confirmation of 
malignancies is part of standard clinical practice; consequently, pathology reports were used where 
possible to confirm diagnosis of any malignancy [293].  Renal insufficiency was defined as an 
estimated glomerular filtration rate (eGFR) below 60 ml/min, using the Cockcroft-Gault equation, 
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confirmed after 3 months or later [293].  The model does not include all age-related co-morbidities.  
This is partly because the ATHENA cohort does not systematically collect data on all co-morbidities, 
but only reports the ones listed above, which are amongst the most important age-related co-
morbidities.   
In the model, the development of co-morbidities is simulated as a function of age and sex.  In 
the 2011 HIV Monitoring Report, the SHM reported how the incidence per 1,000 person-years of 
follow-up of newly diagnosed renal insufficiency, diabetes mellitus, MI, osteoporosis, stroke, and 
malignancy changed with age in the Netherlands for men and women separately after starting cART 
[293].  We used these results for parameterisation of the model, assuming these incidence rates in the 
total ATHENA population would be similar in our study population.   
The incidence of the additional co-morbidities collected by the SHM, namely hypertension 
and hypercholesterol were determined from the data.  Checks were carried out to ensure that the 
above assumption is valid and that the method used to calculate the incidence of the remaining co-
morbidities (hypertension and hypercholesterol) was comparable to the one used in the report.  The 
age- and sex-specific incidence per 1,000 person-years for renal insufficiency and diabetes were 
calculated from the patient population used for model parameterisation and compared to the incidence 
published in the 2011 HIV Monitoring report.  The results were comparable, suggesting that the 
assumption was valid and that the method was comparable.  Table 3.3 represents the incidence and 
95% CIs per 1,000 person-years of follow-up of newly diagnosed co-morbidities used in this model 
by age group.   
Functions were fitted to these incidence data to allow continuous projection of developing co-
morbidity, thus avoiding 10 year jumps in incidence.  These were fitted in Microsoft Excel 2010 using 
Solver and a least square method, using midpoint of age groups.  The results of the model fit to the 
data are presented in Figure 3.7A and B, and the equations best describing these trends are reported in 
Table 3.4.  These equations are used in the model to simulate the development of newly diagnosed co-
morbidity.  The prevalence of co-morbidities before the start of cART was calculated from the 
ATHENA data by age group and is presented in Table 3.5.  These prevalence data are used in the 
model to model the number of patients who initiate cART with pre-existing co-morbidities.   
As the risk of hypertension does not seem to increase in women until after the age of 40, the 
function fitted to the data on hypertension in women overestimated the risk of hypertension in 30-40 
year olds.  In the model it will be assumed that the risk of hypertension in a 30-40 year old is the same 
as that of a 20-30 year old.   
 
3.3.3.3.2 Common Causal Pathways of Co-morbidities 
Several of the co-morbidities modelled in this thesis have common causal pathway [294].  A 
framework of the possible common causal pathways between the co-morbidities was created (Figure 
3.6).  Direct parameterisation using ATHEANA cohort data was not possible using either principle 
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component, correspondence or correlation analysis.  This may be due to the low number of patients 
who were reported to have a certain co-morbidity, and the fact that co-morbidities are not 
systematically collected by the ATHENA cohort so that common pathways could not adequately be 
captured by the various analyses.   
Instead a review of the scientific literature was undertaken by Dr Thyagarajan.  Dr 
Thyagarajan investigated the causal pathway in Figure 3.6 illustrated by the solid arrows, and 
explored whether any reverse interactions have been documented in HIV-infected individuals.  The 
relevant articles were carefully reviewed for model parameterization, and parameter values were 
chosen based on most adequate study design, largest population size and relevance of output (Table 
3.6).  Only one paper was found to adequately investigate the association between diabetes and the 
CVD of interest (hypercholesterol, hypertension, MI, and stroke) amongst HIV-patients [295].  For 
the relationship between renal insufficiency and diabetes and hypertension, several papers were found 
[296–299], all showing similar findings, with final parameter choice based on study design and 
population size.  The remaining parameters illustrated by the dotted lines in Figure 3.6, namely the 
relation between diabetes, hypercholesterol and hypertension, was calculated from the ATHENA data, 
due to time-constraints for the literature review.  There were sufficient data on these co-morbidities to 
get robust results for the model.  Where patients had two or more co-morbidities that could affect the 
development of another co-morbidity, parameters were calculated as the mean of the largest factor f 
and the product of the factors f: 
 
 ̅  
    (  )   ∏ (  ) 
 
 
 
Figure 3.6.  Framework of common causal pathways of different co-morbidities used in model.  Solid 
arrows show those investigated by literature review, dotted arrows were calculated using ATHENA data.   
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Table 3.3.  The incidence per 1,000 person-years of follow-up of newly diagnosed, routinely collected 
serious co-morbidities per age group for male and female patients on cART in ATHENA.   
*Source: items marked with * are from Monitoring report 2011, Appendix [293].   
 Men Women 
 Age category Incidence per 1,000 person-
years (95% CIs) 
Age category Incidence per 1,000 person-
years (95% CIs) 
Diabetes 
mellitus* 
<30 
30-40 
40-50 
50-60 
≥60 
0.5 (0.1-2.0) 
2.5 (1.9-3.3) 
4.4 (3.7-5.2) 
7.2 (5.9-8.8) 
11.7 (9.0-15.1) 
<30 
30-40 
40-50 
50-60 
≥60 
3.0 (1.5-5.3) 
3.8 (2.6-5.3) 
5.7 (3.9-8.1) 
7.2 (3.6-12.9) 
13.6 (6.2-25.8) 
Hypercholest
erol 
<30 
30-40 
40-50 
50-60 
≥60 
25.8 (20.0-32.7) 
34.3 (31.1-37.7) 
59.2(55.4-63.1) 
82.6 (76.0-89.5) 
117.3 (104.6-131.2) 
<30 
30-40 
40-50 
50-60 
≥60 
36.5 (25.8-50.1) 
38.0 (31.4-45.6) 
50.9 (42.4-60.6) 
116.4 (94-7-141.5) 
130.8 (98.9-170.0) 
Hypertension <30 
30-40 
40-50 
50-60 
≥60 
19.3 (14.3-25.4) 
25.8 (23.0-28.8) 
39.7 (36.5-43.0) 
57.8 (52.1-63.9) 
72.3 (61.8-84.1) 
<30 
30-40 
40-50 
50-60 
≥60 
20.1 (13.2-31.9) 
18.8 (14.2-24.5) 
43.4 (35.2-52.9) 
58.1 (41.3-79.5) 
69.5 (45.4-101.8) 
Malignancy* <30 
30-40 
40-50 
50-60 
≥60 
1.4  (0.4-3.2) 
2.3 (1.7-3.1) 
5.1 (4.3-6.0) 
9.6 (8.1-11.3) 
18.5 (15.0-22.6) 
<30 
30-40 
40-50 
50-60 
≥60 
0.3 (0.0-1.5) 
1.9 (1.1-3.1) 
5.2 (3.5-7.5) 
6.5 (3.1-11.9) 
9.9 (4.0-20.4) 
MI* <30 
30-40 
40-50 
50-60 
≥60 
0.0 (.-1.2) 
0.7 (0.4-1.3) 
2.8 (2.2-3.5) 
5.6 (4.4-7.0) 
8.9 (6.5-12.0) 
<30 
30-40 
40-50 
50-60 
≥60 
0.0 (.-1.1) 
0.5 (0.1-1.4) 
0.9 (0.3-2.2) 
0.0 (.-2.4) 
7.5 (2.4-17.5) 
Osteoporosis* <30 
30-40 
40-50 
50-60 
≥60 
0.4 (0.0-2.2) 
0.8 (0.4-1.5) 
2.6 (2.0-3.4) 
3.7 (2.7-4.9) 
5.8 (3.8-8.3) 
<30 
30-40 
40-50 
50-60 
≥60 
0.7 (0.1-2.5) 
0.5 (0.1-1.3) 
2.9 (1.6-4.8) 
10.9 (6.1-17.9) 
16.5 (7.9-30.4) 
Renal 
insufficiency* 
<30 
30-40 
40-50 
50-60 
≥60 
2.8 (1.1-5.7) 
3.5 (2.6-4.7) 
4.7 (3.8-5.6) 
8.4 (6.8-10.1) 
17.7 (14.1-21.9) 
<30 
30-40 
40-50 
50-60 
≥60 
2.4 (1.0-5.0) 
2.1 (1.2-3.6) 
6.2 (4.2-8.9) 
14.8 (9.0-22.8) 
11.4 (4.6-23.4) 
Stroke* <30 
30-40 
40-50 
50-60 
≥60 
1.0 (0.2-2.9) 
0.9 (0.5-1.5) 
1.4 (1.0-1.9) 
3.2 (2.4-4.3) 
7.4 (5.2-10.2) 
<30 
30-40 
40-50 
50-60 
≥60 
0.6 (0.1-2.1) 
1.2 (0.5-2.3) 
1.9 (0.9-3.5) 
2.7 (0.7-6.8) 
7.4 (2.4-17.3) 
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Figure 3.7.  The incidence per 1,000 person years of follow-up of newly diagnosed co-morbidity from the 
data and model fit for men and women on cART.  Note: the graphs of hypercholesterol and hypertension 
have different scales than those of other co-morbidities.   
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Figure 3.7.  [Continued]. The incidence per 1,000 person years of follow-up of newly diagnosed co-
morbidity from the data and model fit for men and women on cART. Note: the graphs of 
hypercholesterol and hypertension have different scales then those of other co-morbidities.   
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Table 3.4.  Model parameter equations for the incidence of newly diagnosed co-morbidities per 1,000 
person-years of follow-up as a function of age for patients on cART.   
*Power equations:  ( )  ∑          and exponential equations: F(x)       (   ) 
 
 Men  Women  
 Function type Parameters Function type Parameters 
Diabetes mellitus Quadratic β1= 0.0016 
β2= 0.0944 
β3= -2.8117 
Quadratic β1= 0.0045 
β2= -0.2069 
β3= 5.4700 
Hypercholesterol Quadratic β1= 0.0364 
β2= -0.9590 
β3= 26.1037 
 
Cubic β1= -0.0019 
β2= 0.3638 
β3= -17.0424 
β4= 266.703 
Hypertension Cubic β1= -0.0009 
β2= 0.1368 
β3= -5.1142 
β4= 75.8735 
Cubic β1= -0.0330 
β2= 4.9647 
β3= -114.245 
β4= 39.2327 
Malignancy Quadratic β1= 0.0069 
β2= -0.2808 
β3= 3.9815 
Quadratic β1= -0.0005 
β2= 0.2584 
β3= -6.0260 
MI Quadratic 
 
β1= 0.0019 
β2= 0.0118 
β3= -1.5064 
Exponential A= 4.6287e^6 
B= 0.2013 
Osteoporosis Quadratic β1= 0.0006 
β2= 0.0678 
β3= -1.8368 
Cubic β1= -0.0005 
β2= 0.0784 
β3= -3.4167 
β4= 45.2435 
Renal 
insufficiency 
Quadratic β1= 0.0085 
β2= -0.4979 
β3= 10.0968 
Quartic β1= -2.0050e^5 
β2= 0.0027 
β3= -0.1089 
β4= 1.23060 
β5= 5.1711 
Stroke Quadratic β1= 0.0043 
β2= -0.2780 
β3= 5.2414 
Quadratic β1= 0.0038 
β2= -0.2205 
β3= 3.9869 
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Table 3.5. Prevalence of co-morbidities by age group at cART initiation.   
 
 Men Women 
 Age category Prevalence (%) Age category Prevalence (%) 
Diabetes <30 
30-40 
40-50 
50-60 
≥60 
0.0 (.-.) 
0.7 (0.3-1.2) 
2.0 (1.4-2.7) 
5.4 (3.8-7.0) 
8.4 (4.9-11.8) 
<30 
30-40 
40-50 
50-60 
≥60 
2.5 (0.5-4.5) 
1.3 (0.2-2.5) 
2.5 (0.3-4.6) 
9.4 (3.4-15.3) 
16.2 (3.8-28.7) 
Hypercholesterol <30 
30-40 
40-50 
50-60 
≥60 
0.3 (0.00-0.07) 
0.6 (0.2-1.0) 
1.3 (0.8-1.8) 
1.6 (0.7-2.5) 
2.8 (0.7-4.8) 
<30 
30-40 
40-50 
50-60 
≥60 
1.3 (0.0-2.7) 
0.8 (0.0-1.7) 
0.0 (.-.) 
2.1 (0.0-5.0) 
2.7 (0.0-8.2) 
Hypertension <30 
30-40 
40-50 
50-60 
≥60 
3.9 (2.4-5.4) 
7.1 (5.9-8.4) 
11.2 (9.8-12.7) 
15.0 (12.4-17.5) 
14.0 (9.6-18.3) 
<30 
30-40 
40-50 
50-60 
≥60 
2.1 (0.3-3.9) 
6.2 (3.7-8.7) 
11.8 (7.3-16.2) 
12.5 (5.8-19.2) 
16.2 (3.8-28.7) 
Malignancy <30 
30-40 
40-50 
50-60 
≥60 
0.6 (0.0-1.2) 
0.4 (0.1-0.8) 
0.6 (0.2-0.9) 
1.7 (0.8-2.6) 
2.4 (0.5-4.3) 
<30 
30-40 
40-50 
50-60 
≥60 
0.4 (0.0-1.2) 
0.0 (.-.) 
1.5 (0.0-3.1) 
1.0 (0.0-3.1) 
2.7 (0.0-8.2) 
Myocardial 
infarction 
<30 
30-40 
40-50 
50-60 
≥60 
0.0 (.-.) 
0.1 (0.0-0.2) 
0.3 (0.0-0.5) 
0.7 (0.1-1.2) 
0.8 (0.0-1.9) 
<30 
30-40 
40-50 
50-60 
≥60 
0.0 (.-.) 
0.0 (.-.) 
0.0 (.-.) 
0.0 (.-.) 
2.7 (0.0-8.2) 
Osteoporosis <30 
30-40 
40-50 
50-60 
≥60 
2.3 (1.2-3.5) 
1.7 (1.0-2.3) 
1.7 (1.1-2.2) 
1.6 (0.7-2.5) 
2.0 (0.3-3.7) 
<30 
30-40 
40-50 
50-60 
≥60 
0.8 (0.0-2.0) 
0.8 (0.0-1.7) 
1.0 (0.0-2.3) 
3.1 (0.00-6.7) 
0.0 (.-.) 
Renal 
insufficiency 
<30 
30-40 
40-50 
50-60 
≥60 
0.2 (0.0-0.5) 
0.3 (0.0-0.6) 
0.1 (0.0-0.2) 
0.0 (.-.) 
0.0 (.-.) 
<30 
30-40 
40-50 
50-60 
≥60 
0.4 (0.0-1.2) 
0.3 (0.0-0.8) 
0.0 (.-.) 
0.0 (.-.) 
0.0 (.-.) 
Stroke <30 
30-40 
40-50 
50-60 
≥60 
0.0 (.-.) 
0.0 (.-.) 
0.2 (0.0-0.4) 
0.7 (0.1-1.2) 
0.4 (0.0-1.2) 
<30 
30-40 
40-50 
50-60 
≥60 
0.0 (.-.) 
0.3 (0.0-0.8) 
0.0 (.-.) 
0.0 (.-.) 
0.0 (.-.) 
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Table 3.6. Parameters defining common causal pathways between co-morbidities with source reference.   
 
Pathway Parameter (HR, 95% CI) Reference 
Diabetes and MI/stroke * 2.31 (1.83-2.92) [295] 
Hypertension and MI/stroke * 1.26 (0.98-1.62) [295] 
Hypercholesterol and MI/stroke * 1.41 (1.12-1.76) [295] 
Diabetes and renal insufficiency * 1.50 (1.05-2.16) [297] 
Hypertension and renal insufficiency * 1.69 (1.26-2.27) [297] 
Diabetes and hypertension 1.396 (1.19-1.64) ATHENA data 
Diabetes and hypercholesterol 1.12 (0.968-1.295) ATHENA data 
Hypercholesterol and hypertension 1.277 (1.16-1.397 ATHENA data 
Source: items marked with * literature review by Dr Thyagarajan.   
 
 
3.3.3.3.3 Co-medication 
A list of the co-medications commonly prescribed to HIV-patients on cART for the co-morbidities 
that were modelled was drawn up with treating physicians in Amsterdam (presented in Table 3.7).  
This list excluded co-medications that are contra-indicated in HIV-patients on cART.  There are 
currently no nationally recommended treatment guidelines for renal insufficiency, and this is reflected 
in the model.  Renal insufficiency, however does result in restrictions in the use of TDF and this will 
be considered when looking at restrictions in ARV use, one of the model outputs (see Section 
3.3.3.3.4 Drug-drug Interactions, page 98).  As the data showed that none of the patients in the 
ATHENA cohort used the calcium channel blocker amlodipine, amlodipine was not modelled.   
It was decided to model only the treatment of co-morbidities that were long-term.  
Consequently, treatment of malignancies was not modelled.  Although patients who are diagnosed 
with cancer may have to change cART regimens because of contra-indications or other 
pharmacological reasons while undergoing treatment for cancer, after the cancer treatment patients are 
generally able to resume previous regimen and thus experience no long-term restrictions in ARV use.   
In the Netherlands, not all HIV-patients with a given co-morbidity receive treatment.  
Consequently, the prevalence of patients taking co-medication for individual co-morbidities was 
calculated from the ATHENA data.  For diabetes, the data show that 78.1% of patients with diabetes 
are on treatment for diabetes, namely a combination of metformin, insulin and/or sulfonylurea 
derivatives [60].  Guidelines and treating physicians outline that patients with diabetes generally first 
receive metformin on its own.  This can sometimes be complemented with sulfonylurea derivatives.  
If patients do not show signs of improvement they are prescribed insulin with metformin [60].  It is 
difficult to determine how and why anti-diabetic medication changes over time from the data, as the 
ATHENA cohort only records the start date for one anti-diabetic medication, thus complicating the 
modelling of changes in the need for anti-diabetics.  From the data we know the proportion of patients 
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who take each of the different diabetes regimens (see Table 3.8).  Consequently, upon being 
diagnosed with diabetes, patients in the model will be on anti-diabetic regimens proportionally to the 
observed proportion (see Table 3.8), and are assumed to be on this medication for life.  Although in 
clinical care, medication prescribed for diabetes can change over time, as we are modelling long-term 
treatment we will assume that these proportions provide a cross-sectional representation of long-term 
treatment of diabetes.  The same assumption was made for all co-medication.  Although patients can 
have their need for co-medication re-evaluated (starting, stopping or changing co-medication), the 
model will assume that patients who developed a co-morbidity will have their co-medication need 
evaluated after diagnosis and that their co-medication status does not change.  This is a limitation of 
the model, but is an assumption that is in line with aim of this model which is to evaluate the effect of 
co-morbidity, and co-medication use in the Netherlands in an ageing population on polypharmacy 
burden and long-term cART restriction.   
 
 
Table 3.7. List of the co-medications that were used in the model.   
 
Co-medication group Drug group Individual drugs 
Diabetes medication  Metformin 
  Insulin 
 Sulfonylurea derivatives Glibenclamide 
Gliclazide 
Glipizide 
Tolbutamide 
Osteoporosis medication  Alendronic Acid 
Cardiovascular 
medication 
Ace Inhibitors 
 
Captopril 
Enalapril 
Lisinopril 
 Beta Blockers Atenolol 
Metoprolol 
 Calcium Channel Blockers Amlodipine 
Nifedipine 
Verapamil 
 Diuretics Bumetanide  
Furosemide 
Hydrochlorothiazide 
 Statins Atorvastatin 
Pravastatin 
Rosuvastatin calcium 
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Table 3.8. Prevalence of patients on medicine for diabetes and osteoporosis.   
 
Modelled treatment Prevalence of patients using co-
medication 
Diabetes medication 78.1% 
Of patients on anti-diabetics  
Metformin alone 57.4% 
Metformin with sulfonylurea derivatives 13.4% 
Metformin with insulin 29.2% 
Osteoporosis  
Alendronic acid 42.9% 
 
 
With cardiovascular disease (CVD), namely hypercholesterol, hypertension, MI and stroke, 
co-medication is further complicated.  The data suggests that the prescription of co-medication can 
depend on the number of CVDs a patient has, so that a patient with more than one CVD is more likely 
to be prescribed CVD medication than a patient with only one CVD.  In addition, medication for CVD 
is also sometimes prescribed in patients with diabetes.  As the data analysis showed that there was a 
considerable difference in the prevalence of patients on CV co-medication according to the number of 
CVD they had and whether they were diagnosed with diabetes, it was decided to use the number of 
CVD and presence or absence of diabetes to model if a patient is prescribed medication for CVD (see 
Table 3.9).  For example, Table 3.9 shows that 4.5% of patients with hypercholesterol and no other 
CVD or diabetes will be prescribed an ACE-inhibitor (angiotensin converting enzyme), and 18.7% of 
patients who have hypercholesterol and at least one other CVD or diabetes will be prescribed an ACE 
inhibitor.  Although patients who have both renal insufficiency and CVD can also receive CVD 
medication, analysis of the data suggested that this is already captured by modelling treatment of 
CVD as described above.  Table 3.10 shows the parameters for the assignment of individual 
cardiovascular co-medication, as calculated from the ATHENA data.   
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Table 3.9. Prevalence of patients on CVD co-medication by number of cardiovascular diseases and 
diabetes status.   
 
 Patients with one CVD or 
diabetes 
Patients with multiple CVDs and/or 
diabetes 
ACE Inhibitors 4.5% (2.9-6.2%) for hyper 
cholesterol 
10.9% (9.0-12.9%) for hypertension 
15.8% (0.0-33.8%) for MI 
6.3% (0.0-19.6%) for stroke 
11.5% (5.0-17.9%) for diabetes 
18.7% (14.8-22.5%) for hyper 
cholesterol 
20.7% (16.8-24.5%) for hypertension 
40.7% (20.9-60.5%) for MI 
39.1% (17.6-60.7%) for stroke 
22.0% (14.8-29.1%) for diabetes 
Beta Blockers 2.3% (1.2-3.5%) for hyper 
cholesterol 
10.0% (8.1-11.8%) for hypertension 
73.7% (51.9-95.5%) for MI 
25.0% (1.2-48.8%) for stroke 
16.7% (9.1-24.3%) for diabetes 
16.7% (13.0-20.3%) for hyper 
cholesterol 
15.9% (12.4-19.4%) for hypertension 
77.8% (61.0-94.5%) for MI 
21.7% (3.5-40.0%) for stroke 
19.7% (12.8-26.6%) for diabetes 
Calcium Channel 
Blockers 
0.2% (0.00-0.5%) for hyper 
cholesterol 
4.3% (3.0-5.5%) for hypertension 
5.3% (0.00-16.3%) for MI 
6.3% (0.00-19.6%) for stroke 
2.1% (0.0-5.0%) for diabetes 
4.7% (2.6-6.8%) for hyper cholesterol 
6.7% (4.3.9.0%) for hypertension 
3.7% (0.00-11.3%) for MI 
13.0% (0.00-27.9%) for stroke 
9.8% (4.7-15.0%) for diabetes 
Diuretics 4.5% (2.9-6.2%) for hyper 
cholesterol 
10.6% (8.7-12.5%) for hypertension 
31.6% (8.6-54.6%) for MI 
6.3% (0.00-19.6%) for stroke 
22.9% (14.4-31.5%) for diabetes 
16.7% (13.0-20.3%) for hyper 
cholesterol 
19.2% (15.5-23.0%) for hypertension 
18.5% (2.9-3.4%) for MI 
34.8% (13.7-55.8%) for stroke 
28.0% (20.3-35.7%) for diabetes 
Statins 16.9% (14.0-19.8%) for hyper 
cholesterol 
4.9% (3.5-6.2%) for hypertension 
78.9% (58.8-99.1%) for MI 
18.8% (0.0-40.2%) for stroke 
18.8% (10.8-26.7%) for diabetes 
34.6% (30.0-39.2%) for hyper 
cholesterol 
32.8% (28.3-37.3%) for hypertension 
70.4% (52.0-88.8%) for MI 
43.5% (21.6-65.4%) for stroke 
40.2% (31.7-48.6%) for diabetes 
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Table 3.10. Percentage of specific cardiovascular co-medications amongst patients prescribed cardio-
vascular medication.   
Co-medication Drug Group Individual drugs  
Cardiovascular 
medication 
Ace Inhibitors 
 
Captopril 
Enalapril 
Lisinopril 
5.4% 
29.9% 
64.7% 
 Beta Blockers Atenolol 
Metoprolol 
12.8% 
87.2% 
 Calcium Channel Blockers Amlodipine 
Nifedipine 
Verapamil 
0.0% 
92.1% 
7.9% 
 Diurectics Bumetanide  
Furosemide 
Hydrochlorthiazide 
7.3% 
41.5% 
51.3% 
 Statins Atorvastatin 
Pravastatin 
Rosuvastatin 
calcium 
31.1% 
44.9% 
24.0% 
 
 
3.3.3.3.4 Drug-drug Interactions 
There are a number of potential drug interactions between HIV-medications and co-medication used 
for age-related co-morbidity.  The Liverpool Drug interaction webpage contains a dataset on the 
interaction between HIV-medication and co-medication.  It features an interactive chart, categorizing 
the severity of these interactions and it has been used in previous studies into drug interactions [300].   
In addition to these drug interactions, certain co-morbidities can cause restrictions in ARV 
use.  For example, the European AIDS Clinical Society (EACS) guidelines state that the use of TDF is 
contra-indicated in patients with renal insufficiency [60].  Similarly patients who are at risk of CVD 
or high cardiovascular risk (in this model defined as ‘ever had’ a stroke or MI) ABC should be used 
with caution [60].   
Table 3.12 illustrates the interaction chart for HIV drugs and the co-medications included in 
this model.  This table and the contra-indications stated by the EACS guidelines can be used to 
quantify future long-term restrictions in HIV-medication, such as the number of HIV-drugs in any 
given ARV class that may require additional monitoring or that is contra-indicated.  Of particular 
interest will be the long-term restrictions to the 2013 EACS recommended regimens (see Table 3.11).   
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Table 3.11.  EACS recommended cART regimen in 2013.  A drug from column A should be combined 
with the drugs listed in column B.   
Source: [60].   
A B Remarks 
NNRTI NRTI backbone  
EFV 
 
OR 
Nevirapine 
TDF/FTC 
ABC/3TC 
OR 
TDF/FTC 
• TDF/FTC co-formulated 
•ABC/3TC co-formulated 
•EFV/TDF/FTC co-formulated 
Ritonavir-boosted PI   
Ritonavir-boosted 
Atazanavir 
Ritonavir-boosted 
Darunavir 
Ritonavir-boosted 
Lopinavir 
TDF/FTC 
ABC/3TCv 
•Ritonavir-boosted Atazanavir: 300/100 mg qd 
• Ritonavir-boosted Darunavir: 800/100 mg qd 
• Ritonavir-boosted Lopinavir: 400/100 mg bid or 
800/200 mg qd 
Integrase inhibitors   
Raltegravir TDF/FTC • Raltegravir: 400 mg bid 
 
3.3.3.4 Mortality   
A number of analyses were carried out on the ATHENA cohort data with the aim of obtaining cause-, 
as well as age- and sex-specific mortality rates.  The analysis included Cox regressions and time-
updated Poisson regression analysis.  However, due to the low number of deaths in the cohort the 
output could not be used for model parameterization.  There were 640 deaths between 1996 and 2010, 
with only 21 deaths due to MIs, so that it was not possible to obtain reliable cause-specific mortality 
rates for separate age groups and sexes.   
Instead, an in-depth literature search found an article by the Data Collection on Adverse 
Events of Anti-HIV drugs (D:A:D) Study Group.  In their study, the D:A:D Study group carried out a 
detailed analyses of mortality amongst HIV-patients using data from 21 countries in Europe, the 
United States and Australia [301].  Their results present both cause-specific death rates and quantify 
how factors associated with death, such as age and sex, influence on mortality rates.  These results 
were used to parameterise the model.  AIDS-related mortality was not included into the model at this 
stage due to the difficulty of assuming future trends of AIDS-related deaths.   
In order to provide an idea of how the cause of death is going to change over time using the 
model output, the number of cause-specific deaths will be calculated.  If i indicates the cause of death, 
xi the rate of death for individuals with cause i, and x refers the total number of deaths, then cause-
specific deaths will be calculated as: 
 
                       
  
∑    
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Table 3.12. Drug interaction chart.   Adapted from http://www.hiv-druginteractions.org/.   
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3.4 Model Checks 
A number of checks were carried out to ensure that the model adequately captures clinical care in the 
Netherlands and could be used to reliably predict the future age-structure, burden of co-morbid 
disease and polypharmacy in the Netherlands.  These checks included comparative eye-balling of 
model and observational data from 2010 to 2012, as the model was trained on pre-2010 data.   
 
3.4.1 Age Check 
Data from the ATHENA cohort from 2010-2012 were used to compute the mean and median age at 
start of treatment.  These were then compared to the model output.  The results showed that the model 
fit could be improved by heretically adjusting the scale of the gamma distribution.  Final parameters 
for the scale and shape parameters of the gamma distribution are presented in Table 3.1.  Results of 
the model output and data are presented in Table 3.13.   
 
Table 3.13. Mean and median age (95% CIs) according to observation data from the ATHENA cohort 
and model output.   
 Mean Median 
 Data Model Data (95% CI) Model 
2010 45.1 44.7 44.6 (38.2-51.2) 43.9 
2011 45.8 45.4 45.3 (38.7-52.1) 44.6 
2012 46.5 46.0 46.1 (39.4-53.1) 45.3 
 
 
3.4.2 Incidence Check 
The number of people starting treatment and the total number of people in follow-up per year was 
compared between the model and data for 2010-2012, to check if the deterministic model of HIV 
incidence was reliable in predicting future trends of HIV-infection.  The model output for the medium 
scenario was compared to the output derived from ATHENA cohort data (in the first few years the 
three epidemic scenarios have the same number of new entries).  The results are presented in Table 
3.14 and show that the incidence model used in the individual-based model is essentially adequate in 
projecting short-term trends in HIV-infection in the Netherlands.   
 
Table 3.14.  Number of patients starting cART according to observational data from the ATHENA cohort 
and model output.   
 Year Data Model 
Number of people starting treatment 2010 1,260 1,009 
 2011 1,142 897 
 2012 899 805 
Number of people on treatment 2010 9,830 10,012 
 2011 10,890 10,830 
 2012 11,692 11,522 
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3.4.3 Mortality Check 
Due to the low number of deaths in the ATHENA cohort, data from the D:A:D Study Group on 
mortality were used to parameterize death-rates.  As the parameters defining mortality had to be taken 
from two different sources, it was important to check that the way the model combined these provides 
mortality rates consistent with data.  One way mortality was validated was to compare the modelled 
standardized mortality ratio (SMR) between the HIV-infected population and general population to 
the SMR obtained in a study by the Collaboration of Observational HIV Epidemiological Research 
Europe (COHERE).  COHERE calculated the overall SMRs of HIV-patients compared to the general 
population in a large European cohort as 4.2 (95% CI 3.5-5.2) [302].   
The mortality parameters were adjusted to better fit the data by varying the background death-
rate reported by the D:A:D Study group.  The baseline death-rate was reduced until the model 
produced an SMR within the 95% confidence intervals reported by the COHERE group.  The SMR in 
COHERE was based on a population with a median age of 37, while the population in the D:A:D 
study had a median age of 39 and ATHENA of 41 years old.  Consequently the model slightly 
overestimated the SMR at the upper confidence limit at 5.0.   
In addition, age-specific death-rates amongst HIV-patients were compared to those in the 
general population in the Netherlands, to ensure that mortality amongst HIV-infected patients was 
similar or greater than in the general population.  Age-specific death-rates were taken from the WHO 
Global Health Observatory Data Repository for the Netherlands and used to model death rates in 
2010, 2020, and 2030 amongst the general population [303].  The model was run on a larger 
population of 100,000 people to control for stochasticity.  Figure 3.8 shows the model outputs and 
confirms that model simulations generate death rates greater than the general Dutch population.   
 
A.     B.  
C.   
Figure 3.8.  Age-specific modelled mortality rates for HIV-infected patients and the general population in 
the Netherlands in  A. 2010, B. 2020, and C. 2030.   
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Finally, the annual percentage of deaths amongst patients in follow-up was compared between 
the model and ATHENA between 2010 and 2012.  The results are presented in Table 3.15 and show 
that the percentage deaths in the model are a good match to the data.   
 
Table 3.15.  Annual percentage of deaths amongst people on treatment according to the observational 
data from the ATHENA cohort and the model output.   
 
 Data Model 
2010 0.8% 0.8% 
2011 0.9% 1.2% 
2012 0.8% 1.2% 
 
3.4.4 Co-morbidity Check 
In the model, HIV-patients develop co-morbidities through a combination of demographic factors 
(age and sex) and medical factors, through a system of common causal pathway, with parameter 
values coming from different sources.  In order to check whether modelling the incidence of co-
morbidity in this way is robust, the number of people who developed each of the co-morbidities 
between 2011 and 2012 data from the ATHENA data were compared with the model output.  The 
results are presented in Table 3.16 and show that the model manages to simulate similar annual 
numbers of new co-morbidities developed in the HIV-population similar to than the ATHENA data, 
with some minor exceptions including an underestimation of osteoporosis in 2011 and overestimation 
of renal insufficiency and strokes in 2011 and of diabetes, hypertension, MIs, in 2012.   
In addition, the incidence of co-morbid disease was compared between HIV-patients and the 
general population to ensure that the model captured the increased risk of co-morbid disease in HIV-
patients.  The incidence of co-morbid diseases was obtained from the literature and the Dutch 
National Public Health Compass.  Age-specific and sex-specific incidence data for the Netherlands 
were available for diabetes [304], renal insufficiency [305], malignancies [176], MI [306], 
osteoporosis [307] and stroke [308].  The remaining, namely hypertension and hypercholesterol, were 
not compared to the incidence in the general population.  The comparison between the incidence in 
HIV-patients and the general population illustrated in Figure 3.7 shows that the incidence of co-
morbidity is generally higher in HIV-infected individuals.   
 
3.4.5. Co-medication 
A final model check that was carried out was to compare the model output on CV medication to 
observational data from the ATHENA cohort.  The results of this comparison are shown in Table 3.17 
and show that the model manages to capture CVD co-medication well.  The exception is an 
underestimation in the number of patients starting ACE inhibitors, statins, and diuretics in 2011.   
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Table 3.16.  The annual number of new co-morbidities developed by HIV-patients according to the 
observational data from the ATHENA cohort and the model output.   
 
 2011 2012 
 Data Model Data Model 
Diabetes 63 74 54 83 
Hypertension 418 438 333 477 
Hypercholesterol 470 598 658 655 
Malignancy 75 69 71 72 
MI 20 32 19 42 
Osteoporosis 238 111 94 96 
Renal insufficiency 63 76 54 87 
Stroke 18 30 13 31 
 
 
Table 3.17.  The number of HIV-patients who start a co-medication according to the observational data 
from the ATHENA cohort and the model output.   
 
 2011 2012 
 Data Model Data Model 
Ace inhibitor 224 132 184 150 
Beta blockers 186 138 146 144 
Calcium blockers 66 52 61 46 
Diuretics 309 137 208 146 
Statins 361 208 298 255 
 
 
3.5 Discussion 
This chapter provides a detailed description of the construction of an individual-based model of the 
ageing HIV-population in the Netherlands.  The model follows HIV-patients from the start of 
treatment, as they age, develop co-morbidities, namely diabetes, hypertension, hypercholesterol, 
osteoporosis and renal insufficiency, experience strokes, MIs or malignancies and are prescribed co-
administered treatment for these conditions.  This individual-based model provides a framework with 
which to quantify the future challenges posed by an ageing HIV-population, by predicting trends in 
age-structure, burden of age-related co-morbidity and polypharmacy on HIV-clinical care.  It is a 
means of quantifying the problem that HIV care providers will face in light of a growing number of -
drug interactions and contra-indications.  Finally, the model provides a tool with which to evaluate 
interventions aimed at tackling these issues, such as the introduction of a polypill for cardiovascular 
disease.   
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The model captures the key aspects affecting clinical care of HIV-patients, including the 
major age-related co-morbidities, their common physiological pathways and their treatment.  The 
design of the model was informed by consultations with treating physicians in the Netherlands, in 
order to incorporate the main clinical aspects involved in the care of these patients.  The 
parameterisation of the model was accomplished using data from the national ATHENA cohort, a 
non-selective dataset of all HIV-patients in clinical care in the Netherlands.  Where the data were 
insufficient, in depth literature reviews were carried out, selecting, where possible, data from large 
international studies.  The incorporation of these common causal pathways allows the model to 
capture the natural aggregation of co-morbid disease within patients (that patients with a certain co-
morbidity are at an increased risk of another co-morbidity through common causal pathways), rather 
than simply model the development of co-morbid disease as a function of age and sex.   
Numerous model checks were completed in order to validate certain assumptions, for 
example the linear increase in mean age.  All checks showed that the parameterization of the model 
concurred with ATHENA data, at least over the short-term.  The deterministic model of HIV-
infection that was incorporated into the individual model, to predict the number of people starting 
treatment in the future, is shown to be an adequate method for predicting future trends in HIV-
infection in the Netherlands.  In the future, this could be updated with new incidence estimates from 
an in-depth incidence model of the Dutch epidemic by Dr van Sighem (unpublished).  The synthesis 
of the demographic and clinical factors affecting the development of co-morbidities in the model has 
output data similar to those observed in the ATHENA cohort, and modelling of co-medication 
appeared to be in line with observational data.  Finally, checks on the model’s output of mortality 
showed that the way the mortality data reported by the D:A:D Study Group was used to simulate 
deaths was a valid approach.  Mortality amongst HIV-patients was higher than in the general 
population, with SMRs within the 95% CI reported by larger European HIV cohorts, and with annual 
percentage of deaths amongst treated patients similar to those reported by the ATHENA cohort.   
Despite the strengths of the model’s design and parameterization, it has a number of 
limitations.  The model simulates major age-related co-morbidities, namely CVD (hypertension, 
hypercholesterol, MI and stroke), diabetes, osteoporosis, malignancies, and renal insufficiency.  The 
ATHENA cohort collected these age-related co-morbidities; however physicians do not record them 
systematically.  This and the fact that not all age-related co-morbidities and their treatment are 
modelled means that trends produced by this model will underestimate the true future burden of co-
morbid disease and co-medication, as well as the consequent impact on drug interactions and long-
term ARV restrictions.  In addition, the model does not currently simulate recurrent MIs, strokes or 
malignancies.  In the future, the model should be further developed to include recurrent CV events by 
using data on recurrence rates and to incorporate a CVD framework, like the Framingham or SCORE 
framework, to better capture CVD.   
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In the future it may be valuable to model other age-related co-morbidities, such as psychiatric 
illnesses and neurodegenerative impairments.  Neurocognitive conditions are a major problem 
amongst older HIV-infected patients, with studies showing that older HIV-patients are more likely to 
develop neurocognitive problems such as dementia than the age-matched uninfected population 
[15,309–312].  Some neurocognitive, age-related co-morbidities such as late-onset Alzheimer and late 
onset Parkinson have a mean age of onset of around 74 and 61 years, respectively [313,314].  So 
while mean age of onset of Parkinson’s and Alzheimer do not currently make them major age-related 
co-morbidities amongst HIV-patients, they will become increasingly important in the future as this 
population ages.  Additional data on these co-morbidities in HIV-patients will be important in the 
future.  It will allow their incorporation into the model and add to the growing picture of the future 
challenges posed by the ageing HIV-population.   
Conditions related to memory loss will become particularly important for the treatment 
efficacy of multi-morbid HIV-patients.  In HIV-patients, dementia can be the result of a number of 
causes, including late-onset Alzheimer, HIV-associated mild neurocognitive disorder or AIDS-related 
dementia [15,309–312].  Studies have shown that HIV can enter the central nervous system via 
infected macrophages.  This can trigger a cascade of events, including the release of neurotoxins that 
affect the formation of memory [315].  Loss of memory can complicate the treatment of HIV-patients.  
Patients can find it difficult to adhere to their treatment regimens, forgetting pills, particularly in light 
of the ever increasing pill burden, thus compromising the effectiveness of both HIV and co-
administered treatments.   
Future expansions of the model may also benefit from modelling individual cancers or groups 
of cancers, rather than non-AIDS malignancies as a whole.  There are many types of cancers, all of 
which differ starkly in their risk factors, treatment and long-term outcomes [316].  It is their large 
number and incidence rate that make them difficult to study in more detail in HIV-infected people. 
For example, the incidence of breast cancer in the UK (the most common cancer in the UK), is 157 
new cases per 100,000 women [317].  The number of HIV-patients in the Netherlands does not 
constitute a large enough population to study the large number of different cancers in any greater 
detail.  Large multi-cohort studies, like the D:A:D Study into adverse events, may provide more data 
in the future [318].  Interestingly, although HIV-patients are at an increased risk of cancer compared 
to the general population, age of onset may only be minimally younger compared to the general 
population [319].  Furthermore, some age-related cancers have not been found to be increased in age-
matched HIV-patients, such as breast cancer in women and prostate cancer in men [319].   
Although one of the strengths of the model is that co-morbidities, including malignancies, 
were defined using  clinical and laboratory tests as per EACS guidelines for diagnosis [60], certain 
conditions, for example hypertension and hypercholesterol are not discreet statuses.  Both blood 
pressure and lipid counts exist on a continuous scale.  The model does not simulate the potential 
treatment of sub-clinical hypertension, hypercholesterol and renal insufficiency nor its impact on 
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other co-morbidities with common causal pathways.  Subclinical hypertension and hypercholesterol 
have been shown to be risk factors for other CVD.  A study by Kuller and colleagues showed that 
patients with subclinical cardiovascular disease were at higher risk of total coronary heart disease 
including CVD-related death and non-fatal MIs than those without subclinical disease [320].   
The physiological mechanisms that affect the development of co-morbidities are numerous 
and multi-factorial.  There is a large body of literature on factors affecting the development of 
different co-morbidities, including lifestyle factors.  CVD, for example, has been associated with a 
large number of different risk factors, including age, sex, hypertension, diabetes mellitus, smoking, 
dyslipidaemia (abnormal amounts of lipids in the blood) [321–324], and smoking is a well-established 
risk factor for lung cancer [234].  In fact, lifestyle factors can be a more important risk factor than 
HIV-infection or HIV-treatment [232,233].  There were insufficient data on lifestyle in the ATHENA 
cohort to incorporate it into the model.  In the future patients could be divided into ‘healthy’ and 
‘unhealthy’ lifestyle category, contributing in this way to their risk of developing co-morbid diseases 
such as CVD, and cancers.  Another approach would be to include a risk framework, such as the 
Framingham or D:A:D framework to better predict the development of co-morbidities.   
ARV use has also been associated with the development of a number of co-morbidities.  HIV-
treatment can cause toxicities affects virtually all organ systems.  Reported toxicities include diabetes, 
hepatotoxicity, renal insufficiency, dyslipidaemia, pancreatitis, neuropathy and lactic acidosis 
[89,218–223] with NNRTIs, Abavcavir and some PIs, for example, associated with cardiovascular 
toxicity [224,225,325] and PIs with osteoporosis [209].  The impact of ARV on patients is complex, 
with some ARVs changing the bioavailability or metabolism of other ARVs.  The decision was made 
not include the effect of ARVs on co-morbidities into the model at this stage.  The historic impact of 
ARV on the development of co-morbidities cannot be disentangled entirely from the current work.  It 
is likely that the model parameters used in this model reflect some aspects of past ARV use, like the 
impact of ABC on CVD.   
Mechanisms that link co-morbidities may also have a time-dependent aspect, with risks for 
other co-morbidities being cumulative in the long-term.  For example, a patient who has hypertension 
is at an increased risk of other cardiovascular events, such as an MI [321–324].  However, the patient 
does not have the same increased risk of experiencing an MI the day his blood pressure rises to above 
the clinical threshold for hypertension.  Rather, his hypertension is going to cause long-term damage 
to his or her cardiovascular system which in the longer-term will put him at an increased risk of an 
MI.  At this stage the model does not capture this aspect.  However, the fact that co-morbidities are 
modelled as a function of age may capture some aspects of this time-dependence in the model.   
One potential source of information that could address many of these limitations is the 
AGEhIV Cohort Study.  The AGEhIV Cohort Study is a prospective cohort study in the Netherlands 
that was established in 2010.  Its aims are to investigate the prevalence and incidence of a broad range 
of age-related co-morbidities and their risk factors in HIV-infected patients and non-HIV-infected 
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controls [326].  It collects a number of clinical markers with the goal of providing data on the 
independent effect of HIV-infection on the development of a number of co-morbidities.  The study 
should allow the model to be expanded, by including other age-related co-morbidities such as 
Alzheimer’s, Parkinson’s and other conditions.  It will also be able to provide parameters on risk 
factors for these co-morbidities, including lifestyle factors.  These results can be expected over the 
next few years.   
One aspect of clinical care that is difficult to capture in a model is the complex and multi-
factorial nature of prescribing medication in multi-morbid HIV-patients, including prescription 
practices and behaviour of clinicians.  Balancing harm and benefit to the patients as well as cost to the 
health care system is paramount [191].  By designing the model with the consultation of treating 
physicians, it was possible to capture some of the main aspects of clinical care of HIV-patients, such 
as the exclusion of co-medication like simvastatin that is contra-indicated in HIV-patients [60,327] .  
However, the treatment of multi-morbid HIV-patients is a complex area of clinical care.  Patients 
differ greatly in terms of their individual medical needs and risk factors.  Two patients who present 
with hyperglycaemia may be treated very differently by the same physician.  Their treatment will 
depend on a number of factors, including their level of hyperglycaemia, age, family history, and 
medical history [60].  An elderly patient with hypertension and diabetes may be put on preventative 
treatment for more serious CVD as well as treatment for their diabetes.  A younger patient with no 
other co-morbidities, who presents with hyperglycaemia, may be encouraged to make lifestyle 
changes prior to putting him or her on treatment.  These individual factors mean that in reality, 
treatment of patients can be very complex.   
The model has to make assumptions about the co-administration of medication.  For example, 
the model assumes that the co-administration of drugs is independent of age and sex.  The model 
further assumes that a patient’s need for co-medication is only evaluated after they are diagnosed with 
a co-morbidity.  The model does not allow for patients to have this need revaluated over time.  While 
this is not what occurs in reality, it is in line with the aims of this model; that is, to quantify the burden 
of polypharmacy and its effects on HIV-treatment at one point in time.   
In the model, it is assumed that prescribing behaviour will continue to follow a similar pattern 
to that observed over the last 15 years.  Prescribing behaviour may change in response to an ageing 
population in that whereas only a proportion of co-morbid patients currently receiving co-medication, 
this may change with ageing of patients in clinical care.  As mentioned, the clinical care of patients 
depends on the combination of unique factors.  The increasing number of older patients may change 
prescribing behaviour significantly in the future, as older patients may be seen to be at ‘higher’ risk.  
Consequently, the model projections may underestimate the true future burden of polypharmacy.  
Furthermore, guidelines for the treatment of co-morbid HIV-patients may change, as new research is 
published on drug interactions and polypharmacy in older HIV-patients, and new drugs are developed.   
Chapter 3 – Model construction 
109 
The model could have been designed with increased complexity.  For example, it could have 
included assumptions surrounding lifestyle factors or modelled additional co-morbidities, as described 
above.  However, this would have come at the cost of the reliability of the output.  The fact that the 
model was designed after consulting treating physicians was created using a large non-selective 
database that collects data from all HIV-infected patients in clinical care in the Netherlands, and is 
informed by an extensive literature review means this is a very powerful model.  The right balance 
was achieved, utilizing data, literature and assumptions to create a robust model.   To my knowledge 
this is the first model to capture key aspects of an ageing Dutch HIV-population, including co-
morbidity, polypharmacy and cART and it will be valuable tool in providing a picture of the future 
challenges in clinical care of an ageing HIV-population in the Netherlands.  The future aim is to 
further expand this model through continued collaboration with the ATHENA cohort and the AGEhIV 
Cohort Study and to adapt the model to new settings through new collaborations.  The direction of 
future work is outlined in detail in Chapter 6 (Section 6.5 Future Work, page 159), and includes the 
numerous points outlined above.   
In summary, an individual-based model of an ageing HIV-population in the Netherlands was 
constructed.  This model can be used to predict the future age-structure, and the burden of age-related 
co-morbidity and polypharmacy on HIV care, as well as to the impact of interventions aimed at 
improving patient outcome and clinical care.  It provides a powerful tool that can be used in a range of 
applications, and can be adapted to a number of different settings to quantify the future demands on 
the health care system as well as to inform policy on how to ensure a continued high standard of care.   
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Abstract 
Background As the HIV-population is ageing and HIV clinical care is becoming increasingly 
complex to manage, it is important to quantify the scale of the problem facing HIV care in 
Netherlands in the future.  The individual-based model of an ageing HIV-population described in 
Chapter 3 provides a powerful framework to carry out a thorough analysis of the issues facing HIV 
care in the Netherlands.   
 
Method An individual-based model of the ageing HIV-population in the Netherlands was constructed 
and parameterized based on scientific literature and data from 10,278 patients in the Dutch ATHENA 
cohort between 1996 and 2010.  The model follows people on HIV-treatment as they age, develop co-
morbidities including CVD (hypertension, hypercholesterol, MI and stroke), diabetes, renal 
insufficiency, osteoporosis and malignancies, and start co-medication for these co-morbidities.  We 
aim to use this mathematical model to quantify the future age structure, burden of co-morbid disease 
and polypharmacy in the Netherlands.   
 
Results The age of the HIV-patients in clinical care in the Netherlands will shift to an older age; the 
median age of patients in clinical care in the Netherlands is expected to increase from 43.9 years in 
2010 to 56.6 in 2030.  The proportion of HIV-patients aged ≥50 years will increase from 28% in 2010 
to 73% in 2030.  As a consequence, more patients will suffer from co-morbid disease; by 2030 84% 
of patients are expected to suffer from at least one co-morbidity, up from 29% in 2010, and 28% will 
suffer from three or more co-morbidities.  The increase in the burden of co-morbidity will be driven 
by a steep increase in CVD.  Consequently, by 2030, 54% of patients will be prescribed at least one 
co-medication, compared to only 13% in 2010, and 15% of patients in clinical care in 2030 will take 
three or more co-medications.  Cardio-vascular medication will make up the largest part of 
polypharmacy.  The number of patients who will experience potential drug-drug interactions will 
increase; by 2030 40% of patients may experience complications with current recommended 
regimens.  36% of these patients may experience potential interactions, requiring additional 
monitoring and 4% will be prescribed a combination of co-medication and HIV-medication with 
currently unknown drug-drug interactions, compared to 6% and 1% respectively in 2010.   
 
Conclusion The age-structure of HIV-patients in the Netherlands is rapidly shifting to an older age.  
By 2030, almost three quarters of patients will be aged 50 or over.  This will result in an increased 
burden of co-morbidity, polypharmacy and an increasing proportion of patients who will experience 
potential complications with their HIV-treatment.   
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4.1 Background 
In the last 30 years, the HIV epidemic has emerged as one of the major global health challenges, 
becoming one of the world’s leading cause of mortality and disease burden over the decades 
[2,4,328].  HIV has continuously presented the scientific community with challenges; from the first 
cases of a hitherto unknown disease to the identification of the human immunodeficiency virus in 
1983 [171], from developing the first ARV, zidovudine, in 1987 [37], to the introduction of effective 
treatment with triple therapy in 1996.  The great leaps and developments in the field of HIV are now 
throwing up a new challenge; that of an ageing HIV population.  Effective treatment has resulted in 
HIV-patients increasingly suffering from age-related non-infectious co-morbidities that they 
previously did not live long enough to endure [15].  Whereas the incidence of AIDS-defining 
mortality has decreased markedly over time [329], mortality related to non-AIDS diseases has 
increased amongst HIV-1 infected patients on cART [9,10,330–333].  The increasing prevalence of 
co-morbidity complicates the management of HIV-patients [14,15].  Comorbid disease causes 
problems with polypharmacy, the co-administration of multiple co-medications with HIV-medication, 
leading to higher pill burden [14,15], potential drug interactions and drug toxicity, loss of efficacy of 
the co-administrated medication and virological breakthrough.   
The issue of co-morbidity is amplified amongst HIV-patients by the fact that HIV-infected 
people develop more co-morbidity and may do so at an earlier age than in the age-matched uninfected 
population [5,9,10,196,197,334].  This has been shown for a number for co-morbidities, including 
cardiovascular disease [198–201,231], non-AIDS malignancies [203,204], liver and kidney disease 
[206–208], and osteoporosis [209,210].  In addition, correlations have been demonstrated between 
stroke, MI, renal failure, diabetes and a number of risk factors such as hypertension and 
hypercholesterol [335–338], suggesting that people with one or more co-morbidities could be at 
higher risk of developing others.  In addition to traditional risk factors such as hypertension and 
hypercholesterol, and lifestyle factors such as smoking, HIV-infected patients seem to be at increased 
risk of co-morbidities due to a combination of several other factors.  Long-term use of ARVs can 
cause metabolic abnormalities, for example dyslipidaemia, insulin resistance, diabetes, and 
lipodystrophy,  and sustained HIV-associated immune activation and chronic inflammation have all 
been shown to be associated with increased risk of co-morbid disease [191,206,325].   
The ageing HIV-population will put new demands on the health care system, creating several 
important implications for the clinical care of HIV-infected patients [14,15,190,191].  Public health 
experts say that treatment services established in response to the AIDS epidemic will need to expand 
to address the unique health problems of the world’s ageing HIV population.  Until recently, this 
population has been relatively ignored.  Most studies of HIV-treatment have excluded patients of 
advanced age and those with co-morbid disease [15].  Little data exist on the long-term toxicity of 
cART, on dosing and the pharmacokinetics of HIV and co-morbid drugs in older HIV-patients, or on 
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the ideal cART regimen in older patients.  With these patients becoming increasingly complex to 
manage it is important to quantify the scale of the problem facing the Netherlands in the future.  We 
aim to use a mathematical model, parameterized using the ATHENA Dutch cohort data to quantify 
the age structure, and burden of co-morbid disease and polypharmacy in the Netherlands.   
 
 
4.2 Method 
The full details of the model structure can be found in Chapter 3.  Briefly, the model follows HIV-
patients from the start of treatment, as they age, develop co-morbidities, namely diabetes, 
hypertension, hypercholesterol, osteoporosis and renal insufficiency or experience a stroke, MI or 
malignancy, and start co-medication for these co-morbidities.   
The model also simulates the number of patients who will initiate cART in the future.  Three 
incidence scenarios for the future of HIV-infection in the Netherlands were assumed (minimum, 
medium and maximum incidence rate, (see Chapter 2, Section 3.3.3.2 Incidence of Starting 
Treatment, page 84), for more details).  This chapter will present the results when assuming a medium 
incidence rate.  Results for simulations using the minimum and maximum incidence rate can be found 
in Appendix D.  The pattern of the output is similar between all three scenarios, with the main 
difference being the total number of people initiating treatment.   
 
4.2.1 Aims 
We aim to use a mathematical model, parameterized on the ATHENA Dutch cohort data to: 
 predict the future age structure of HIV-patients in the Netherlands, 
 quantify the future burden of co-morbidity as well as identify the key co-morbidities,  
 quantify the future burden of polypharmacy and types of co-medication commonly 
prescribed,  
 quantify the burden of drug interactions and long-term restrictions in recommended cART 
regimens.   
 
 
4.3 Results 
4.3.1 Changing Age Structure 
The median age of people in clinical care in the Netherlands is rapidly shifting to an older age (Figure 
4.1A).  The model predicts that the median age of patients in follow-up will increase from 43.9 years 
in 2010 to 50.5 years old in 2020, and 56.6 years in 2030.  As a consequence, the age structure will 
move increasingly to patients aged over 50 years old, with 73% of HIV-patients aged above 50 years 
Chapter 4 - The future of an ageing HIV-population 
114 
by 2030 compared to 28% in 2010.  The proportion of patients aged ≥60 and ≥70 will increase from 
9% and 2%, respectively, in 2010 to 39% and 12% by 2030.   
In parallel, the number of younger HIV-patients will decrease; the number of patients aged 
<30 years old and 30 to 40 years old will decrease from about 800 and 2,900 in 2010 to 100 and 800 
by 2030.  In contrast the number of HIV-patients aged 60-70 and over 70 years old will increase from 
about 700 and 200 to 4,000 and 1,700 (Figure 4.1B), if current linear trends in age at start of treatment 
continue in the future.   
 
A. B.  
Figure 4.1.  A. Future age distribution of HIV-patients in clinical care in the Netherlands.  B. Projection 
of number of people per age group assuming a medium HIV-incidence rate.   
 
4.3.2 Causes of Deaths 
The ageing HIV-population will result in an increase in mortality amongst HIV-patients on cART.  
An analysis of mortality amongst HIV-patients in clinical care shows that annual percentage deaths 
amongst patients on cART will increase from around 1% of HIV-patients in care in 2010 to around 
3% by 2030.  This increase will largely be driven by an increase in the number of people dying as a 
consequence of CVD, as well as those dying due to complications arising from diabetes (Figure 4.2).  
Mortality due to CVD will account for 51% of deaths, and mortality due to complications from 
diabetes for around 25% of deaths, when excluding AIDS related deaths.   
 
 
Figure 4.2.  Changes in the number of cause-specific deaths between 2010 and 2030 amongst HIV-patients 
in clinical care in the Netherlands.   
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4.3.3 Burden of Co-morbid Disease 
The burden of co-morbid disease amongst HIV-infected patients in the Netherlands is expected to 
increase from 2010 to 2030 as a result of the ageing HIV-population.  The proportion of people with 
one or more co-morbid disease will increase from 29% in 2010 to 84% in 2030.  This increase is 
expected to level off after 2028, reflecting a reduction in the total number of HIV-patients in clinical 
care in the Netherlands, as more patients die than enter care annually, under the assumption of a 
medium HIV incidence rate.   
As co-morbidities, as well as age, can increase the risk of developing other co-morbidities 
(see Chapter 3, Section 3.3.3.3.2 Common Causal Pathways of Co-morbidities, page 87), the number 
of patients suffering from multi-morbidity, i.e. three or more co-morbidities, will also increase 
between 2010 and 2030. In 2010 0.3% of patients had three or more co-morbidities, 1% of patients 
over 60 and 0.7% of those aged 50 or over.   By 2030 multi-morbidity will affect 28% of patients in 
clinical care, with 46% of patients aged over 60 and 36% of patients 50 years and over experiencing 
three or more co-morbidities.  Meanwhile, the proportion of patients with no co-morbid disease will 
decrease from 71% in 2010 to 16% in 2030 (Figure 4.3).   
 
       
Figure 4.3.  Stacked bar graph of the burden of co-morbidities in HIV-patients between 2010 and 2030 as 
projected by the model.   
 
 
We used the model to investigate which co-morbidities will drive this increased burden.  We 
focused on the co-morbidities with common causal pathways, namely CVD, renal insufficiency and 
diabetes.  Figure 4.4 illustrates the changes in these co-morbidities from 2010 to 2030.  The results 
clearly show that the majority of co-morbidity will be caused by CVD, including hypertension, 
hypercholesterol, strokes and MIs (Figure 4.4).   
In 2010, 19% of HIV-patients in clinical care were diagnosed with at least one CVD.  In 2020 
63% of HIV-patients will suffer from at least one CVD, by 2030 this will increase to 79%.  Diabetes 
will make up the second major of those three co-morbidities in the future, with the prevalence of 
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             CVD 
            Renal Insufficiency 
           Diabetes 
diabetes increasing from 3% in 2010 to 11% in 2030.  Only 1% of patients had renal insufficiency in 
2010, however by 2030 this will increase more than ten-fold to 14%.  In 2010 multi-morbidity was 
diagnosed in 2% of patients in clinical care.  Model projections suggest that in 2030 26% of patients 
will suffer from more than one of these co-morbidities, up from 14% in 2020.   
 
 
Figure 4.4. Diagrams representing the changes in the relative number of patients with specific co-
morbidities types and overlap in co-morbidity types in A. 2010, B. 2020, and C. 2030, with the area being 
representative of the number of HIV-patients with co-morbidities.   
 
 
4.3.4 Burden of Polypharmacy 
Unsurprisingly, one of the main consequences of the increasing burden of co-morbidity will be an 
increase in the number of patients who take co-administered medication (Figure 4.5).  Our model 
predicts that the proportion of HIV-patients taking one or more co-medication will increase from 13% 
in 2010 to 54% by 2030.  In parallel, the overall proportion of patients with three or more co-
morbidities is expected to increase to 15% by 2030, with 20% of patients over 50 and 36% of patients 
aged 60 and over prescribed three or more co-medications.  In 2010 only 2% of patients were 
prescribed three or more co-medications.  Amongst patients aged ≥50 and ≥60, this proportion was 
6% and 14%, respectively.  This increase in polypharmacy will drive a decrease in the proportion of 
patients taking no co-medication from 87% in 2010 to 46% in 2030 (Figure 4.3).   
A consequence of the rising burden of CVD is the fact that the increase in polypharmacy will 
mainly be driven by an increase in the number of patients prescribed medication for CVD (Figure 
4.6).  Figure 4.6 shows the co-medication profile of patients in clinical care in the Netherlands, based 
on a cross-sectional representation of 1,000 patients.  The figures show that the changes in co-
medication between 2010 and 2030 will be driven by the changes in co-morbid disease with an 
increasing number of patients prescribed medication for CVD and for diabetes.  In 2010 cardio-
vascular medication was used by 9% of HIV-patients in the Netherlands.  This is predicted to increase 
to 50% of HIV-patients by 2030.  In parallel, the proportion of patients who will take both anti-
 
 
 
A.      B.  
C.      
2030 
2010 2020 
Chapter 4 - The future of an ageing HIV-population 
117 
diabetic and cardio-vascular co-medication is projected to increase from 2% in 2010 to 7% in 2030, 
which may reflect the physiological links between diabetes and some CVDs (see Chapter 3, Section 
3.3.3.3.2 Common Causal Pathways of Co-morbidities, page 87).  The proportion of patients taking 
both CVD medication and osteoporosis medication will increase from 0.1% in 2010 to 3% in 2030.   
 
 
Figure 4.5. Stacked bar graph of the burden of co-medication in HIV-patients on cART between 2010 and 
2030 as projected by the model.   
 
A.      B.  
C.   
Figure 4.6.  Changes in prevalence of co-medication between A. 2010, B. 2020, and C. 2030 as projected 
by the model.  Figure represents cross-sectional number of patients on the different types of co-
medications based on a 1,000 patients, with the black area indicating patients on treatment and the white 
area indicating the patients not on treatment.   
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4.3.5 Impact of Polypharmacy on HIV Treatment 
Due to the increase in co-morbidity and polypharmacy, the number of HIV-patients experiencing 
drug-interactions and contra-indications will increase between 2010 and 2030.  The Liverpool Drug 
Interaction webpage contains information on the potential drug interactions between HIV-medication 
and co-medication (Chapter 3 Table 3.12, page 100), providing information on which combinations 
are contra-indicated and may require additional monitoring or should not be co-administered.  In 
addition to this table, the EACS guidelines show that certain co-morbidities are contra-indicated for 
certain ARVs, for example renal disease and TDF and severe CVD and ABC.  Figure 4.7A to D 
shows what impact the increased burden of polypharmacy and co-morbidity may have on different 
ARV subclasses according to the Liverpool Drug interaction list and EACS guidelines, assuming that 
no new ARVs are licensed for HIV-treatment.  The figures show that drug interactions will become a 
major challenge for HIV care.   
The number of people who will require additional monitoring for all seven NRTIs is predicted 
to increase from around 300 patients (3%) in 2010 to around 800 patients (6%) in 2030 (Figure 4.7A), 
because of  the increased number of patients who will be starting alendronic acid for the treatment of 
osteoporosis.  A steeper increase will be observed in the number of people who will require additional 
monitoring for one or more of the NRTIs.  These patients will all require additional monitoring for 
either ABC and/or TDF, which together form the backbone to all recommended cART regimens.  
EACS guidelines provide recommendations on additional monitoring, for example, patients on TDF 
will require additional monitoring of their creatine levels [60].  If future trends in prescribing patterns 
for co-medication continue, around 4,700 patients (33%) will require additional monitoring for at least 
one NRTI by 2030 compared to only 600 patients (6%) in 2010 (Figure 4.7A).  Across all ARV 
subclasses, the number of patients taking co-medication with unknown interaction is driven up 
because of the increased use of the ACE inhibitor captopril, and the diuretics bumetanide or 
hydrochlorothiazide.  The proportion of people on co-medication who experience no known drug-
drug interactions with any NRTI will decrease from 45% in 2010 to 38% in 2030 (Figure 4.7A).   
A similar pattern can be observed with NNRTIs (Figure 4.7B).  Patients prescribed alendronic 
acid for osteoporosis or the calcium blocker verapamil for CVD will require increased monitoring if 
they are on any NNRTI.  These patients will increase from around 300 patients (3%) in 2010 to 
around 800 patients (6%) by 2030 (Figure 4.7B).  An increase in the use of the anti-diabetic 
glibenclamide, the calcium blockers amlodipine and nifedipine, and the statin atorvastatin will result 
in a steep increase in the number of patients who will require additional monitoring if they are on any 
NNRTI except for rilpivirine.  These patients will make up 13% of patients in clinical care by 2030.  
Overall the number of patients requiring additional monitoring for at least one NNRTI will increase 
from around 900 patients (9%) in 2010 to around 5,500 patients (38%) in 2030.  The number of 
patients taking co-medication with unknown interactions with NNRTIs will increase from about 100 
patients (1%) in 2010 to about 600 patients (4%) in 2030.  In contrast, the proportion of people on co-
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medication who experience no known drug interactions will decrease from 22% in 2010 to 18% in 
2040 (Figure 4.7B).   
The increased use of sulfonylurea derivatives (anti-diabetics), cardiovascular medication 
including all calcium blockers, and the statins atorvastatin and rosuvastatin, as well as the use of 
alendronic acid for osteoporosis will result in an increased need to monitor patients on any PI.   The 
number of patients being prescribed at least one of these co-medications will increase nearly 55-fold 
from 650 (7%) in 2010 to around 3,000 (21%) in 2030 (Figure 4.7C).  Overall the number of people 
needing additional monitoring for at least one PI will increase from 600 patients (6%) in 2010 to 
3,500 (26%) in 2030.  The number of people using co-medication with unknown drug-interactions 
with PIs is predicted to increase from 100 patients (1%) in 2010 to 500 (7%) in 2030, while the 
proportion of people who will experience no known drug-interactions will decrease from 23% in 2010 
to 14% in 2030 (Figure 4.7C).   
Finally, the number of patients who will have drug interactions while on any integrase or 
entry inhibitor will more than double between 2010 and 2040, from around 300 patients (3%) to 
around 800 patients (6%) in 2030 (Figure 4.7D).  This change will be driven by increased use of 
alendronic acid for the treatment of osteoporosis.  Further drug interaction with one or more of the 
entry inhibitors or integrase inhibitors will be due to the increased prescription of anti-diabetic 
medication, calcium blockers, the beta blocker metoprolol and the statin atorvastatin.  These patients 
will need additional monitoring for any potential drug interactions.   
As can be expected, the rise in drug interactions and contra-indications are going to cause an 
increase in the proportion of patients in clinical care who will experience restrictions or potential 
problems with recommended cART.  Figure 4.8 shows the potential impact that the increased burden 
of polypharmacy and co-morbid disease will have on cART regimens recommended by 2013 EACS 
guidelines (see Chapter 3 Table 3.11, page 99).  The results show that the proportion of individuals 
who will experience drug-interactions with recommended regimens will increase from 7% in 2010 to 
36% by 2030.  The proportion of people who will take co-medication with unknown drug-interactions 
with recommended cART will increase from 1% in 2010 to 4% in 2030.  Consequently, the ageing 
population will result in potential complications in up to 40% of patients in clinical care in the 
Netherlands by 2030, making current recommended regimens a burning platform in the absence of 
new ARVs with fewer drug interactions.  These issues with the regimens recommended by current 
EACS guidelines will mainly be driven by an increase in the use of alendronic acid for osteoporosis, 
and calcium blockers and sulfonylurea derivatives for diabetes.   
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C. D.  
Figure 4.7. Stacked bar graph of the number of HIV-patients with potential interactions between their co-medication and A. NRTIs, B.  NNRTIs, C. PIs and D. 
Entry, fusion and integrase inhibitors.   
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A. B.  
 
C.  
Figure 4.8.  Impact of increasing prevalence of polypharmacy on drug interactions with recommended 
cART regimens in A. 2010, B. 2020, and C. 2030.  Recommended regimens are a backbone of TDF/FTC 
or ABC/3TC combined with either EFV, nevirapine, raltegravir or ritonavir-boosted atzanavir, 
darunavir or lopinavir as listed by the current Europe AIDS Clinical Guidelines.   
 
 
4.4. Discussion 
The age of the HIV-population in clinical care in the Netherlands is rapidly shifting to an older age.  
The median age of patients in clinical care is expected to increase from 43.9 in 2010 to 56.6 years by 
2030.  The proportion of HIV-patients aged ≥50 will increase to 73% in 2030.  As a consequence of 
this ageing patient population, co-morbid disease will become an increasing problem among HIV-
patients, with 84% of patients expected to suffer from at least one or more co-morbidities in 2030, up 
from 29% in 2010.  More concerning, 33% of patients in 2030 will suffer from multi-morbidity of 
three or more conditions compared to only 0.5% of patients in 2010.  This increased burden of co-
morbidity will be driven by a steep increase in CVD.  The increase in co-morbid disease will also 
result in an increased burden of polypharmacy.  By 2030, 54% of patients will be prescribed at least 
one co-medication, compared to only 13% in 2010, and 15% of patients will be taking three or more 
co-medications.  The majority will be on cardio-vascular medication, reflecting the increase in CVD.  
These changing trends will lead to an increase in the number of patients who will experience potential 
problems with HIV-medication.  By 2030 40% of patients may experience complications with the 
current recommended regimens; 36% of those may experience potential interactions, requiring 
additional monitoring and 4% of HIV-patients will be taking a combination of co-medication and 
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HIV-medication with currently unknown drug interactions, up from 6% and 1%, respectively, in 
2010.   
The projections in age-structure are similar to those reported by Jansson and colleagues and 
the HIV Monitoring Foundation [185,186,339].  Jansson et al. constructed an agent-based stochastic 
geographical model to determine future demographic patterns of HIV-infected people in Australia.  
Their model predicted that, by 2020, 44.2% of HIV-infected people will be aged 55 years or over 
[339].  The HIV Monitoring Foundation projected that by 2015, 41% of the HIV-patients registered in 
the HIV-treatment centres in the Netherlands will be aged over 50 [185,186].  Our model estimates 
that by 2020 around 50% of HIV-patients will be aged 50 or over.  Similarly, in the USA it has been 
estimated that by 2015, around 50% of the HIV-population will be 50 years or older [340].  In 
contrast to the developed world, current estimates in sub-Saharan Africa report that around 13% of 
HIV-patients are aged 50 years or older [341], which differs starkly from the current 37% in the 
Netherlands, according to the 2013 Monitoring Report [175].  A model of the age-composition in sub-
Saharan Africa by Hontelez and colleagues projects that this proportion will increase to around 25% 
by 2040 [342].  In comparison, for the Netherlands we projected that around 72.9% of HIV-patients 
will be aged over 50 by 2030.  This gap reflects the differences in the population structure and 
epidemic between the developed and developing world.  Overall, the projections surrounding an 
ageing HIV-population rely on the assumption that the population is going to age at a similar rate as it 
has done since the introduction of cART in 1996.  In the Netherlands, the SHM reports that while 
medium age overall and amongst those starting cART in the cohort is still on the increase, there is 
also an observed increase in the number of new infections occurring in younger birth cohorts [175].   
A number of studies have shown a shift in the causes of deaths of HIV-patients since the 
introduction of cART from AIDS-related to non-AIDS related deaths [57,176,343].  A recent study by 
Weber and colleagues looked at mortality rates amongst HIV-patients in clinical care in the Swiss 
cohort [343].  They found that non-AIDS malignancies accounted for 19% of deaths, AIDS for 16%, 
liver failure for 15%, and MIs for 6% of deaths [343].  Their study differs compared to our model 
analysis of causes of deaths, where the majority of deaths were caused by CVD and complications 
related to diabetes, so it is difficult to compare our output to the real world finding of Weber and 
colleagues.  One of the main differences is that the two studies looked at causes of deaths differently, 
and that the model in this thesis does not include AIDS-related mortality.  In the future it may be 
interesting to simulate CD4 counts and its relationship to AIDS-mortality in order to model how cause 
of death will change over time. It may also be interesting to include better data on the independent 
effect of HIV-infection on the development of co-morbid disease (see Chapter 3, Section 3.5 
Discussion, page 104).  This would help to provide an estimate of the proportion of deaths that are 
linked to HIV-infection.  A study by Braithwaite and colleagues estimated the proportion of deaths 
amongst HIV-infected patients not directly attributed to HIV to be 36% for 30 year olds and 72% in 
50 year olds [344].   
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No studies could be found that projected the burden of co-morbidity or polypharmacy in the 
future.  Morzolini and colleagues investigated current prevalence of co-medication and potential drug-
drug interactions in Switzerland.  They found that 68% of patients were taking at least one co-
medication and that 40% of patients had experienced potential side effects [300].  In contrast, our 
model of the HIV-population in the Netherlands shows that only 12.5% of patients were taking one or 
more co-medications and 8% had potential drug interactions with recommended regimens in 2010.  
These differences may in large part be explained by the fact that the Swiss study included all co-
medication, compared to only the limited number investigated in our model, and that in the Swiss 
study potential drug interactions with all ARVs were taken into account, compared to only the ARVs 
in the recommended regimens in our model.  Although the model output could not be compared to 
other similar studies, model checks have shown that trends produced by this model are comparable to 
ATHENA data, at least in the short-term (see Chapter 3, Section 3.4 Model Checks, page 101).   
What the model and other studies of ageing of HIV-patients clearly demonstrate, is that the 
ageing HIV-population will put new demands on the health care system, creating several important 
implications for health care providers and for the health of HIV-infected patients in clinical care 
[14,15,190,191,196,197,202,211,345].  Miller and colleagues found that patients older than 42 years 
old with more than three co-morbidities were at a higher risk of drug interactions [346], which may in 
part be explained by the fact that older HIV-patients have better adherence rates to HIV-treatment 
compared to younger patients [347].  Treatment services established in response to the HIV-epidemic 
will need to expand to address the unique health problems of the world’s ageing HIV-population, 
shifting from a vertical health care approach to HIV-treatment to a more horizontal approach, with 
more communication between specialists.   
Studies and controlled trials on therapeutic and clinical outcomes in older HIV-infected 
patients are needed.  Until recently, this population has been relatively ignored, with most randomized 
trials of cART excluding older patients or those with co-morbid disease [15].  Consequently, many 
questions remain about the clinical care of ageing HIV-patients, the tolerability of cART in multi-
morbid patients, the impact of a large pill burden on treatment outcome, pharmacodynamics and 
pharmacokinetics in older patients, and the -drug interactions between cART and co-administered 
medication, all of which will be discussed in more detail below.   
As shown by the evaluation of clinical care since 1996 (Chapter 2), although newer drugs 
with better tolerability and simpler dosing have significantly improved the tolerability of cART, 
toxicity remains one of the main problems in clinical care in the Netherlands today.  Studies in other 
countries also report toxicity as the main reason that patients switch cART regimens 
[149,150,152,279].  An ageing HIV-population with an increased need for polypharmacy is likely to 
exacerbate this problem.  Yet, there are relatively little data on toxicity of cART in older HIV-
patients.  There is an urgent need for data about treatment tolerability, drug interaction with ARVs 
and co-medication and the effect of short- and long-term toxicity of cART in ageing HIV-patients 
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[15].  Toxicity is a major cause of morbidity, reducing quality of life, and can compromise adherence 
leading to sub-optimal cART efficacy, virological breakthrough and resistance [14,15].   
As the need for polypharmacy increases, another problem that will arise is that of a growing 
‘pill burden’.  A large pill burden can compromise adherence, as patients forget to take pills, get tired 
of taking pills or choose to miss pills to avoid or reduce toxicity.  In HIV-treatment near-perfect 
adherence is necessary to achieve suppression of viral load, maintain a healthy immune system, and 
slow disease progression [348].  Studies have shown that greater regimen complexity can result in 
reduced adherence [349].  Polypharmacy and pill burden in older patients are further complicated by 
other barriers, including dementia and reduced mobility [350].   
Another area where more data are needed is that of the pharmacodynamics and 
pharmacokinetics of drugs in older patients.  Pharmacodynamics refers to the relationship between 
drug concentration and the resulting effect and pharmacokinetics refers to the time course of drug 
absorption, metabolism and excretion [351].  Age-related changes in physiology can affect the 
pharmacodynamics and pharmacokinetics of medications by altering the function of drug-eliminating 
organs, such as the liver and kidney.  One major change in the body’s composition is an increased 
proportion of body fat as lean body mass and total body water decreases [352].  This can result in 
lipophilic drugs having an increased volume of drug distribution and prolonged half-life, and water-
soluble drugs having a decreased distribution volume [352].  In turn, this may imply a need for dose-
adjustment of drugs.  Other age-related physiological changes include declines in hepatic and renal 
function.  As hepatic metabolism and renal elimination are crucial to the clearance of drugs, older 
patients can experience reduced drug elimination and drug accumulation in the absence of dose-
adjustment [352].  This is particularly important when prescribing the majority of PIs and NNRTIs, as 
they can be hepatoxic [352].  It will be increasingly crucial to understand how changes in physiology 
affect the pharmacodynamics and pharmacokinetics of cART and co-administered medication in order 
to ensure continued efficacy of the treatment of HIV-patients and limit toxicity.   
The adverse consequences of polypharmacy have been linked to increased cost to both the 
patient and the health care system [352].  As described above, side effects reduce the quality of life of 
patients and even minor additional drug interactions can lead to increased frequency of visits to 
physicians, the need for additional laboratory tests, and switching to new medication to treat the new 
symptoms.  At their worst, drug interactions can lead to the need for consultation with specialists or 
even hospital admission.  A US survey into medical expenditure found that the prescription of 
inappropriate medication in older patients cost the health care system $7.2 billion between 2000 and 
2001[352,353].   
The increasing medical complexity of older multi-morbid HIV-patients will require a shift in 
clinical care of this sub-population.  Although physicians accumulate a wealth of experience on how 
to treat their patients to the highest standard of care, they often do so in their own medical field.  This 
can lead to a vertical approach to the medical care of patients, with HIV physicians managing a 
Chapter 4 - The future of an ageing HIV-population 
125 
patient’s HIV-infection, and cardiovascular physicians treating a patient’s cardiovascular conditions.  
Gurwitz and colleagues carried out a study of the incidence of preventable adverse drugs events 
amongst older patients in ambulatory settings.  They found that 28% of adverse drug events were 
preventable.  More concerning was their finding that 42% of adverse events categorised as serious, 
life-threatening or fatal were preventable [354].  Several studies have found that patients at greatest 
risk were those with multi-morbid disease, who were seen by several physicians, and whose 
prescriptions were filled by several different pharmacies [352].  These studies illustrate the need for a 
thorough review of a patient’s medication prior to prescribing additional medication.  Physicians can 
be reluctant to take a patient off a medication that was prescribed by another doctor.  Regular reviews 
of a patient’s prescribed medication and a horizontal approach to the management of these patients 
with a more cross-disciplinary clinical approach will become increasingly important in order to assure 
continued high quality care.   
Established frameworks for tailoring the care of multi-morbid patients exist [191,352].  The 
Beer criteria and the Medication Appropriateness Index are two such tools.  The Beer criteria provide 
a guidance on which drugs are contra-indicated for given pre-existing conditions in elderly patients, 
while the Medication Appropriateness Index provides a tool with which to establish the 
appropriateness of prescribing a particular medication, given a patient’s medical history.  However, 
some studies have shown that adherence to clinical practice guidelines in the care of older patients can 
be to the detriment of the patient.  A study by Boyd and colleagues evaluated the applicability of 
clinical practice guidelines, developed to improve the quality of care for chronic conditions, in the 
care of older patients with multi-morbid disease.  They found that adherence to these guidelines in the 
care of multi-morbid older patients could result in diminished quality of care, for example by 
increasing drug-interactions.  It is now a mandatory part of HIV clinical care for treating HIV-
physicians in the Netherlands to ask their patients to bring an overview of all their pharmacy.   
It remains unclear whether guidelines for the treatment of older HIV-patients should be 
modified.  For example, should the CD4 threshold for cART initiation be changed in older patients? 
How do the risks and benefits of early cART initiation differ in older patients? For instance, what is 
the trade-off between the benefits of early initiation versus the long-term toxicity of cART on the 
development of co-morbid disease, and does this differ with a patient’s age?  What is clear is that this 
new sub-population of patients is increasingly presenting with very complex medical histories, and 
will require tailored high quality care.  In addition to tailored co-management of HIV-infection and 
co-morbid disease, these patients will require routine and targeted medical care, including regular 
screening for particular co-morbidities.  Future research will be needed to inform how the health care 
system can best address the care of these patients, moving away from the ‘one-size-fits-all’ approach.   
Effectively addressing the issues of clinical care of older HIV-patients will not only require a 
large body of evidence, but also political will to strengthen the health care system, and support the 
financial and human resources needed to expand services and acquire expertise [355].  As stated by 
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Mills and colleagues: “political will is needed to put ageing of the epidemic on the agenda 
worldwide” [355].  In the past, political pressure has been very successful in the fight against the HIV 
epidemic; it helped mobilize donors, pharmaceuticals to drive down the annual price of cART from 
more than $10,000 to less than $100 per person in Africa [355].  Similar political commitment will 
help to put the problem of an ageing HIV-population on the international agenda and potentially help 
drive down prices for the treatment of important age-related co-morbidities, such as cancer [355].  
Providing a quantification of the issues arising as a consequence of the ageing HIV-population will be 
an important first step.   
To my knowledge this is the first model to simulate the future challenges of an ageing 
population, by quantifying future age-structure, burden of co-morbid disease, polypharmacy and drug-
drug interactions.  The accuracy of the predictions made by this model relies on the assumptions and 
limitations of the model, which are described in detail in Chapter 3.  By designing the model with the 
consultation of treating physicians in the Netherlands, using a large non-selective HIV dataset, and 
relying on in-depth literature review for parameterization, the model provides a powerful tool to carry 
out projections of an ageing population in the Netherlands.   
HIV-infection has become an increasingly complex chronic disease that is characterised by an 
increased burden of co-morbidity and polypharmacy.  As a result, an increasing proportion of patients 
are suffering from complications with their HIV-treatment.  These HIV-patients will increasingly put 
new demands on the health care system.  Treatment services established in response to the HIV-
epidemic will need to expand to address the unique health problems of the world’s ageing HIV-
population.  This will require a large body of research and political will.   
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Abstract 
Background Cardiovascular disease (CVD) is an increasingly important problem amongst HIV-
patients in the Netherlands.  Effective interventions are needed to address this emerging challenge for 
effective HIV care.   
 
Aims The aim of this Chapter is to compare the impact of a smoking cessation programme and a 
polypill for CVD as primary preventions for CVD in an ageing HIV-patient population in the 
Netherlands.   
 
Method An individual-based model of the ageing HIV-population in the Netherlands was used to 
compare the impact of a smoking cessation programme and a polypill on the primary prevention of 
CVD, patient outcome and treatment cost.  The model was parameterized using data from the Dutch 
ATHENA cohort and follows people on HIV-treatment from 2010 to 2030 as they age, develop co-
morbidities including CVD (hypertension, hypercholesterol, MI and stroke), diabetes, renal 
insufficiency, osteoporosis and malignancies, and start co-medication for these co-morbidities.   
 
Results Both a smoking cessation programme and the introduction of a polypill for CVD would have 
a positive impact on the clinical care of HIV-patients in the Netherlands, resulting in a long-term 
reduction in the burden of co-morbidity, polypharmacy and mortality. A smoking cessation 
programme would have the smallest impact on the clinical care of HIV-patients, while the 
introduction of a polypill for CVD for all HIV-patients aged 45 and over would have the greatest 
impact.  The polypill for HIV-patients aged 45 and over could result in a 13% reduction in multi-
morbidity and polypharmacy, and a 7% reduction in drug interactions.  A polypill intervention would 
result in health-care savings of 23 million Euros over a twenty-year period compared to standard care 
or 1,300 Euros per HIV-patient in care, when including the potential cost of the polypill.  All 
interventions have a cost per disability-adjusted life year (DALY) averted that is under the estimated 
WHO cost-effectiveness threshold of three times the per capita GDP.  The smoking cessation 
programme has the lowest cost per DALY averted, at €70 compared to €290 for a polypill 
intervention for HIV-patients aged 45 and over, although it would require a more than ten-fold higher 
initial investment than a polypill intervention.   
 
Conclusion Integrating a smoking cessation programme or changing HIV-treatment guidelines to 
include prescribing a polypill for CVD to all HIV-patients aged 45 or 55 years and over could 
improve the burden of CVD, improve patient outcome and be cost saving in the long-term.   
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5.1. Background 
CVD is becoming an increasingly important problem amongst HIV-patients in the Netherlands (see 
Chapter 4) as well as globally [149,222,325].  Effective HIV-treatment has resulted in HIV-patients 
increasingly suffering from age-related non-infectious co-morbidities that they previously did not live 
long enough to endure [15], with CVD now developing into an increasingly common cause of 
morbidity and mortality in HIV-patients [356,357].  In a recent study by the D:A:D Group it was 
reported that the prevalence of risk factors for CVD is increasing amongst HIV-patients [325].   
The major risk factors for CVD are well established [358], with nine out of ten potential 
modifiable risk factors accounting for approximately 90% of the population’s attributable risk for MIs 
and strokes [359,360].  In addition to traditional risk factors such as hypertension, hypercholesterol, 
and lifestyle factors such as smoking, HIV-infected patients are at increased risk of CVD due to 
factors associated with HIV-infection and HIV-treatment.  Sustained HIV-associated immune 
activation and chronic inflammation have been shown to be associated with increased risk of co-
morbid disease [191,206,325,357], while long-term use of ARVs has been shown to cause metabolic 
abnormalities, for example dyslipidaemia, insulin resistance, diabetes, and lipodystrophy 
[191,206,325,357].  The D:A:D Study found that the risk of an MI was increased by 13% and 16% for 
every additional year of exposure to an NRTI and a PI, respectively [361].  Despite the increased 
CVD risk associated with cART, strict adherence to HIV-treatment is vital to slow disease 
progression and prolong life expectancy [357].  Consequently, targets for primary prevention of CVD 
should be modifiable risk factors, such as smoking, high blood pressure and elevated lipids levels.   
There are different approaches to prevention.  One population-level approach to the 
prevention of CVD could involve the wide use of “proven inexpensive, and safe pharmacologicals” 
[360], which reduce multiple risk factors without increasing pill burden or toxicity [360,362].  The 
idea of such a “polypill” to reduce cardiovascular-related deaths was first proposed by Salim Yusuf in 
an article to the Lancet in 2002 and in more detail in a study by Wald and Law in 2004 [363,364].  
The polypill is a medication in single-pill form that combines multiple active pharmaceutical 
ingredients.  A polypill for the prevention of CVD includes effective and inexpensive drugs to reduce 
cardiovascular risk.  Yusuf hypothesized that a polypill containing aspirin, a beta-blocker, a statin and 
an ACE-inhibitor could reduce CVD by up to 75% in patients with a history of CVD.  Wald and Law 
suggested that a polypill containing three half-dose blood pressure-lowering drugs, aspirin, a statin 
and folic acid could reduce CVD by around 80% when prescribed to all patients 55 years of age or 
over, irrespective of their individual risk factors [363,364].  Their study further suggested that such a 
polypill could be used safely in the absence of screening or monitoring for risk factors, making it an 
ideal candidate for a low cost population-level intervention [360,364].   
Only a few studies have evaluated the effectiveness of the polypill for the primary prevention 
of CVD [365–368] (see Table 5.1).  These trials and studies used methods similar to Wald and Law 
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[369] (multiplying relative risks and a Markov model) to estimate the 5-year relative risk reduction in 
CVD [360,370,371].  The results found that a full-dose polypill could reduce the risk of coronary 
heart disease (CHD) by 70-80% and stroke by 64-75%, lower than estimates produced by Wald and 
Law [360,364,366].  A half-dose polypill was found to reduce the risk of CHD by 34-62% and stroke 
by 21-56% [365,368,371] (see Table 5.1).  None of the trials evaluated the impact of a polypill for 
CVD in HIV-infected patients.  The concept of the polypill has been hailed by some as revolutionary 
but strongly criticised by others as ‘medicalised’ prevention [360].   
Critics of the polypill are concerned that such an approach could lead people to abandon 
healthy lifestyle changes [360].  They favour an individual-level approach, targeting behavioural and 
lifestyle improvements, such as smoking cessation.  Smoking is an important modifiable risk factor 
for CVD amongst HIV-patients, that can be treated effectively with behavioural or treatment therapy 
[372,373].  Studies by the D:A:D Group and by Barbaro and colleagues found that smoking was a 
significant risk factor for CVD amongst HIV-infected individuals  [224,374].  More recently, the 
SMART study reported that HIV-patients who smoked were twice as likely to suffer various 
cardiovascular events compared to non-smokers [373,375].   
Smoking in particularly is an important risk factor amongst HIV-infected individuals.  Several 
studies have shown that smoking is more prevalent amongst HIV-infected individuals than in the 
general population.  Estimates report that between 50-70% of HIV-infected people in Europe and 
North America are current smokers [376–382].  In the Dutch ATHENA cohort, around 48% of HIV-
patients smoke, with 37% having an unknown smoking status.  In comparison only 27% of the 
general population in the Netherlands smokes [383].  Despite its importance and a call by the U.S. 
National Institute of Health State-of-Science on Tobacco Use to evaluate smoking cessation 
interventions in people with co-occurring conditions, few studies have investigated tobacco control 
interventions in HIV-patients and tobacco control has not been a priority in HIV-care [384,385] 
As HIV-infected individuals are increasingly at risk of CVD as they age, it will be important 
to develop evidence-led interventions targeting this new challenge, and ensuring continued high-
quality care.  Lifestyle interventions such as smoking cessation programs are attractive, as they are 
perceived as more ‘natural’ than interventions such as the polypill and because they aim to change 
lifestyle factors rather than treat them.  However, while individual-level prevention allows for a 
tailored approach, it can often involve high screening and programme costs.  Large studies have 
shown that educational or behavioural interventions only have modest and often unsustainable impact, 
failing to reduce the risk of CVD in the long-term [360,362,386].  Furthermore, despite established 
smoking cessation interventions, it is common for smokers to take multiple quitting attempts prior to 
become long-term quitters [384,387].  There is a need to evaluate the impact of different strategies for 
addressing CVD risk in HIV care.  The aim of this Chapter is to compare the impact of a smoking 
cessation programme and a polypill for CVD as primary prevention strategies for CVD in an ageing 
HIV-patient population in the Netherlands using a mathematical model.   
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Table 5.1.  List of studies of the polypill for the primary prevention of CVD.  The table illustrates the 
polypill formulation and the reported long-term risk reduction in coronary heart disease and stroke.   
Study Formulation Reduction in Risk, % Reference 
  CHD* Stroke Time 
period 
 
Wald and Law 2003 Simvastatin 40 mg, three blood pressure drugs, 
Aspirin 75 mg.   
88% 80% 5 years [369] 
Wald et al 2012 Simvastatin 40 mg, Amlodipine 2.5 mg, Losartan 
25 mg, Hydrochlorothiazide 12.5 mg.   
72% 64% 5 years [366] 
Indian Polycap Study 
2009 (low-dose)** 
Simvastatin 20 mg, Ramipril 5 mg, Atenolol 50 
mg, Hydrochlorothiazide 12.5mg,, Aspirin 100 mg.   
62% 48% 5 years [371] 
Indian Polycap Study 
2010 (full-dose) 
Simvastatin 40 mg, Ramipril 10 mg, Atenolol 100 
mg, Thiazide 25 mg, Aspirin 200 mg.   
70-
80% 
65-
75% 
5 years [360] 
Malekzadeh et al 
2010 
Atorvastatin 20 mg, Enalapril 2.5 mg, 
Hydrochlorothiazide 12.5 mg, Aspirin 81 mg.   
34% 21% NA [368] 
PILL Collaborative 
Group 2011 
Simvastatin 20 mg, Lisinopril 10 mg, 
Hydrochlorothiazide 12.55 mg, Aspirin 75 mg.   
60% 56% 5 years [365] 
 * CHD – Coronary heart disease   
 **Estimates used in our model 
 
5.2 Methods 
The full details of the mathematical model can be found in Chapter 3.  In brief, the model follows 
HIV-patients from the start of treatment as they age; develop co-morbidities, namely diabetes, 
hypertension, hypercholesterol, osteoporosis and renal insufficiency; experience a stroke, MI or 
malignancy, and start co-medication for these co-morbidities.  This individual-based model was used 
to evaluate the impact of interventions aimed at addressing the rising burden of CVD in this 
population compared to standard care.  Two interventions were tested: a smoking cessation 
programme for HIV-patients and the prescription of a polypill for CVD for all HIV-patients over a 
certain age.   
 
5.2.1 Aims 
We aim to compare a smoking cessation programme for HIV-patients and the prescription of a 
polypill for CVD to all patients aged 55 or 45 and over in terms of: 
 the burden of co-morbidity and polypharmacy 
 the burden of CVD in particular 
 the rate and causes of death 
 drug interactions with recommended cART regimens 
 number of disability-adjusted life years (DALYs), DALYs averted, the total treatment 
cost and the average cost per DALY averted as a measure of programme success and cost 
comparison 
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5.2.2 Smoking Cessation Program 
5.2.2.1 Prevalence of Smokers by Age Group 
The ATHENA cohort records smoking status of HIV-patients in follow-up at the time of enrolment 
into clinical care.  The data shows that 48% of HIV-patients in follow-up in 2010 were ever smokers, 
15% of patients were non-smokers, whereas for 37% no information on smoking status was available.  
In the model, parameters determining smoking status will be based on ATHENA data from patients 
with a known smoking status.  The model assumes that people with an unknown smoking status have 
ratio of smokers and non-smokers similar to the ratio of those with a known status.  As smoking is 
associated with an increased risk of death, prevalence of smokers is likely to change with age.  
Therefore, the model assigns smoking status at the start of treatment by age, using age-prevalence 
from the ATHENA data at entry to follow-up (Table 5.2).  The model assumes that in the absence of a 
smoking intervention smokers do not become long-term quitters.   
 
Table 5.2. Age-specific percentage smokers and non-smokers at entry in care amongst patients in follow-
up in the ATHENA cohort (excluding patients with unknown smoking status).   
Age Group Non-smoker Smoker 
20-30 20.5 79.5 
30-40 21.3 78.7 
40-50 21.7 78.3 
50-60 18.1 81.9 
60-70 15.9 84.1 
70+ 36.11 63.9 
All ages 24 76% 
 
 
5.2.2.2 Effectiveness of Smoking Cessation 
Parameters for the effectiveness of a smoking cessation programme were obtained from the literature.  
A Cochrane review by Willemsen and colleagues evaluated the efficacy of smoking cessation 
methods in the general population in the Netherlands.  They found that effectiveness of smoking 
cessation methods, measured as a percentage of 12 months continuous abstinence, ranged between 7% 
for individual counselling to 24% for nortriptyline (an anti-depressant also used for smoking 
cessation) [388].  A study by Tesoriero and colleagues carried out a survey on smoking amongst HIV-
positive individuals in New York [376].  They found that three quarters of HIV-infected individuals 
indicated an interest in quitting [376].  The D:A:D Study Group estimated the rate of developing a 
number of CVDs after smoking cessation in HIV-patients [389], including amongst others MIs and 
strokes.  They found that rates of CVD were reduced by 35% for various CV outcomes and by 50% 
for MIs [389].   
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The model assumes that a smoking cessation programme will be an integral part of clinical 
care of HIV-patients in the Netherlands.  It assumes that guidelines recommend that all HIV-patients 
who are known to smoke attend at least one counselling session, or follow a treatment cessation 
program.  The model will assume that, as per the New York study, 75% of HIV-patients in the 
Netherlands have a willingness to quit and will do so using a treatment method, for example using 
nortriptyline, with a 24% success rate.  The remaining 25% of smokers will only have a counselling 
session with a 7% success rate.  The impact of the smoking cessation programme on the development 
of co-morbidities is illustrated in Figure 5.1.  The long-term quitters will have half the risk of 
developing an MI and 35% reduced risk of developing hypertension, hypercholesterol or having a 
stroke.   
 
Figure 5.1.  Diagram showing how CVD interventions, namely a smoking cessation programme for all 
smokers HIV-patients and polypill for patients aged 45 or 55 years and over, impact on the development 
of co-morbidities.   
 
 
5.2.2.3 Cost of Smoking Cessation 
The Dutch Care Insurance Board carried out a review of the cost per quitter for a number of cessation 
methods.  Using the information available they estimated the average cost per quitter to be €1,300 
[390].  The model will assume that on average every HIV-patient who becomes a long-term quitter 
will cost the healthcare system €1,300.  The cost was discounted at 3%, the rate used by the WHO 
[391].   
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5.2.3 Polypill Intervention 
5.2.3.1 Polypill Roll-out 
In their study, Wald and Law suggested that the polypill should be administered to all patients aged 
55 years and over.  As HIV-infected individuals have been shown to have an earlier age of onset for a 
number of co-morbidities [5,9,10,196,197], including CVD, than the age-matched general population, 
the model will compare two scenario; one where the polypill is prescribed to all HIV-patients aged 55 
and over and those aged 45 and over.  It is assumed that the prescription of the polypill will be 
included in current European HIV-treatment guidelines, and prescribed to all HIV-patients 45 or 55 
years and over as part of their HIV care as a primary intervention (preventing CVD) not a secondary 
intervention (treating CVD).  The model assumes that patients on the polypill will take one additional 
co-medication and that patients are 100% adherent for the purpose of this model.  The model also 
assumed that the polypill used in HIV-patients will have no contra-indications with HIV-treatment 
(unlike the current polypill formulations tested).   
 
5.2.3.2. Effectiveness of Polypill in Preventing Cardiovascular Disease 
The impact of the polypill on the development of co-morbidities is illustrated in Figure 5.1.  The 
efficacy of the polypill for primary prevention of CVD has been evaluated by a number of studies 
(Table 5.1).  The model will simulate the efficacy of the Indian Polycap trial, one of the largest studies 
[371], whose reported efficacy corresponds more or less to the average effect reported by the studies 
in Table 5.1.  We will assume that the reported reduction in the risk of coronary heart disease can be 
translated into a reduction in the risk of hypertension, hypercholesterol and MI in our model of people 
living with HIV.   
 
5.2.3.3 Polypill Cost 
In 2011 van Gils and colleagues carried out a study evaluating the cost-effectiveness of the Indian 
Polycap pill in the Netherlands [392].  In their study they outlined the expected yearly cost of the 
polypill, including fees for prescription and drug delivery, assuming the polypill cost was equal to the 
sum of its individual components [392].  Table 5.3 shows the costs of individual components of the 
polypill, as well as delivery and prescription costs in the Netherlands.  The average cost of the polypill 
in our model will be based on the costs presented by van Gils and colleagues, with an annual cost of 
€83.48 including delivery and prescription costs, discounted at 3% annually [391].   
 
5.2.4 Cost of Treating Co-morbidities  
The average annual costs of treating co-morbidities were obtained from the literature, focusing on cost 
data from European countries, where possible, or otherwise from other developed countries.  Table 
5.4 shows the annual direct medical costs of treating individual co-morbidities per patient that will be 
used in the model.  Costs were converted into Euros using December 2013 exchange rates from.   
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Table 5.3.  Estimated costs of polypill, its delivery and prescription costs in the Netherlands.   
Source: created using information from work by de Gils and colleagues [392].   
Item Unit Cost per patient per year 
Laboratory  €1.70 
Drug delivery costs 1 year €22.96 
Drug costs   
Simvastatin 40 mg 1 year €6.69 
Ramipril 2.5mg 1 year €22.48 
Atenolol 50 mg 1 year €22.48 
Thiazide  12.5 mg 1 year €3.47 
Aspirin 100 mg 1 year €3.70 
Total cost 1 year €83.48 
 
5.2.5 Cost of HIV Treatment 
In addition to the costs of treating co-morbidities, data on the cost of first-line and second-line cART 
are needed to provide an overview of the economic impact of the interventions.  A reduced risk of 
developing co-morbidities may translate into an increased life-expectancy and consequently more 
time spent on more expensive second-line and third-line cART.  This in turn will influence the overall 
costs and cost savings of any intervention.  A cost-effectiveness study by Walensky and colleagues 
reports the average annual cost of first-line (TDF/FTC/EVF) to be 10,985 Euros and of second-line 
(TDF/FTC with ritonavir-boosted atazanavir) as 15,867 Euros [393].   
Duration from start of treatment to switching from first-line to second-line was assessed in the 
ATHENA data from 2000 to 2010.  Several distributions were tested to establish the one that best 
described the observed distribution of time, namely normal, Weibull and gamma distribution.  
Analysis showed that a gamma distribution best described this distributions (p-value<0.001 
Kolmogorov-Smirnov, Cramer-von Mises and Anderson-Darling test), with a shape of 1.625 and a 
scale of 1.164.  Figure 5.3 illustrates the gamma distribution for the time between starting first-line 
and switching to second-line.  Switching is implemented independent to rest of model processes.   
 
Figure 5.2. Distribution of time (in months) from start of first-line cART to switching to second-line 
cART as fitted to the observational ATHENA data cohort from 2000 to 2010.   
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5.2.6 Disability Weights and Cost Cut-offs 
In order to calculate the DALYs averted by the interventions, disability weights were obtained from 
the Global Burden of Disease Study 2010 [3].  Disability weights are weight factors between 0 and 1 
that reflects the severity of a disease [391].  Perfect health is assigned the value 0 and 1 is equivalent 
to death [391].  As the disability weights are sometimes reported for specific disease stages, averages 
were taken across stages to compute a disability weight for disease groups used in the model.   
The World Health Organisation’s cost-effectiveness threshold for financing health 
interventions is three times the GDP per capita per DALY averted [394].  In 2012, the World Bank 
reported the Dutch GDP per capita at $45,955 or €33,980 [395].  Consequently, the cut-off for health 
care expenditure would be a programme costing €101,940 or less per DALY averted.  The cut-off will 
be used to evaluate value for money of the smoking cessation programme and polypill intervention.   
 
5.3. Results 
5.3.1. Impact on Burden of Co-morbidity and Polypharmacy 
The model was used to evaluate the impact of a smoking cessation programme for all HIV-patients 
and a polypill for CVD for patients 45 or 55 years old and over on the burden of co-morbidity and 
polypharmacy compared to standard care.  The results show that all the interventions will result in 
long-term improvement in the burden of co-morbidity and polypharmacy (Figure 5.3 A to D) 
compared to standard care.  A smoking cessation programme will have the smallest impact with a 
polypill intervention for patient aged 45 and over having the greatest impact.   
Under standard care, 86% of patients in clinical care in 2030 will suffer from at least one co-
morbidity (Figure 5.3A).  A smoking cessation programme for HIV-patients could reduce this to 85% 
of patients (Figure 5.3A), while guidelines recommending the polypill for all HIV-patients aged over 
55 and 45  would reduce this number to 83%  and 78% by 2030, respectively (Figure 5.3A).  Equally, 
the number of people suffering from three or more co-morbidities in 2030 could be reduced from 33% 
under standard care, to 32% with a smoking cessation program, 27% with a polypill intervention for 
patients 55 and over, and to 20% for patients 45 and over (Figure 5.3B).   
A reduction in the number of patients suffering from co-morbidities is expected to cause a 
reduction in the burden of polypharmacy.  A smoking cessation programme would reduce the number 
of patients who take at least one additional co-medication by 2% (from 54% under standard care to 
52%), and those who take three or more co-medications by 1% compared to standard care (from 16% 
to 15%) (Figure 5.3C and D).  In contrast a polypill for CVD would reduce the number of patients 
taking at least one additional co-medication by 6% when given to those 55 years and older and by 
13% when given to all patients aged 45 and over (Figure 5.3C).  In addition, the polypill would reduce 
the number of HIV-patients taking three or more co-medications from 15% to 12% and to 10% in a 
scenario where it is prescribed to HIV-patients aged 55 or 45 and over, respectively (Figure 5.3D).   
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Table 5.4.  Direct medical cost per patient of treating individual co-morbidities.   
Co-morbidity Setting Year  Number 
of patients 
Type of study Cost details Cost in 
reported 
currency  
Cost 2013 
Euros 
Cost unit Reference 
MI USA 1999 206 Retrospective cohort analysis from 
third party perspective.   
Hospitalizations, outpatient visits, pharmacy, and 
emergency room visits.   
 US 
$18,577 
€ 13,512 
 
Per event [396] 
Stroke Germany 2006 2,458 Incidence-based, bottom-up direct-
cost study from third-party 
perspective.   
Inpatient and outpatient costs, rehabilitation costs 
and nursing costs.   
€ 43,129 € 43,129 Per event [397] 
Hypertension USA 1999 3,769 Longitudinal evaluation of medical 
and pharmacy claims data from 
independent practice association and 
group cross-references with diagnosis.   
Pharmacy costs, costs of physician visits, 
laboratory costs.   
US $ 1,803 € 1,311  Per year [398] 
Chronic Kidney 
disease 
UK 2012 1.8 million 
people 
Analysis of NHS and NHS Reference 
Costs and Hospital Episode Statistics.   
Primary care, pharmacy, outpatient attendance, 
admitted patient care and hospital admissions 
and renal-replacement therapy. 
£ 795 € 950  Per year [399] 
 
Diabetes Germany 2005 Diabetic 
patients in 
Germany 
Analysis of the health care data of the 
Federal Office of Statistics.   
Outpatient and inpatient costs, pharmacy, 
ambulance, and other costs.   
€ 4,600  € 4,600  Per year [400] 
Osteoporosis Netherland
s 
2013 117 active 
patients- 
Economic quantification of direct and 
indirect medical costs of osteoarthritis 
patients entering care.   
Direct medical costs including doctor’s visits, 
medication, imaging and aids.   
€1,788 in 
the 
Netherland
s 
€ 1,788 Per year  
Cancer UK 2011 Cancer 
patients in 
UK- 
Report of NHS expenditure  Cost of cancer diagnosis and treatment across 
UK NHS (98%), private (9%) and voluntary 
(4%) sectors.   
£30,000 € 35,863 Per event [401] 
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Figure 5.3. Impact of a smoking cessation programme and a polypill for CVD at age 45 or 55 and over 
compared to standard care on percentage of HIV-patients in care with A. any co-morbidity, B. three or 
more co-morbidities, and patients taking C. any co-medication, or D. three or more co-medications.   
 
A. B.  
C. D.  
 
5.3.2 Impact on Cardiovascular Disease  
Both interventions are aimed at targeting the increasing burden of CVDs in the HIV population.  
Figure 5.4 illustrates their impact on the number of cardiovascular events compared to standard care.  
The results show that by 2030 a smoking cessation programme would have the smallest impact on 
CVD; resulting in a cumulative reduction of 990 (10%) patients with hypercholesterol, 870 (10%) 
patients with hypertension, 110 (8%) strokes and 120 (7%) of MIs.  A polypill for those aged 55 and 
over or 45 and over could result in a cumulative reduction of 1,600 and 3,000 (19 and 35%) patients 
with hypercholesterol, 1,800 and 3,150 (19 and 33%) patients with hypertension, 530 and 610 (40 and 
46%) strokes, and 510 to 870 (32 and 54%) MIs, respectively (Figure 5.4).   
 
5.3.3 Impact on Mortality 
The different interventions are also likely to have an impact on both the number and causes of deaths 
(Figure 5.5A and B).  The results show that a smoking cessation programme could cause 55 (1%) 
fewer deaths by 2030.  In comparison, a polypill intervention could result in 150 (3%) and 170 (3%) 
fewer deaths by 2030 when prescribed to all HIV-patients aged 55 or 45 and over, respectively 
(Figure 5.5A).   
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The interventions could also cause a shift in the causes of deaths (Figure 5.5B).  Model 
simulations show that all interventions will cause a reduction in the proportion of deaths caused by 
CVD, paralleled by an increase in deaths resulting from other causes (Figure 5.5B), as patients are 
dying of non-CVD related causes.  A polypill for all HIV-patients aged 45 and over would result in 
10% reduction in CVD deaths and a 7% increase in deaths caused by ‘other’ reasons (Figure 5.5B).   
 
Figure 5.4.  Impact of a smoking cessation programme or polypill for CVD compared to standard care 
from 2010 to 2030 on A. hypercholesterol, B. hypertension, C. MIs and D. strokes.   
 
A. B.  
C. D.  
 
Figure 5.5.  Impact of a smoking cessation programme and polypill for CVD on A. the cumulative 
number of deaths and B. the causes of deaths compared to standard care.   
 
A. B.  
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5.3.4 Impact on Drug Interactions with HIV Medication 
Naturally, a reduction in the number of HIV-patients who suffer from CVD and require co-
administered medication will result in a reduction in the proportion of patients who will experience 
potential drug-interactions with recommended cART regimens (Figure 5.6).  A smoking cessation 
programme is expected to have the smallest impact, resulting in a 2% reduction in the number of 
HIV-patients who may experience potential drug-interactions with recommended cART regimens and 
a 1% increase in the number of people who will take co-administered medication with unknown drug 
interactions with recommended cART regimens by 2030 (Figure 5.6B).  In comparison by 2030 a 
polypill for CVD could reduce potential interactions with recommended cART by 3% and 7% 
compared to standard care if given to HIV-patients aged 55 or 45 and over (Figure 5.6C and D).  The 
number of people who would be using co-medication with unknown drug-drug interactions is unlikely 
to change with the use of the polypill compared to standard care (Figure 5.6C and D).   
 
A. B.  
C. D.  
Figure 5.6.  Comparison of A. standard care, B. a smoking cessation program, and the polypill for HIV-
patients aged C. 55 years and over and D. 45 years and over on drug-drug interaction with recommended 
cART in 2030.  Recommended regimens are a backbone of TDF/FTC or ABC/3TC combined with either 
EFV, nevirapine, raltegravir or ritonavir-boosted atzanavir, darunavir or lopinavir as listed by the 
current Europe AIDS Clinical Guidelines.   
 
5.3.5 Impact on DALYs and Health Expenditure 
A smoking cessation programme or polypill for CVD will have a positive impact on the health 
outcome of HIV-patients compared to standard care.  All interventions could reduce the number of 
disability adjusted life years (DALYs) suffered by HIV-patients and reduce health care expenditure 
for HIV care (Figure 5.7) compared to standard care.  Model simulations show that the greatest 
impact on the total number of DALYs, the number of DALYs averted and cumulative health care 
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costs can be attained with the introduction of a polypill for CVD for HIV-patients aged 45 and over.  
The smallest impact will be generated by a smoking cessation program.  A smoking cessation 
programme could avert 2,800 DALYs, compared to 3,600 and 5,000 DALYs with a polypill for HIV-
patients aged 55 and 45 and over (Figure 5.7A and B).   
All interventions will be cost saving in the long-term, although annual costs for all 
interventions and for standard care will be similar (Figure 5.7E).  Under standard care, the cumulative 
cost of HIV-treatment and of treating co-morbidities will add up to 4,873 million Euros from 2010 to 
2040.  In comparison, a smoking cessation programme will have cumulative treatment costs including 
intervention cost of up to 4,859 million Euros, and the roll-out of the polypill will result in health care 
expenditure of treating HIV and co-morbidities and prescribing a polypill for HIV-patients aged 55 
and 45 years and over of 4,866 million and 4,850 million Euros, respectively.  The polypill for 
patients aged 45 years and over will result in 23 million Euro savings.   
The similarities in the overall cumulative health care expenditure can be explained by a shift 
in health care needs.  All interventions will result in a reduction in the burden of CVD, and 
consequent costs of treating cardiovascular events compared to standard care (Figure 5.7D).  
Consequently, patients will live longer, and spend more time on more costly subsequent-line regimens 
(second-line, third-line, etc.) (Figure 5.7C).  The cumulative cost of treating CVD under standard care 
is 371 million Euros between 2010 and 2030, compared to 253 million Euros with a polypill 
intervention for all HIV-patients aged 45 years and over.  Under standard care, cumulative costs of 
HIV-treatment are estimated to add up to 4,246 million Euros between 2010 and 2030 compared to 
4,260 with the roll-out of a polypill for patients aged 45 years old and over.  
All interventions have a long-term cost per DALY averted that is under the estimated WHO 
cost-effectiveness threshold of three times GDP per capita.  The model estimates that by 2030 the cost 
per DALY averted will vary from around €70 for a smoking cessation programme to €180 and €290 
for a polypill intervention for HIV-patients over 55 and 45 years old (Figure 5.7F).  Although the 
smoking cessation programme has the lowest cost per DALY averted by 2030, its initial cost in 2010 
will be much higher than the introduction of the polypill in HIV-care; €146,000 per DALY averted 
compared to €6,400 and 13,000 for the polypill intervention.   
In fact, the integration of a smoking cessation programme into HIV care will not be cost 
saving until 2015 (Figure 5.7G).  In 2010, a smoking cessation programme would cost an additional 
1.6 million Euros compared to standard care.  In comparison, the roll-out of the polypill is expected to 
be cost-saving from the first year with around €300,000 saving in 2010.  By 2015 all programs will be 
cost-saving compared to standard care, saving 1.5 million Euros for the smoking cessation programme 
and 2.4 or 1.6 million Euros with the roll-of the polypill for HIV-patients aged 55 or 45 years and 
over (Figure 5.7G).  Yet, in the long-term, the roll-out of the polypill for HIV-patients aged 55 and 45 
and over will come at a higher annual cost than standard care, costing an additional 4.1 and 5.4 
million Euros in 230, compared to a saving of €370,000 with a smoking cessation program.   
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Figure 5.7.  Impact of smoking cessation programme and a polypill for CVD compared to standard care 
on A. cumulative DALYs from 2010 to 2030, B. cumulative DALYs averted from 2010 to 2030, C annual 
costs of HIV-treatment, D. annual costs of treating CVD, E. total annual HIV care costs, F. cost per 
DALY averted, and G. Intervention costs compared to standard care from 2010 to 2020.   
A. B.  
C. D.  
E. F.
G.  
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5.3.6 Impact of Adherence to Polypill and Willingness to Quit Smoking 
The model was used to test the impact of adherence to the polypill, as well as the percentage of HIV-
patients willing to quit smoking on the impact of the interventions (as measured by the number of 
DALYs averted) as these are some of the main drivers of the results.  It was assumed that the 
relationship between the effectiveness of and adherence to the polypill was linear.  The results are 
presented in Figure 5.8.  It shows that with perfect adherence the roll-out of a polypill for HIV-
patients aged 45 and 55 years and older will have a higher impact on the number of DALYs averted 
compared to standard care then a scenario where 100% of HIV patients who smoked were willing to 
quit .  The red dotted line (Figure 5.8 A) illustrates the percentage of smokers willing to quit that was 
used in the model (75%), and the adherence needed for the two polypill scenarios to achieve the same 
results (Figure 5.8 B).  The figure shows that for a scenario where the polypill is prescribed to all 
HIV-patients 55 years old and over adherence greater than 60% would yield better than a smoking 
cessation programme where 75% of patients have a willingness to quit.  For the polypill roll-out for 
patients 45 years and over adherence greater than 25% would be sufficient to generate similar results 
(Figure 5.8 B).  Thus sub-optimal adherence of polypill would not be expected to over-turn the key 
results presented above.   
 
 
 
Figure 5.8.  Impact of adherence to polypill and percentage willing to quit smoking on the number of 
DALYs averted compared to standard care.  The red dotted line illustrates the percentage of HIV-
patients assumed to have a willingness to quit used in the model (75% of smokers), and the adherence to 
the polypill needed to achieve the same number of DALYs averted.   
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5.4. Discussion 
Both a smoking cessation programme for HIV-patients and the introduction of a polypill for CVD for 
all HIV-patients aged 55 or 45 and over would have a positive impact on the clinical care of the 
ageing HIV-population in the Netherlands.  These interventions will result in a long-term reduction in 
the burden of CVD, polypharmacy and mortality.  In addition, they are expected to reduce drug 
interactions with recommended cART regimens compared to standard care.  Together this will result 
in an improvement in the patients’ health, as measured by the number of DALYs averted, as well as a 
reduction in treatment costs compared to standard care.  The model suggests that a smoking cessation 
programme will have the smallest health impact on the primary prevention of CVD with the 
introduction of a polypill for CVD for all HIV-patients aged 45 and over having the greatest impact.  
Changing HIV-treatment guidelines, to recommend the prescription of a polypill for CVD to all HIV-
patients aged 45 and over could result in a 13% reduction in multi-morbidity and polypharmacy, 
along with a 7% reduction in drug interactions.   
All interventions considered will result in cost saving between 2010 and 2030 compared to 
standard care and have a long-term cost per DALY averted that is under the estimated WHO cost-
effectiveness threshold of three times GDP per capita.  The smoking cessation programme has the 
lowest cost per DALY averted, at €70 compared to €180 for a polypill intervention for HIV-patients 
aged 45 and over, although it will require nearly a ten-fold higher initial investment then a polypill 
intervention.  In fact, the smoking cessation programme is unlikely to be cost saving for the first five 
years, unlike a polypill intervention which is expected to be cost-saving from the first year.  However, 
the roll-out of the polypill is likely to no longer be cost-saving in the long-term compared to standard 
care.  This may be driven by the increasing number of HIV-patients who live longer as a consequence 
of the polypill, spend more time on expensive cART regimens, thus outstripping the savings in CVD 
treatment achieved.  Consequently, cost comparison results will be sensitive to the cost estimates for 
first-line and subsequent-line cART.  The results are unlikely to be affected by sub-optimal adherence 
to the polypill.   
No studies could be found that compared the impact of a smoking cessation programme and 
polypill interventions for the primary prevention of CVD amongst HIV-patients.  A study by 
Rubenstein and colleagues investigated the cost-effectiveness of various interventions (treatment of 
hypertension and hypercholesterol, smoking cessation, reduction in salt content in bread and mass 
education strategies) on CVD in the general population in Buenos Aires, Argentina [402].  They 
found that lowering the salt content in bread, mass education and a polypill strategy were the most 
cost-effective [402].  Studies evaluating the efficacy and cost-effectiveness of smoking cessation 
programs in the general population generally find that smoking cessation programs are good value for 
money in terms of health gains, and that uptake in these programs can be greatly improved if offered 
by health care providers than if patients have to pay for them themselves [403].  Two studies 
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evaluated the cost-benefit of a polypill intervention in the general population in the Netherlands 
[392,404].  One study looked at the cost-effectiveness of the polypill in terms of QALYs, and found 
that the polypill would be a cost-effective intervention for the primary prevention of CVD in the 
Netherlands, with estimated costs ranging between €7,900-12,300 per QALY compared to standard 
care [405].  Franco and colleagues estimated the maximum cost of the polypill for it to be cost-
effective for the primary prevention of CVD in the general population in the Netherlands.  They 
estimated that the polypill should cost under €302-410 annually (depending on age for roll-out) 
including prescription and delivery costs to be of value (using €20 000/year as a cut-off).  They 
stipulate that although the polypill could have a significant impact on CVD in the Netherlands its cost 
could be a caveat [404], as they estimate its total cost to be higher than €302-410.  One explanation is 
that the group assumes a large number of GP visits, prescription renewals, and pharmacist’s fees as 
well as blood tests [404].  As, HIV-patients are in frequent contact with healthcare providers, they 
provide a great target population for intervention, with great potential for cost savings on delivery 
costs.   
Despite the importance of CVDs and other non-AIDS co-morbidities in the clinical care of 
HIV-patients, interventions aimed at tackling these challenges have received relatively little attention 
[406].  This lack of attention could in part be explained by the fact than in the past HIV-care focused 
on the treatment of life-threatening conditions and opportunistic infections, and the perceived lack of 
relevance of ensuring long-term healthy lifestyles in this population [406].   
Smoking cessation techniques have been well established and widely used in the general 
population.  Many different effective cessation techniques exist, including behavioural and 
pharmacological interventions [407], with several studies showing that smoking cessation medications 
have a 1.5 to 2 fold higher success rate than behavioural interventions [384,408–411].  However, most 
smoking cessation programs as primary prevention for CVD have focused on healthy populations 
[406,407].  So while smoking cessation programs have proven to be effective in the general 
population, it remains to be shown how effective and suitable these techniques are for HIV-infected 
individuals [407].  Little is known about reasons for the high prevalence of smokers amongst HIV-
infected individuals compared to the general population [373,376–382], few clinical trials have 
evaluated the efficacy of smoking cessation programs in HIV-infected cohorts [373], and even fewer 
programs are specifically geared towards HIV-infected individuals [407,412].   
The few trials and studies of smoking cessation in HIV-cohorts have shown that smoking 
cessation programs are generally well received by HIV-infected individuals and that they can 
successfully be implemented in HIV clinical care [357,378,412,413].  However, their reported success 
rates amongst HIV-infected cohorts vary from study to study.  Fuster and colleagues found that only 
14% of smokers enrolled in a smoking cessation programme in Spain, with a 25% quit rate at 12 
months follow-up [372].  A pilot study by Elzi and colleagues evaluated smoking cessation programs 
amongst HIV-infected individuals.  They found that a programme consisting of nicotine replacement 
Chapter 5 – Interventions targeting CVD 
146 
therapy (NRT) with counselling resulted in self-reported smoking abstinence in 38% compared to 7% 
in the group with no intervention [378].  A randomized control trial by Lloyd-Richardson and 
colleagues compared the efficacy of standard counselling with NRT and intensive motivational 
enhanced treatment with NRT.  They found that 6-months cessation rates where 9% and 10% for 
standard counselling compared to intensive counselling [413].  A further RCT found that HIV-
patients who received a mobile phone delivered intervention were 4.3 times more likely to quit 
smoking at 3-months follow-up compared to those receiving standard care (advice to quit, tailored 
leaflets and nicotine patches) [412].   
In the future it will be vital to better evaluate the long-term effectiveness of smoking cessation 
programs in HIV-populations, and identify unique factors affecting their success and impact on co-
morbidities such as CVD in these populations.  Focus groups have highlighted the fact that HIV-
positive smokers believe they would not live long enough to experience the adverse effects of long-
term tobacco use [406,414].  Psychological conditions such as depression and anxiety are common 
amongst HIV-infected individuals [375,377].  One survey amongst HIV-infected individuals found 
that 62% of smokers suffered from depression [381], and another showed that 38% met criteria for 
major depression [415].  Smokers are also more likely to suffer from polysubstance abuse, such as 
alcohol or drugs [375,384], which in turn can be a risk factor for failure to quit smoking 
[375,381,407,415].  Although there are no known interactions between nicotine replacement therapies 
and cART, in vitro studies have shown that ARVs such as nelfinavir, ritonavir and efavirenz could 
inhibit systems and metabolic pathways used by some nicotine replacement therapies [384,416].  
Future research will have to evaluate how best to tailor such programs to unique needs and challenges 
in HIV-populations.   
Although we may never be able to estimate the true attributable risk of smoking on CVD, it 
appears logical that a reduction in the prevalence of smoking amongst HIV-patients could improve the 
patients’ general clinical outcome [357,406].  Addressing the disproportionate burden of tobacco use 
amongst HIV-patients in the Netherlands could help reduce the morality gap that still exists between 
HIV-patients and the general population  [58,384,417].  The long-term success of smoking cessation 
programs amongst HIV-infected individuals will in part depend on whether and how smoking 
prevalence amongst HIV-patients will change in the future.  Two studies reported decreasing rates of 
smoking over time [418,419], which may in part be explained by mortality in older smokers but could 
be related to changes in the social acceptability of smoking.  One of the most important factors for the 
success of a smoking cessation programme is the relationship between smoking and CVD.  A study 
by Clair and colleagues evaluated the impact of smoking on CVD and found that smoking was a risk 
factor for CVD, independent of weight [420].  In contrast, Price and colleagues found that smoking 
status was associated with increased alcohol intake and poor diet, with the relationship between 
smoking CVD likely being mediated by other lifestyle factors related to smoking [421].   
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In contrast the polypill is a novel prevention intervention.  The idea of a polypill for CVD was 
first introduced in 2002 [363,364].  The first polypill was marketed by Pfizer in 2011. Caduet is a 
combination of amlodipine (calcium channel blocker) and atorvastatin and exists in a full range of 
dosing combinations [422].  Little is known about the feasibility, acceptability and effectiveness of 
using the polypill for the primary prevention of CVD at population-level, nor the impact of sub-
perfect adherence.  Only few trials have evaluated different formulations of the polypill for the 
primary prevention of CVD (see Table 5.1).  A meta-analysis by Elley and colleagues found that the 
polypill was effective in reducing both blood pressure and lipids and was well tolerated with toxicity 
only moderately different to those on placebo [423].  To this date no trials have evaluated the efficacy 
and tolerability of the polypill in an HIV-cohort.  However, the benefits of lipid-lowering drugs for 
the prevention of CVD have been demonstrated in HIV-infected individuals, albeit not in a controlled 
trial setting  [373,424].   Trials of the polypill in HIV-infected individuals would contribute valuable 
knowledge to the field, including the ideal threshold age to start this intervention in HIV-patients, as 
well as questions surrounding the relationship between adherence and effectiveness of the polypill.   
More studies will have to be carried out on the benefits and long-term safety of a polypill in 
the primary prevention of CVD in HIV-infected individuals.  Although trial data have generally found 
the polypill to have very good tolerability in the general population, this may be different in HIV-
infected patients on cART, especially if they have multiple morbidities are taking co-administered 
medication.  The polypill may be unsuitable for some patients; for example, beta-blockers are contra-
indicated for patients with asthma and some people are intolerant to aspirin [369].  In HIV-patients, 
tolerability of a polypill may be compromised further by the use of ARVs.  For example, European 
treatment guidelines state that simvastatin, which is drug used in many polypill formulations (see 
Table 5.1), should not be co-administered with ritonavir-boosted atazanavir, darunavir or lopinavir 
[60].  Simvastatin is also reported to have potential drug interactions with efavirenz, etravirine and 
nevirapine [60].  The side effects of statins in general have been much discussed recently [425], and 
any formulation used amongst HIV-patients will need to take into consideration side effects as well as 
drug interactions with ARVs.   
It may be more realistic to consider several different formulations of the polypill [362], 
including ones tailored for use in the HIV-infected population on antiretroviral medication.  The 
formulation of a pill with four or more components can be complex [360,362]  For each formulation 
the bioavailability (proportion of a drug able to have an active effect), pharmacodynamics and 
pharmacokinetics, possible interactions and toxicity will have to be documented [360,362,426].  A 
study by Patel and colleagues found that there are no indications of pharmacokinetics for any of the 
components with the bioavailability of ingredients being well preserved [426].  Yet, the there is still 
no consensus on the final formulations of the polypill, with questions around the most effective 
ingredients and dosages.  Questions also remain about the potential inclusion of aspirin in any polypill 
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formulation [360,362].  Its benefits on CVD are relatively small compared to other components and 
can increase the risk of gastrointestinal bleeding [360,362].   
The success of a polypill intervention will depend on a number of factors including the 
acceptability of the polypill amongst treating physicians and patients.  Some physicians question the 
use of age as an independent risk factor for CVD, however the scientific literature reports that up to 
95% of MIs and stroke deaths occur in people aged 55 and over, regardless of other risk factors [427].  
Healthy patients may be reluctant to comply with a daily regimen of the polypill for prevention, and 
the size and shape of the pill (for ease of swallowing) is likely to influence adherence patterns.  
However, even imperfect adherence to the polypill could confer significant public health impacts (as 
shown in 5.3.6 Impact of Adherence to Polypill and Willingness to Quit Smoking, page 143).  With 
many of its potential components available as generics, the polypill is likely to be a promising novel 
approach to CVD prevention, constituting a simple, safe and low-cost population-level approach with 
low pill burden, particularly for use patients who are at high risk of CVD such as HIV-patients.   
The health care setting provides a unique opportunity for the implementation of both a 
smoking cessation programme or polypill intervention for HIV-infected patients [375,428].  As HIV-
patients interact frequently with health care providers and physicians as part of their HIV-treatment 
follow-up and care, there are a multiple of opportunities to initiate discussion about potential health 
care led interventions [375].  Current literature shows that lipid-lowering medication may be under-
prescribed in the clinical care of HIV-patients [373].  The D:A:D Study Group reported that only 23% 
of HIV-patients were prescribed lipid-lowering medication at the time of any cardiovascular event and 
only 45% were treated in the following months [429].  This may link back to the potential lack of a 
more horizontal approach to the care of HIV-patients discussed in Chapter 4.  Even when lipid-
lowering medication is used, only 50% of HIV-patients are found to reach recommended lipid levels 
[373].  Despite recommendations, many HIV physicians are not assessing their patients’ smoking 
status [375], with one study showing that less than half the New York City HIV service providers 
reported assessing smoking status or willingness to quit [376].   
Yet, as the model results and other studies clearly demonstrate, CVD is going to become an 
increasingly important challenge to HIV care [14,15,190,191,196,197,202,211,345].  A body of 
research is paramount to ensuring evidence-led changes to HIV-treatment guidelines to ensure 
continued high quality care of HIV-patients.  Interventions such as the polypill will likely have to be 
used in combination with lifestyle changes, such as reduction in tobacco use, increased physical 
activity and improved diet.  A combined intervention was not modelled at this stage, however in the 
future the aim is to incorporate CVD risk, such as the D:A:D and Framingham framework to evaluate 
a number of different CVD interventions independently and in combination.  At a time when shifting 
demography around the world is leading to an increasingly ageing population and rising obesity 
resulting in new challenges to health care of both the population in general and for HIV-care in 
particular, lifestyle interventions will likely become an increasingly important pillar to health care 
Chapter 5 – Interventions targeting CVD 
149 
provision.  It therefore remains a shock that in 2012 the Lancet reported that the Dutch government 
was closing down its tobacco control operations and world-renowned tobacco control centre 
STIVORO [430].   
To my knowledge this is the first model to evaluate the potential impact of different 
interventions on the primary prevention of CVD in an ageing HIV-population.  The limitations of the 
model structure are described in detail in Chapter 3.  In addition, the analysis has a number of other 
limitations.  Firstly, the results do not represent the uncertainly that exists due the imperfect 
knowledge of disease inter-relation, intervention effectiveness, and other aspects of the epidemic.   
The varying results of studies investigating smoking cessation programs make it difficult to 
establish exactly what the impact of a smoking cessation programme would be on long-term quitting 
rates and on cardiovascular events.  As there are no studies of the polypill in HIV-patients, it is 
difficult to predict what impact the polypill could have in this group of patients at high CVD risk.  
Yet, it is thought that the parameters used for these interventions were based on high quality data and 
will provide a sound estimation of the potential impact of these interventions in HIV-cohorts.  Studies 
of the polypill are currently being carried out in HIV-patients [431], which will likely provide useful 
information for this analysis.  Equally, it may be useful to carry out surveys on the willingness to quit 
amongst HIV-patients in the Netherlands to better inform the model.   
Sensitivity analyses highlight that the cost of first-line and subsequent-line cART in particular 
are important factors in estimating cost saving and carrying out cost comparison of the interventions 
in this model.  In the future it would be helpful to work with health economists in the Netherlands to 
get better costing data to generate more robust cost outputs.  This would also allow us to capture the 
indirect costs and cost-savings of the interventions compared to standard care as well as a more 
integrated approach to modelling switching of cART regimens. As both interventions reduce the 
burden of CVD and CVD co-medication they are likely to reduce hospitalization of patients by 
reducing the number of drug interactions and therefore a decreased need to switch patients from first-
line to second-line.   
Furthermore, this Chapter only evaluated the impact of a smoking cessation programme and 
polypill intervention on CVD.  However, a smoking cessation programme in HIV-patients could have 
benefits on a number of other co-morbidities and, as well improve overall health-related quality of life 
[357,384,414,432].  Including further positive consequences of smoking cessation, such as a reduced 
risk of cancer, will likely result in an improved outcome for the smoking cessation program.  The link 
between smoking and lung cancer and other lung diseases is well established in the general population 
[234,433].  Large studies have demonstrated a three to four-fold increase in the incidence of lung 
cancer in HIV-infected individuals compared to HIV-negative individuals [204,379,434,435], a risk 
which is partially but not entirely explained by the increased prevalence of smokers among people 
living with HIV compared to the general population [434–436].  This is particularly concerning as 
lung cancer is the leading cause of non-AIDS defining malignancy amongst HIV-infected individuals 
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[437].  Both smoking and HIV-infection are associated with suppression of lung defences, resulting in 
an increase in pulmonary diseases such as bacterial pneumonia, chronic obstructive respiratory 
disease, [357,414,432,438,439] and tuberculosis [436,440,441].  So despite the models showing that 
smoking cessation would have a smaller impact on CVD compared to the polypill, it may likely have 
an improved overall impact on patient outcome and treatment cost compared to the polypill, when 
other smoking-related non-CVD illnesses are included [442–444].  However, research suggests that 
the polypill could also have an impact on co-morbidities other than CVDs, with recent evidence 
showing that daily use of aspirin, one component of the polypill, reducing the risk of cancer [442].   
A further limitation surrounds the cost data and DALY weights.  The direct medical costs 
were taken from the literature from a number of different countries and date from different years.  
Medical costs can differ vastly between countries and change over time.  There were also difficulties 
finding good estimates of average treatment costs for disease groups such as cancers, which can vary 
in their treatment types, and find that duration and cost of treating renal insufficiency, where treatment 
costs vary greatly by disease stage.  Similarly, DALY weights had to be generated for disease groups, 
such as cancers, from studies reporting them by cancer type and stage.  However, I believe that the 
cost data and DALY weights were comparable and captured the ball-park figures of treatment costs, 
providing adequate means with which to evaluate the interventions.  The OECD (Organisation for 
Economic Co-operation and Development) is finalising a project on health expenditure by disease 
group, age and sex (personal communication), which should allow the model to be re-run using better 
cost estimates.   
Finally, treatment costs were estimated by disease.  However, studies have shown that the 
costs of treating patients with several co-morbidities can vary compared to the cost of treating only a 
single condition.  Amin and colleagues estimated the direct medical costs for the treatment of diabetes 
and hypertension separate and combined [398].  They found that the cost of treating patients with both 
cost $13,446 compared to $8,493 and $8,424 for treating patients with only diabetes or hypertension, 
respectively [398].  This model is limited by its assumption that treatment costs for individual 
conditions will remain the same in patients with one or several co-morbidities.  Nor does the model 
take into account indirect medical costs, which can be vast.  Hermans and colleagues estimated the 
cost of knee osteoarthritis in the Netherlands to be around €10,500 per year per patient, with 17% 
accounting for direct medical costs and 83% accounting for productivity loss [445].  In the future it 
may be valuable to carry out a detailed economic analysis of CVD interventions in HIV-patients to 
inform health care services.   
HIV-positive people are experiencing an increasing risk of CVD.  Integrating a smoking 
cessation programme or changing HIV-treatment guidelines to include prescribing a polypill for CVD 
to all HIV-patients aged 45 years and over could improve the burden of CVD, improve patient 
outcome and produce long-term cost savings.   
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6. 1 Introduction 
In the last 30 years, the HIV epidemic has emerged as one of the major global health challenges, 
becoming one of the world’s leading causes of mortality and disease burden [1–3].  HIV has 
continuously presented the scientific community with challenges; from the identification of the virus 
in 1983 [171], developing the first ARV, zidovudine, in 1987 [37], to the introduction of effective 
treatment with triple therapy in 1996.   
Since 1996, over twenty new antiretroviral drugs have been licensed for the treatment of HIV-
infection [37].  Early cART regimens were often complicated, consisting of multiple drugs with 
different administration frequencies [122,270].  In the last several years, more convenient dosing and 
increased tolerability have improved the treatment of HIV-infected patients [6].  The introduction of 
fixed-dose combination tablets, such as Combivir (AZT/3TC) in 1997 [271] have simplified dosing 
requirements, and once-daily combination tablets like Truvada (TDF/FTC) in 2004 [272] or Atripla 
(TDF/FTC/EFV) in 2006 [273], have reduced daily pill burden and improved tolerability 
[84,87,88,95,114–116].  A number of clinical trials and studies have compared specific antiretroviral 
drugs or regimen types with respect to selected clinical outcomes [87,88,90,92,95,96,109,112,114–
116,275].  However, it remains unclear how the improved efficacy of new antiretroviral drugs 
reported in trials has translated into population-level effectiveness in general clinical care [275].   
In addition, the great leaps and developments achieved in the field of HIV are now throwing 
up a new challenge, that of an ageing HIV population.  Effective treatment has resulted in HIV-
patients increasingly suffering from age-related non-infectious co-morbidities that they previously did 
not live long enough to experience [15].  Whereas the incidence of AIDS-defining mortality has 
decreased markedly over time [446], it has been paralleled by an increase in non-AIDS diseases 
mortality amongst HIV-1 infected patients on cART [9,10,330–333].  Also, the increasing prevalence 
of co-morbidity is complicating the management of HIV-patients [14,15].  Co-morbid disease causes 
problems with polypharmacy, the co-administration of multiple medications with HIV-medication, 
leading to higher pill burden [14,15] and potential drug-drug interactions and drug toxicities, with loss 
of efficacy of the co-administrated medication and virological breakthrough as consequences.   
Continuous evaluation of the quality of HIV clinical care is vital.  Not only recording 
progress but also identifying treatment gaps and future challenges in a timely manner is of paramount 
importance in order to develop frameworks to address these emerging issues.  This allows for 
evidence-based changes to clinical guidelines to inform continued high quality patient care.   
The work presented in this thesis is important in that it fulfils the unmet need for a formal 
evaluation of cART and clinical management in a robust, systematic and affordable manner, using the 
Netherlands as a case study.  To my knowledge this was the first attempt to document progress in 
population-level effectiveness of HIV-treatment in the Netherlands since 1996 across a large number 
of clinical and non-clinical markers, and to predict the future challenges posed by an ageing HIV-
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population.  By using the Dutch ATHENA dataset to review the changing patterns of cART use and 
trends in patients’ short-term clinical outcomes, this work provides a valuable insight into the progress 
achieved in HIV care, how HIV-treatment has changed, and the impact this has had on treatment 
success.  This evaluation allowed the identification of future challenges namely that of an ageing 
HIV-population.  By designing an individual-based model of the ageing HIV-population with the 
consultation of treating physicians and using ATHENA data, one of the first ageing models was 
constructed incorporating key aspects of ageing and age-related non-infectious co-morbid disease.  It 
provides a powerful tool to carry out projections of an ageing population in the Netherlands, including 
quantifying future age-structure, burden of co-morbid disease, polypharmacy and drug interactions, 
and some of the first model evaluations of the potential impact of different interventions on the 
primary prevention of CVD in an ageing HIV-population.   
 
 
6.2 Overall Results 
The first aim of this thesis was to document progress in HIV-treatment since 1996 by reviewing 
changing patterns of cART use and relating those to trends in patients’ short-term clinical outcomes 
between 1996 and 2010.  A non-selective database that collects data from all HIV-infected patients in 
clinical care in the Netherlands provided a unique opportunity to record the progress of cART since 
1996 across a variety of clinical and non-clinical markers.   
The results of this evaluation showed that the use of first-line cART in the Netherlands 
closely follows changes in guidelines, to the benefit of patients.  Between 1996 and 2010, cART 
regimens changed from mainly 3TC/AZT-based or d4T/3TC-based regimens with unboosted-PIs to 
TDF/3TC or TDF/FTC with NNRTIs.  Despite these changes, there was no significant improvement 
in short-term mortality, likely because the greatest impact on short-term mortality had already 
occurred as a consequence of the introduction of combination therapy [4,5,10,52,53,55–58].  
However, newer drugs with better tolerability and simpler dosing schemes resulted in significantly 
improved immunological and virological outcomes and reduced incidences of switching due to 
toxicity and virological failure.  Short-term incidence of switching has decreased significantly since 
1996 on all cART lines, indicating that the duration patients spend on a cART-line before switching 
has improved substantially over time.  The incidence of switching to simpler or newer medications in 
the absence of virological failure or toxicity has increased between 1996 and 2010.  As far as we can 
tell these changes are related to new drugs becoming available rather than improvements in other 
aspects of clinical care.  This suggests that the changing guidelines have rapidly resulted in patients 
shifting to newer ARV regimens and the results have been to the benefit of patients in care.  However, 
toxicity remains the main reason for switching cART, accounting for 50% of switches of all lines in 
2006-2010.  The main problem is short-term toxicity, occurring within three months of starting a 
regimen, in particular, short-term side effects such as rashes, nausea, diarrhoea and anaemia.  This 
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will likely be aggravated in the future, with a growing number of ageing multi-morbid patients 
increasingly experiencing drug-drug interactions.  Ideally, newly developed drugs will have reduced 
toxicity, while maintaining the high effectiveness of current ARVs and be able to be safely co-
administered with other co-medications.   
The second aim of this thesis was to investigate the future challenges that will arise in clinical 
care in the Netherlands, and to formulate strategies to address these.  The documentation of progress 
in HIV-treatment since 1996 in this thesis and literature highlighted that a model of an ageing HIV-
infected population in the Netherlands was the natural next step to achieving these goals.  With the 
improvement in cART, HIV has become an increasingly chronic infection characterised by an ageing 
HIV-population.  As these patients are becoming increasingly complex to manage it is important to 
quantify the scale of the problem facing the Netherlands in the future.  An individual-based model of 
the ageing HIV-infected population in the Netherlands was constructed, capturing key aspects 
affecting clinical care of HIV-patients, including the major age-related co-morbidities, their common 
physiological pathways and treatment.  The design of the model was carried out with the consultation 
of treating physicians in the Netherlands, in order to incorporate the main clinical aspects involved in 
the care of these patients and parameterisation was based on the Dutch national ATHENA cohort.   
Model simulations showed that the age of the HIV-population in clinical care in the 
Netherlands is rapidly shifting to older age.  Median age of patients in clinical care in the Netherlands 
is expected to increase from 43.9 to 56.6 years by 2030, with nearly 80% of HIV-patients aged ≥50 
years.  The burden of co-morbidity (age-related non-communicable conditions in addition to HIV) 
will increase significantly, with 86% of patients expected to suffer from at least one or more co-
morbidities by 2030 and a third of patients suffering from multi-morbidity, largely driven by a steep 
increase in CVD.   This increase in co-morbidity will result in a massive increase in polypharmacy.  
By 2030 half of patients in care are expected to take at least one additional co-medication and over a 
sixth of the patients will be taking three or more additional co-medications.  The majority of patients 
will be on cardio-vascular medication, reflecting the increase in CVD.  These changing trends in the 
use of co-medication are expected to lead to an increase in the number of patients with problems with 
HIV-medication.  According to our model 40% of patients are expected to experience potential 
complications with recommended cART regimens by 2030.   
The final chapter aimed to evaluate measures that could be integrated into HIV-care to 
address the growing problem posed the increasing burden of CVD.  Standard care was compared to 
the integration of a smoking cessation programme and the introduction of a polypill for the primary 
prevention of CVD for all HIV-patients over a certain age, either 45 or 55.  The results showed that 
both interventions could have a positive impact on the clinical care of the ageing HIV-population in 
the Netherlands, though the impact of a polypill would likely be greater.  The model found that these 
interventions are expected to result in a long-term reduction in the burden of CVD, polypharmacy and 
mortality.  In addition, they are expected to reduce the number of patients with potential drug-drug 
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interactions with recommended cART regimens compared to standard care, although the analysis does 
not take into account potential side effects of the polypill, which will depend on the specific 
formulation.  Together this will result in an improvement in patient health, as expressed by the 
number of DALYs averted, as well as a reduction in treatment costs compared to standard care.  The 
model suggests that of the interventions considered, a smoking cessation programme will have the 
smallest impact on the primary prevention of CVD whilst the introduction of a polypill for all HIV-
patients aged 45 and over would have the greatest impact.  Changing HIV-treatment guidelines to 
recommend the prescription of a polypill for CVD to all HIV-patients aged 45 years and over could 
result in a 13% reduction in multiple morbidities and polypharmacy, a 7% reduction in potential drug-
drug interactions, and a saving of 23 million Euros in treatment costs over a twenty year period 
compared to standard care.  It should be noted that the polypill will have to be reformulated for HIV-
patients due to drug-interactions between statins and some ARVs.  All interventions have a long-term 
cost per DALY averted that is under the estimated WHO cost-effectiveness threshold of three times 
the GDP per capita.  The smoking cessation programme has the lowest cost per DALY averted, at €70 
compared to €290 for a polypill intervention for HIV-patients aged 45 and over, although it would 
require nearly a ten-fold higher initial investment than a polypill intervention.  By 2015 all 
interventions considered would be cost saving compared to standard care, although the roll-out of the 
polypill would likely to come at a higher cost than standard care after 20 years.  This may be driven 
by the increasing number of HIV-patients who live longer as a consequence of the polypill, and spend 
more time on expensive second-line and third-line cART regimens, thus outstripping the savings in 
CVD treatment achieved.   
 
 
6.3 Limitations 
The limitations of this work fall into the following three broad categories; data quality, modelling 
restrictions, and research gaps.  Large cohort studies like the ATHENA cohort are a valuable source 
of data.  However, the quality of ‘additional’ information which is not central to the aim of the cohort, 
such as the collection of co-morbidities and co-medication, can often be suboptimal.  The fact that the 
ATHENA cohort does not systematically collect data on patient co-morbidities and co-medications as 
part of routine data collection means that the model cannot completely capture the true burden of co-
morbidity and polypharmacy in HIV-patients in the Netherlands.  Other cohort studies, including the 
AGEhIV Cohort Study [326], provide additional information, and will be able to address many of the 
limitations posed by the ATHENA cohort in years to come.   
The observational nature of the data also implies that analytical power is limited with regards 
to comparing long-term outcomes and model validation.  The analytical work comparing patient 
outcomes over time could not compare long-term outcomes between time periods, nor could it control 
for all factors influencing certain outcomes.  For example, the data do not capture clinical decision 
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protocols such as those putting patients who are sicker on specific regimens.  Consequently, it can be 
hard to tease apart some of the observed results, and a solid understanding of the data and national 
guidelines is vital.  Equally, the power of the analysis is constrained by the small number of events 
observed so that, for example it is not possible to use some of the ATHENA data for model 
parameterization and the remainder for validation.  Large international cohorts could not only provide 
more data on rare events such as deaths, but could also inform model parameterization and validation.  
The drawback of using such large international cohorts would include considerations about the 
generalizability of data across multiple countries.  Although it should be noted that the 
generalizability of these results are limited by the fact that throughout the thesis, analysis of data 
excluded women known to be pregnant during follow-up, due to the treatment changes that occur 
during pregnancy.  While this may not impact greatly on the generalizability to other European 
countries, where the epidemic is largely driven by MSM, it may be important other settings with a 
different epidemic and a more generalised epidemic such as in parts of Africa.   
Modelling the medical aspects of HIV-treatment and care is complex, and models will never 
be able to capture all aspects of medical care.  Treatment of patients depends on a large number of 
multi-factorial elements, including patient characteristics and medical judgements made by clinicians, 
including those based on information and perceptions that are not necessarily recorded in patients’ 
records.  While new research will inform some aspects of the future of HIV care, it will never be 
possible to fully capture all aspects of the treatment of HIV-patients.  However, models can capture 
the key aspects of clinical care, provide useful projections for the future, and estimate the potential 
impact of health care interventions.  They can provide an important tool in public health care 
evaluation.  Translating model findings into policy or changes in treatment guidelines will require 
close collaboration with treating physicians, policy makers and health care providers.   
Research gaps meant that the model had to make a number of assumptions.  For instance, it is 
unclear what the independent impact of HIV-infection is on the development of co-morbidities or how 
antiretroviral drugs, either individually or as part of a combination regimen affect the risk of co-
morbidities.  Few studies exist on interventions targeted at changes in the clinical care of HIV-
patients.  Little is known about the feasibility, acceptability and effectiveness of interventions focused 
on preventing co-morbidity in HIV-patients.  However, parameters were based, as far as possible, on 
large, high-quality studies in relevant settings, allowing the model to provide future predictions.   
A further limitation surrounds the data on costs.  It can be difficult to obtain good quality, 
country-specific cost data.  Studies looking at individual conditions usually report direct medical costs 
from a particular setting.  However, the definitions surrounding ‘direct’ medical costs can vary from 
study to study and medical costs can differ vastly between countries and can also change over time.  
Any cost analysis is further complicated by the difficulty of obtaining good DALY weight estimates 
for the specific conditions or disease groups.  As a result, the analysis on interventions targeting CVD 
had to be restricted to a basic cost comparison analysis.  A universal assessment of expenditure by 
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disease group would provide a useful way to cross-calibrate the model for these analyses.  The OECD 
is finalising a project on health expenditure by disease group, age and sex (personal communication), 
which could provide a good source of information.  In future, it would be valuable to repeat this work 
in collaboration with health economists and carry out a detailed analysis of the cost-effectiveness of 
interventions targeting ageing HIV-populations to better inform health care services.   
 
 
6.4. Public Health Implications 
There are important public health implications resulting from this work.  First, despite the 
improvement in cART and patient clinical outcomes since 1996, patients still have to deal with a 
lifetime of antiretroviral treatment that is often associated with a plethora of issues, ranging from the 
minor to the life-threatening.  Toxicity in particular remains the main reason patients switch cART 
regimens in the Netherlands (see Chapter 2) as well as globally [149,150,152,279].  With the 
improvement of HIV therapy and the decline in the incidence of switching due to other reasons (like 
switching to newer regimens in the absence of clinical reason), toxicity has in fact become, relatively 
speaking, an even more dominant reason that patients switch.  In the future physicians will have to 
assist patients with the management of a wide array of side effects associated with cART regimens, in 
order to ensure that the near-perfect adherence needed to maintain treatment efficacy is not 
compromised [148].  This will become even more important in the face of an ageing HIV-population, 
with co-morbid disease becoming an increasing problem [15].  Co-morbid disease will complicate 
management of HIV-patients due to an increasing need for polypharmacy and drug-drug interactions, 
which in turn may result in more toxicity [14,15].   
The results of this and other studies [149,150,152,279] suggest that the management of 
toxicity must remain key to the care of HIV patients, to avoid undermining the developments 
achieved in clinical care over the last 15 years.  Staying on cART regimens longer can increase the 
beneficial effect of cART, slow disease progression, reduce clinical disease and prevent virological 
failure [290].  Prolonging the durability of first-line cART is particularly important for treatment 
success.  Future drug development will have to focus on new antiretroviral drugs with reduced 
toxicity and fewer drug-drug interactions, especially with cardiovascular medication, while 
maintaining the high levels of effectiveness that have been achieved to date.   
Globally, HIV care providers should shift their attention from mainly focusing on the 
treatment of life-threatening conditions and opportunistic infections resulting from HIV-infection to 
focusing on ensuring long-term provision of care.  As the prevalence of older HIV-patients increases, 
treating physicians will have to focus on the management of co-morbid disease, complex 
polypharmacy, higher pill burdens and drug-drug interactions.  Physicians will have to be trained to 
respond to this growing complexity of HIV care.  The development of drugs and guidelines will 
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increasingly have to look to the future and recognise the shifting demographic and health status of 
HIV-infected patients.   
The integration of tailored screening for other diseases among patients with HIV will be 
crucial in the future.  HIV-patients are at higher risk for a host of conditions, including diabetes, 
cancers and CVD.  Several studies, for instance, have shown that HIV-infected individuals aged 50 
years and over were significantly less likely to be up to date with their colorectal screening (according 
to national guidelines) than their age-matched controls  [15,312,447,448].  Although it could be 
argued that more HIV-infected MSM may be aware of the pre-stages of anal cancers compared to 
non-infected MSM, due to their increased risk.  Health care providers will have to be more vigilant 
themselves, and propose screening to diagnose and treat co-morbid conditions early, with screening 
decisions taking into considerations cost-benefit trade-offs [15,311].   
Treatment frameworks will have to be introduced to respond to the increasing burden of 
polypharmacy.  Polypharmacy can not only compromise cART compliance, particularly in older 
patients with additional psychosocial barriers, dementia and reduced mobility [350], it will also make 
the management of drug-drug interactions increasingly complex.  Mismanagement of polypharmacy 
can lead to toxicity and hospitalization due to drug-drug interactions and is linked to higher costs for 
both the patient and the health care system [352].  Even minor additional drug-drug interactions can 
lead to increased visits to physicians, the need for additional laboratory tests and new medication 
being prescribed to treat the new symptoms (something that was not considered in this analysis as it 
was outside the scope of this work).  Drug-drug interactions can lead to the need for consultation with 
specialists or even hospital admission.  Several studies have shown that adverse drug events and drug-
drug interactions in older adults not only increase morbidity and mortality [352,449], and are a 
common cause of emergency hospitalisation [450,451].  Patients prescribed anticoagulants, 
antibiotics, diuretics, hormones, antidepressants and corticosteroids in particular have been found to 
be at an increased risk of adverse events [352].  A US survey into medical expenditure found that the 
prescription of inappropriate medication in older patients cost the health care system $7.2 billion 
between 2000 and 2001[353].   
HIV care is going to have to adopt an increasingly horizontal approach.  Aligning health care 
and integrating different services into HIV care could not only benefit HIV-patients but potentially 
reduce treatment costs.  A cross-disciplinary clinical approach could ensure regular reviews of patient 
medications prior to prescribing additional medication and could help ensure continued high quality 
care.  HIV-infection is likely to serve as a model for accelerated ageing, with the lessons learned in 
the complex management of patients with multiple morbidities likely to be applicable to geriatric 
services for the general population.  Training geriatric service providers and infectious disease 
clinicians could be valuable in the future to facilitate integration of geriatric principles into infectious 
disease care and vice versa [452].   
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Finally, in addition to screening for and managing of co-morbidities in HIV-patients, HIV 
clinical care will have to integrate proven interventions for the primary prevention of co-morbid 
disease.  These interventions will have to adequately address the unique needs of HIV-patients.  The 
health care setting provides a unique opportunity for the implementation of interventions amongst 
HIV-patients, including risk factor management, and interventions targeting lifestyle factors such as 
smoking cessation, physical activity, and diet [375,428].  HIV-patients interact frequently with health 
care providers and physicians as part of their treatment, providing great opportunities for health care-
initiated interventions [375].  At a time when the world is experiencing a shifting demography to an 
increasingly ageing population, with rising levels of obesity resulting in new challenges to health care 
of both the general and HIV-population, lifestyle interventions will likely become an increasingly 
important pillar to health care provision [375,428].  It therefore remains a shock that the Dutch 
government has closed its tobacco control operations and world-renowned tobacco control centre 
STIVORO [430].  In the future national health care services will have to refocus their efforts of 
driving lifestyle changes.   
A large body of research addressing the issues outlined above and political will is going to be 
paramount to ensuring that evidence-led changes in treatment guidelines are made and that high 
quality care of both HIV-patients and other multi-morbid patient populations is continued.  This will 
require the strengthening of the health care system, and financial and human resources to expand 
services and acquire the necessary expertise [355].   
 
 
6.5 Future Work 
Given the importance of side effects of HIV-treatment as reasons for switching regimens and for 
reduced adherence, it is disappointing that they are studied so poorly [148].  For regulatory approval, 
only side effects affecting major organ systems, such as the central nervous, cardiovascular, and 
respiratory systems have to be reported [148].  In terms of post-marketing data collection, the 
reporting of side effects occurs passively, with little consensus on the definition of side effects or 
method of collection [148].  There is an unmet need for more detailed data about treatment 
tolerability, drug interaction between ARVs and co-medication, and the effect of short- and long-term 
toxicity of cART, especially in ageing HIV-patients [15].  Long-term post marketing surveillance of 
cART was one of the primary reasons that the ATHENA cohort was set up [176], and in the 
immediate future it will be important to indicate to such long-term cohorts on the additional data that 
they should be collecting going forward.  Many studies into toxicity have until recently excluded 
patients of advanced age or with co-morbid disease [15].  International consensus on definitions of 
toxicity and collaborative collection of side effects will be important steps in the continued research 
on toxicity and HIV.   
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In addition, studies and controlled trials on therapeutic and clinical outcomes of older HIV-
infected patients are needed.  Until recently, this population has been relatively ignored, with most 
randomized trials of cART excluding older patients or those with co-morbid disease [15].  
Consequently, many questions remain about the clinical care of ageing HIV-patients, the tolerability 
of cART in patients with multiple morbidities, the impact of large pill burdens on treatment outcomes, 
pharmacodynamics and pharmacokinetics in older patients, and the drug interactions between cART 
and co-administered medication.  It remains unclear whether guidelines for the treatment of older 
HIV-patients should be modified.  For example, should the CD4-threshold for cART initiation be 
changed in older patients to counteract the role of inflammation on the development of co-morbidities 
[227–229]?  How do the risks and benefits of early cART initiation differ in older patients; what are 
the benefits of early initiation versus the long-term toxicity of cART on the development of co-morbid 
disease, and does this differ with a patient’s age?  How should screening and treatment protocols be 
changed in light of the changing demography? What interventions are the most effective for the 
primary prevention of co-morbid disease in HIV-patients and how can they best implemented to 
respond to the unique needs of these complex patients as they age? 
Despite the importance of these questions they have so far received little attention.  Clinical 
research will have to evaluate the efficacy, safety and tolerability of these programs in HIV-cohorts, 
as well as potential interactions with ARVs and effects on adherence.  Behavioural research will have 
to be carried out to evaluate the feasibility and acceptability of these interventions and how best to 
tailor them to this sub-population.  Systems-based research will have to be carried out to identify the 
barriers to implementation and how best to address them.   
New cohorts will bring a valuable tool to answering some of the many questions that remain.  
Cohorts such as the AGEhIV Cohort Study, a prospective cohort study in the Netherlands established 
in 2010, are increasingly investigating the therapeutic and clinical outcomes of older HIV-infected 
patients [326].  These studies will provide vital information on some of the key questions, including 
the role of inflammation in the early onset of non-communicable diseases amongst HIV-patients.  
They will provide the means to expand the model presented in this thesis to provide a more rounded 
picture of the future of the clinical care of an ageing HIV-population.  In the first analysis of their 
cohort data, they found that after controlling for a number of key factors, HIV-infected individuals 
were at an increased risk of having one or more co-morbidities compared to non-infected individuals.  
Their study showed that HIV-patients had a significantly higher prevalence of hypertension, MIs, 
peripheral arterial disease and reduced renal function, as well as borderline higher prevalence of 
diabetes compared to non-infected individuals (Peter Reiss (2013) personal communication).  
Understanding how HIV-infection affects the development of specific co-morbidities will better 
inform the model and improve predictions of the burden of co-morbidity and the conditions driving 
their increase.   
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My future aims are to continue researching this topic.  Through continued collaboration with 
the ATHENA cohort and thanks to a joint interest with the AGEhIV Cohort Study, the model will be 
further developed in the future.  While there are a number of improvements that can be made to the 
model, the main points that will become the focus of continued collaboration with ATHENA are 
outlined in Figure 6.1, Part 1, Section A.   
First, the goal will be to include key lifestyle factors such as smoking status, alcohol 
consumption and diet in the model and estimate their impact on the development of co-morbidities 
(Figure 6.1, Part 1, Section A, Point 1).  In order to simulate the impact of lifestyle factors on the 
development of malignancies, the model should simulate malignancies in more detail, for example by 
including key cancer types (Figure 6.1, Part 1, Section A, Point 5).  The model should also simulate 
recurrent MIs and strokes and incorporate a CVD framework, similar to the Framingham or SCORE.  
In the future the aim is to incorporate CVD risk, such as the D:A:D and Framingham framework to 
better evaluate a number of different CVD interventions independently and in combination.   
The AGEhIV Cohort Study will form a valuable source of data for model expansion.  For 
example, the cohort collects information on additional co-morbidities which should be incorporated 
into the model (Figure 6.1, Part 1, Section A, Point 2).  In particular, the focus should be on 
incorporating neurodegenerative disorders such as Alzheimer’s disease into the model.  
Neurocognitive conditions are expected to become a major problem amongst older HIV-patients, with 
conditions related to memory loss resulting in adherence issues, compromising the efficacy of HIV-
treatment [15,309–312].  Any additional co-medication for those conditions should be included in the 
model (Figure 6.1, Part 1, Section A, Point 6) and information on drug interactions with additional co-
medications updated (Figure 6.1, Part 1, Section A, Point 7).   
In addition, incidence data on the co-morbidities already incorporated in the model will be 
checked against D:A:D estimates and estimates of the AGEhIV Cohort Study, to determine whether 
and how the current model is underestimating the true burden of co-morbidity (Figure 6.1, Part 1, 
Section A, Point 4), and to update estimates where necessary.  As mentioned previously, the 
ATHENA cohort does not systematically collect data on co-morbidity resulting in a potential 
underestimation of the true burden of co-morbidities in the cohort.   
The AGEhIV Cohort Study will also provide additional information on the independent effect 
of HIV-infection, including inflammation and HIV-treatment on the development of co-morbidities to 
include in the model (Figure 6.1, Part 1, Section A, Point 3).  As the first analyses of the cohort are 
only just being undertaken, it was not possible to utilize the AGEhIV cohort data in the work 
presented in this thesis.   
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Figure 6.1. Details of future work on Part 1: Model expansion and Part 2: Adaptation of the model to 
different geographical and demographic settings.  Part 1 Sections B to D show the basic model structure.  
Current model follows HIV-patients from treatment initiation until death or closing year of model (2030) 
(Section C).  It simulates how HIV-patients ageing over time (Section D), develop co-morbidities, start co-
medication for these conditions and how these co-medications affect HIV-treatment (Section B).  Future 
plans for model expansion are listed in Section A. Part 2 shows plans to adapt the model from a European 
setting to an African setting (Section 1), to use it as an ageing model for the general population (Section 2) 
(red men represent HIV-infected and black men represent non-HIV infected individuals) and to 
incorporate economic analysis into the model to inform policy (Section 3).   
Source: world map from http://www.travelmagma.com/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
    1. African setting              2. General population          3. Economic analysis 
         
 
 
 
    1. African setting              2. General population          3. Economic analysis 
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Finally, in addition to the above model extensions, the next important step will be to expand 
the model, for example to explore these issues in an African setting (Figure 6.1, Part 2, Section 2, 
Point 1), where health care systems currently largely provide episodic care for acute symptomatic 
conditions [350,453,454] or services for maternal and infant health [350,455].  Recent studies have  
found similar trends of shifting demography of HIV-patients in sub-Saharan Africa, where 
life expectancy of HIV-infected individuals has increased considerably over the past decade [12].  In 
South Africa life-expectancy of people living with HIV has been reported to have increased from 56.5 
years in 2009 to 60 years in 2011 [12], probably due to the increasing delivery of HIV-treatment and 
prevention of mother-to-child-transmission [456].  An ageing population, both in HIV-infected and 
non-infected, will put new demands on health systems, and require continuity of care with specialists 
in chronic disease management.  The model will provide a valuable tool in evaluating this need.   
As mentioned previously, HIV-infection is likely to serve as a model for accelerated ageing, 
with the lessons learned regarding the complex management of patients with multiple morbidities  
likely to be applicable to geriatric services for the general population (Figure 6.1, Part 2, Point 2).  
Adaptation of the model to an African setting or for the general population and integration of relevant  
health economic  data (Figure 6.1, Part 2, Point 3) providing valuable insight and inform Health 
Ministries on investing in future care of ageing populations in settings with high HIV prevalence.  
These expansions will require extensive data for parameterization.  Adapting the model to the general 
population in particular is going to have data or make assumptions about the causes of ageing and 
reasons why patients with the same age suffer disproportionately differently from co-morbid disease.   
 
 
6.6 Final Conclusion 
HIV clinical care has made significant improvements since the introduction of cART.  New drugs 
with improved efficacy and tolerability have transformed HIV-infection into a chronic disease, 
characterised by an ageing HIV-population suffering from an increasing burden of co-morbidity and 
polypharmacy.  These HIV-patients will increasingly put new demands on the health care system.  In 
addition to co-managing HIV-infection and co-morbid disease effectively, these patients will require 
routine and tailored medical care, including regular screening for particular co-morbidities, and 
primary prevention interventions.  Most health care systems will need to adapt to these changes in 
HIV care, particularly in developing settings.  Treatment services established in response to the HIV-
epidemic will need to diversify to address the unique health problems of the world’s ageing HIV-
population.  This will require a large body of cutting edge research, making now an exciting time to 
be working in this field.   
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Smit M; Smit C; Cremin I; Garnett, GP, Hallett T; De Wolf F.  Could better tolerated HIV drug 
regimens improve patient outcome? AIDS 2012; 26 (15), p 1953-1959.  * 
 
Smit M; Smit C; Geerlings S, Gras L, Brinkman K, Hallett TB, De Wolf F.  Changes in first-line 
cART regimens and short-term clinical outcome between 1996 and 2010 in the Netherlands.  PLoS 
One 2013; 8(9): e76071. doi:10.1371/journal.pone.0076071.  * 
 
 
Conference and meeting presentations 
 
Smit M; Smit C; Cremin I; Hallett T; De Wolf F; Garnett GP. New Drugs Targeting Toxicities Have 
Highest Hope of Impacting Patients Prognosis. International Society for Sexually Transmitted 
Diseases Research. Quebec City, Canada, Jul 2011 (Poster).   
 
Smit M; Smit C; Geerlings S; Gras L; Hallett TB; De Wolf F. Changes in first-line cART regimens 
and clinical outcome between 1996 and 2010 in the Netherlands.  6
th
 Netherlands Conference on 
HIV Pathogenesis, Prevention and Treatment.  Amsterdam, The Netherlands, Nov 2012 (Oral).   
 
SHM Advisory Board Meeting: “The future challenges in clinical care of HIV-patients: modelling an 
ageing HIV-population”.  Held in Amsterdam, The Netherlands, December 2013 (Oral).   
 
MRC meeting: "The future challenges in clinical care of HIV patients: modelling an ageing 
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Appendix B - List of side effects collected by the ATHENA cohort 
Side effects are diagnosed and recorded by the treating physicians.   
 
Cancer  
Anal dysplasia 
Hodgkin’s lymphoma 
Hodgkin’s stage 3b 
Other malignant disease 
 
Cardiovascular  
Angina pectoris or angina (chest pain due to ischemia (lack of blood)) 
Arrhythmia (to be specified by physicians) 
Cardiomyopathy (heart muscle disease /deterioration) 
Cerebrovascular accident (stroke) 
Endocarditis (inflammation of the inside lining of the heart chambers and valves) 
Heart failure 
Hypertension 
Myocardial infarction (heart attack) 
Varicose (swollen twisted, sometimes painful, veins) 
Other cardiovascular event (to be specified by physician) 
 
Dermatological 
Dermatitis (includes eczema) 
Dry skin 
Eczema 
Folliculitis (inflammation of one or more hair follicles) 
Furunculosis (recurring boils) 
Herpes simplex, mucocutaneous 
Herpes zoster, uni-dermatatological 
Itchiness 
Mollusca contagiosa (viral infection causing warty bums (Mollusca)) 
Mycosis (fungal infection) 
Psoriasis (autoimmune disease) 
Rash 
Warts (not genital) 
Other dermatologic events 
Appendix B - List of side effects collected by the ATHENA cohort 
215 
 
Ear, Nose and Throat conditions 
Acute otitis media (inflammation of the middle ear) 
Angular cheilitis (fissure of the corner of the mouth) 
Change in taste 
Cough 
Common cold 
Dry mouth 
Gingivitis (inflammation of the gums) 
Cold, sore throat 
Oral ulcer 
Pharyngitis (sore throat, or discomfort in the throat) 
Rhinorrhoea (nasal cavity filled with mucous fluid) 
Sinusitis 
Sore throat 
Stomatitis (inflammation of mucosal lining of any structure in the mouth) 
Other Ear-Nose-Throat events 
 
Gastrointestinal 
Abdominal distension (elevated abdominal pressure/volume) 
Abdominal/epigastric pain (stomach pain) 
Anal fissure 
Cholecystitis (sudden inflammation of the gallbladder) 
Cholelithiasis (gallstones) 
Constipation 
Diarrhoea 
Dysphagia (difficulty in swallowing) 
Flatulence (passing gas) 
Gastroenteritis (stomach bug/infection) 
Haemorrhoids (swelling in the lining of the anus) 
Indigestion, dyspepsia 
Loss of weight 
Loss of appetite 
Nausea and vomiting 
Nausea 
Vomiting 
Other gastrointestinal event 
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Hematologic 
Anaemia 
Clotting disorder 
Cystitis (urinary tract infection) 
Genital and perianal warts 
Gonorrhoea 
Herpes genital 
Leucocytosis (raised white blood count) 
Leucocyturia (the presence of white blood cells in the urine) 
Leucopenia (a decrease in white blood cells) 
Lymphadenopathy' – disease of the lymph nodes) 
Neutropenia (an abnormally low number of white blood cells) 
Pancytopenia (reduction in the number of red and white blood cells) 
Renal insufficiency (renal failure) 
Thrombocytopenia (low amount of platelets) 
Thrombocytosis (high platelet counts, can lead to thrombosis) 
Other haematological disorder' 
 
Liver-related toxicity 
Diabetes mellitus 
Elevated ALAT levels 
Elevated alkaline phosphatase (ALP,ALK) level 
Elevated amylase level 
Elevated ASAT level 
Elevated bilirubin level 
Elevated cholesterol level 
Elevated CPK level 
Elevated creatinine 
Elevated gamma-GT level 
Elevated triglycerides level 
Elevated uric acid level 
Glucosuria (excretion of glucose into the urine) 
Hepatic steatosis (fatty liver) 
Hepatitis A 
Hepatitis B 
Hepatitis C 
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Hepatitis (chronic) 
Hepatomegaly (enlarged liver) 
Hyperglycemia (high blood sugar) 
Hypoglycemia (low blood sugar) 
Icterus (jaundice) 
Lactate acidosis (high acid in the body) 
Lipodystrophy (selective change of body fat) 
Lipodystrophy, weight loss 
Lipodystrophy, fat accumulation 
Liver cirrhosis (liver scarring) 
Liver fibrosis (first stage of liver scarring) 
Oesophagus varices (enlarged blood vessel in oesophagus) 
Pancreatitis (inflammation of the pancreas) 
Proteinuria (protein in the urine) 
Splenomegaly (enlarged spleen) 
Other chemistry or liver event 
 
Musculoskeletal 
Arthralgia (joint pain) 
Arthritis (inflammation of the joints) 
Avascular necrosis (bone death caused by poor blood supply) 
Myalgia (muscle ache) 
Myopathy (muscle wasting) 
Myositis (inflammation of the muscles) 
Osteopenia (bone mineral density is lower than normal) 
Osteoporosis 
Other muscle or joints events' 
 
Neurologic/Psychiatric 
Alcohol abuse 
Anxiety 
Concentration disorders 
Confusion 
Depression 
Dizziness 
Drug abuse 
Epileptic insults, seizures 
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Erectile dysfunction 
Headache 
Hepatic encephalopathy 
Loss of libido 
Loss of memory 
Mood change 
Nightmares 
Peripheral neuropathy 
Phobia 
Psychosis 
Sleeping disorder 
Suicide (attempt) 
Transient numbness/tingling (paraesthesia) 
Other neurological problems 
Other sexual problems 
Other psychosocial problems 
 
Pulmonary 
Rhinorrhoea (runny nose) 
Sore throat 
Bronchitis 
Dyspnoea (shortness of breath) 
Pneumonia 
Chest pain/discomfort 
CCOPD (asthma, emphysema) 
Pulmonary hypertension 
Respiratory disorder 
 
VISUAL  
Loss of vision 
Blepharitis (inflammation of eyelids) 
Keratitis (inflammation of the cornea) 
Conjunctivitis (eye infection) 
Bleaching of the eyelids 
Extra- ocular muscle paralysis 
Keratopathy (excluding keratitis, non-inflammation disease of cornea) 
Retinopathy (impairment/loss of vision) 
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Other visual disorder 
 
Systemic 
Abacavir hypersensitivity 
Fatigue 
Fever 
Flu syndrome/ flu-like illness 
General malaise 
Malaria 
Night sweats 
Other systemic event 
 
Urogenital 
Balanitis (inflammation of the glans penis (the end of the penis)) 
Candidiasis genital (irritation) 
Chlamydia infection (genital) 
Genital ulcers 
Haematuria (blood in urine) 
Nephrolithiasis (kidney stones) 
Prostatism (lower urinary tract infection) 
Renal dialysis 
Renal transplantation 
Trichomonas infection (parasite infection) 
Urethritis (swelling and irritation of the urethra) 
Other urogenital event 
 
Other 
Pregnancy 
Intoxication 
Hospital admittance 
No toxicity 
Link not matched with AE 
Drug not matched with link 
Not matched 
Other 
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Table 1. Adjusted hazard ratio (95% Confidence intervals) of reaching CD4 increase of 150 cells/mm
3 
by 12 
months on first-line.   
Source: Smit et al 2013 [275].   
 
Variables Model 1: Calendar time  Model 2: Calendar time and regimen 
type 
 Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 0.96 (0.90-1.03) 0.28 1.01 (0.89-1.15) 0.83 
2001-2005 0.94 (0.88-0.99) 0.03 0.97 (0.89-1.06) 0.46 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 0.97 (0.96-0.98) <.0001 0.97(0.96-0.99) 0.0001 
Sex     
Male [Reference]  [Reference]  
Female 1.18 (1.08-1.29) 0.0002 1.26 (1.14-1.38) <.0001 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 0.98 (0.89-1.08) 0.72 1.00 (0.90-1.11) 0.98 
Sub-Saharan Africa 0.72 (0.66-0.80) <.0001 0.71 (0.64-0.78) <.0001 
Other 0.86 (0.80-0.92) <.0001 0.87 (0.81-0.94) 0.0007 
Route of transmission     
Heterosexual 0.82 (0.76-0.89) <.0001 0.80 (0.74-0.87) <.0001 
MSM [Reference]  [Reference]  
Injecting Drug Use 0.49 (0.38-0.63) <.0001 0.51 (0.39-0.67) <.0001 
Other 0.83 (0.74-0.93) 0.0009 0.85 (0.75-0.96) 0.007 
Clinical     
CD4 cell count at start of cART     
CD4 ≤200  0.83 (0.77-0.91) <.0001 0.84 (0.77-0.92) 0.0003 
CD4 201-350  1.00 (0.92-1.09) 0.99 1.02 (0.93-1.12) 0.66 
CD4 351-500  [Reference]  [Reference]  
CD4 >500 0.81 (0.72-0.93) 0.002 0.76 (0.65-0.89) 0.0004 
RNA at start of cART     
RNA ≤100 000 [Reference]  [Reference]  
RNA 100 000-1 000 000 1.40 (1.33-1.49) <.0001 1.37 (1.29-1.46) <.0001 
RNA >1 000 000  2.07 (1.84-2.31) <.0001 1.97 (1.73-2.25) <.0001 
cART Type     
3TC/d4T + PI   1.03 (0.85-1.26) 0.75 
3TC/d4T + Boosted-PI   1.30 (1.08-1.57) 0.01 
3TC/d4T + NNRTI   0.74 (0.53-1.02) 0.06 
3TC/AZT + PI   0.88 (0.76-1.03) 0.12 
3TC/AZT + Boosted-PI   1.04 (0.94-1.16) 0.42 
3TC/AZT + NNRTI   0.91 (0.81-1.01) 0.08 
TDF/3TC or TDF/FTC + Boosted-PI   1.18 (1.07-1.29) 0.0006 
TDF/3TC or TDF/FTC + NNRTI   [Reference]  
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Table 2. Adjusted hazard ratio (95% Confidence intervals) of reaching CD4 increase after switching of 150 
cells/mm
3 
by 12 months on second-line treatment.   
 
Variables Model 1: Calendar time  Model 2: Calendar time and 
regimen type 
 Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 1.08 (0.97-1.21) 0.16 1.03 (0.83-1.28) 0.81 
2001-2005 0.98 (0.89-1.07) 0.60 1.05 (0.90-1.23) 0.56 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 0.96 (0.94-0.98) 0.0003 0.98 (0.95-1.01) 0.11 
Sex     
Male [Reference]  [Reference]  
Female 1.31 (1.16-1.49) <.0001 1.27 (1.06-1.52) 0.01 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 0.98 (0.84-1.15) 0.81 1.07 (0.87-1.31) 0.51 
Sub-Saharan Africa 0.79 (0.69-0.91) 0.0008 0.79 (0.65-0.96) 0.02 
Other 0.92 (0.83-1.03) 0.16 0.94 (0.80-1.10) 0.42 
Route of transmission     
Heterosexual 0.87 (0.77-0.98) 0.02 0.91 (0.77-1.08) 0.27 
MSM [Reference]  [Reference]  
Injecting Drug Use 0.62 (0.45-0.85) 0.003 0.80 (0.51-1.27) 0.34 
Other 0.85 (0.72-1.00) 0.06 0.82 (0.65-1.04) 0.10 
Clinical     
CD4 cell count at start of cART     
CD4 ≤200  0.79 (0.98-0.87) 0.79 0.89 (0.75-1.05) 0.17 
CD4 201-350  1.06 (0.95-1.19) 0.29 0.98 (0.84-1.14) 0.75 
CD4 351-500  [Reference]  [Reference]  
CD4 >500 0.81 (0.73-0.92) 0.0008 0.76 (0.65-0.88) 0.0003 
RNA at start of cART     
RNA ≤100 000 [Reference]  [Reference]  
RNA 100 000-1 000 000 2.25 (1.99-2.55) <.0001 2.57 (2.11-3.13) <.0001 
RNA >1 000 000  3.02 (2.20-4.15) <.0001 3.17 (1.73-5.66) <.0001 
cART Type     
3TC/d4T + PI   1.32 (0.93-1.87) 0.12 
3TC/d4T + Boosted-PI   1.43 (1.07-1.92) 0.02 
3TC/d4T + NNRTI   1.36 (1.01-1.81) 0.04 
3TC/AZT + PI   1.19 (0.85-1.67) 0.31 
3TC/AZT + Boosted-PI   1.32 (1.08-1.61) 0.007 
3TC/AZT + NNRTI   0.92 (0.75-1.13) 0.43 
TDF/3TC or TDF/FTC + Boosted-PI   1.41 (1.21-1.65) <.0001 
TDF/3TC or TDF/FTC + NNRTI   [Reference]  
Appendix C – Additional results for Chapter 2 
222 
Table 3. Adjusted hazard ratio (95% Confidence intervals) of reaching CD4 increase after switching of 150 
cells/mm
3 
by 12 months on third-line treatment.   
 
 
Variables 
Model 1: Calendar time  Model 2: Calendar time and 
regimen type 
 Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 1.17 (1.02-1.35) 0.02 1.12 (0.87-1.43) 0.39 
2001-2005 1.01 (0.91-1.13) 0.81 1.06 (0.89-1.26) 0.52 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 0.95 (0.93-0.98) <.0001 0.93 (0.90-0.96) <.0001 
Sex     
Male [Reference]  [Reference]  
Female 1.40 (1.20-1.63) <.0001 1.37 (1.12-1.66) 0.002 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 0.93 (0.76-1.13) 0.44 0.95 (0.74-1.22) 0.71 
Sub-Saharan Africa 0.81 (0.68-0.95) 0.01 0.76 (0.61-0.94) 0.01 
Other 0.97 (0.84-1.11) 0.61 0.95 (0.80-1.14) 0.60 
Route of transmission     
Heterosexual 0.84 (0.72-0.98) 0.02 0.78 (0.65-0.95) 0.01 
MSM [Reference]  [Reference]  
Injecting Drug Use 0.92 (0.68-1.24) 0.59 0.87 (0.59-1.26) 0.46 
Other 0.86 (0.71-1.05) 0.15 0.79 (0.61-1.02) 0.07 
Clinical     
CD4 cell count at start of cART     
CD4 ≤200  0.98 (0.84-1.15) 0.79 1.00 (0.81-1.22) 0.98 
CD4 201-350  1.23 (1.07-1.42) 0.005 1.25 (1.04-1.50) 0.02 
CD4 351-500  [Reference]  [Reference]  
CD4 >500 0.87 (0.75-1.00) 0.05 0.94 (0.78-1.12) 0.48 
RNA at start of cART     
RNA ≤100 000 [Reference]  [Reference]  
RNA 100 000-1 000 000 2.07 (1.78-2.41) <.0001 2.31 (1.92-2.77) <.0001 
RNA >1 000 000  2.18 (1.44-3.30) 0.0002 2.30 (1.40-3.76) 0.001 
cART Type     
3TC/d4T + PI   1.25 (0.84-1.85) 0.28 
3TC/d4T + Boosted-PI   1.43 (1.03-1.99) 0.03 
3TC/d4T + NNRTI   0.88 (0.62-1.24) 0.46 
3TC/AZT + PI   1.17 (0.85-1.62) 0.33 
3TC/AZT + Boosted-PI   1.00 (0.79-1.26) 0.98 
3TC/AZT + NNRTI   1.05 (0.84-1.31) 0.70 
TDF/3TC or TDF/FTC + Boosted-PI   1.38 (1.17-1.64) 0.0002 
TDF/3TC or TDF/FTC + NNRTI   [Reference]  
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Table 4. Adjusted hazard ratio (95% confidence intervals) of virological suppression  below 1,000 copies/ml by 12 
months on first-line.   
Source: Smit et al 2013 [275].   
 
Variables Model 1: Calendar time Model 2: Calendar time and 
regimen type 
 Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 0.79 (0.75-0.84) <.0001 0.91 (0.82-1.01) 0.07 
2001-2005 0.90 (0.86-0.95) <.0001 0.95 (0.88-1.01) 0.12 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 1.00 (0.99-1.02) 0.43 1.00 (0.99-1.02) 0.61 
Sex     
Male [Reference]  [Reference]  
Female 1.04 (0.96-1.11) 0.34 1.06 (0.98-1.14) 0.16 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 0.92 (0.85-1.00) 0.06 0.90 (0.82-0.98) 0.02 
Sub-Saharan Africa 0.96 (0.89-1.04) 0.33 0.95 (0.87-1.03) 0.19 
Other 1.01 (0.95-1.08) 0.68 1.01 (0.94-1.07) 0.88 
Route of transmission     
Heterosexual 0.90 (0.84-0.96) 0.001 0.88 (0.82-0.95) 0.0004 
MSM [Reference]  [Reference]  
Injecting Drug Use 0.80 (0.68-0.96) 0.01 0.78 (0.64-0.94) 0.01 
Other 0.92 (0.84-1.01) 0.07 0.92 (0.83-1.02) 0.11 
Clinical     
CD4 cell count at start of cART     
CD4 ≤200  0.99 (0.92-1.06) 0.67 0.95 (0.88-1.03) 0.19 
CD4 201-350  1.02 (0.95-1.09) 0.62 0.96 (0.89-1.04) 0.34 
CD4 351-500  [Reference]  [Reference]  
CD4 >500 1.02 (0.91-1.13) 0.75 0.95 (0.84-1.07) 0.38 
RNA at start of cART     
RNA ≤100 000 [Reference]  [Reference]  
RNA 100 000-1 000 000 0.65 (0.62-0.68) <.0001 0.67 (0.64-0.71) <.0001 
RNA >1 000 000  0.50 (0.45-0.55) <.0001 0.50 (0.45-0.57) <.0001 
cART Type     
3TC/d4T + PI   0.87 (0.74-1.03) 0.11 
3TC/d4T + Boosted-PI   0.90 (0.77-1.06) 0.21 
3TC/d4T + NNRTI   0.85 (0.67-1.09) 0.20 
3TC/AZT + PI   0.71 (0.63-0.81) <.0001 
3TC/AZT + Boosted-PI   0.82 (0.75-0.89) <.0001 
3TC/AZT + NNRTI   0.97 (0.88-1.06) 0.48 
TDF/FTC or TDF/3TC + Boosted-PI   0.87 (0.81-0.95) 0.001 
TDF/FTC or TDF/3TC + NNRTI   [Reference]  
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Table 5. Adjusted hazard ratio (95% confidence intervals) of virological suppression below 1,000 copies/ml by 12 
months on second-line.   
 
Variables Model 1: Calendar time Model 2: Calendar time and 
regimen type 
 Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 0.72 (0.63-0.84) .<.0001 1.01 (0.75-1.36) 0.95 
2001-2005 0.84 (0.74-0.95) 0.004 0.95 (0.77-1.17) 0.61 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 1.01 (0.99-1.04) 0.41 1.03 (0.99-1.07) 0.17 
Sex     
Male [Reference]  [Reference]  
Female 1.22 (1.04-1.43) 0.02 1.25 (1.00-1.55) 0.05 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 0.78 (0.62-0.97) 0.03 0.61 (0.44-0.86) 0.005 
Sub-Saharan Africa 0.85 (0.71-1.01) 0.07 1.02 (0.80-1.30) 0.86 
Other 0.88 (0.76-1.03) 0.10 0.94 (0.76-1.15) 0.54 
Route of transmission     
Heterosexual 0.80 (0.69-0.94) 0.006 0.81 (0.65-1.01) 0.06 
MSM [Reference]  [Reference]  
Injecting Drug Use 0.56 (0.39-0.82) 0.003 1.45 (0.97-2.15) 0.07 
Other 0.92 (0.75-1.14) 0.45 0.84 (0.62-1.14) 0.27 
Clinical     
CD4 cell count at start of cART     
CD4 ≤200  1.51 (1.51-1.80) <.0001 1.11 (0.87-1.42) 0.40 
CD4 201-350  1.35 (1.13-1.62) 0.001 1.50 (1.18-1.90) 0.0009 
CD4 351-500  [Reference]  [Reference]  
CD4 >500 1.03 (0.83-1.29) 0.77 1.23 (0.88-1.72) 0.23 
RNA at start of cART     
RNA ≤100 000 [Reference]  [Reference]  
RNA 100 000-1 000 000 0.88 (0.78-0.99) 0.03 0.89 (0.76-1.06) 0.18 
RNA >1 000 000  0.80 (0.60-1.07) 0.13 0.70 (0.46-1.07) 0.10 
cART Type     
3TC/d4T + PI   0.83 (0.51-1.37) 0.46 
3TC/d4T + Boosted-PI   0.82 (0.56-1.20) 0.30 
3TC/d4T + NNRTI   0.81 (0.54-1.21) 0.30 
3TC/AZT + PI   0.50 (0.34-0.74) 0.0004 
3TC/AZT + Boosted-PI   0.76 (0.59-0.98) 0.03 
3TC/AZT + NNRTI   1.14 (0.87-1.50) 0.36 
TDF/FTC or TDF/3TC + Boosted-PI   0.77 (0.62-0.95) 0.02 
TDF/FTC or TDF/3TC + NNRTI   [Reference]  
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Table 6. Adjusted hazard ratio (95% confidence intervals) of virological suppression below 1,000 copies/ml by 12 
months on third-line.   
 
Variables Model 1: Calendar time Model 2: Calendar time and 
regimen type 
 Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 0.89 (0.75-1.05) 0.17 1.01 (0.75-1.36) 0.95 
2001-2005 0.86 (0.75-0.99) 0.04 0.95 (0.77-1.17) 0.61 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 1.02 (0.99-1.05) 0.18 1.03 (0.99-1.07) 0.17 
Sex     
Male [Reference]  [Reference]  
Female 1.11 (0.93-1.33) 0.24 1.25 (1.00-1.55) 0.05 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 0.81 (0.63-1.04) 0.10 0.61 (0.44-0.86) 0.005 
Sub-Saharan Africa 0.90 (0.74-1.10) 0.32 1.02 (0.80-1.30) 0.86 
Other 0.83 (0.71-0.99) 003 0.94 (0.76-1.15) 0.54 
Route of transmission     
Heterosexual 0.86 (0.72-1.03) 0.09 0.81 (0.65-1.01) 0.06 
MSM [Reference]  [Reference]  
Injecting Drug Use 0.96 (0.69-1.34) 0.81 1.45 (0.97-2.15) 0.07 
Other 0.88 (0.69-1.12) 0.30 0.84 (0.62-1.14) 0.27 
Clinical     
CD4 cell count at start of cART     
CD4 ≤200  1.37 (1.12-1.67) 0.002 1.11 (0.87-1.42) 0.40 
CD4 201-350  1.66 (1.36-2.02) <.0001 1.50 (1.18-1.90) 0.0009 
CD4 351-500  [Reference]  [Reference]  
CD4 >500 1.10 (0.85-1.42) 0.48 1.23 (0.88-1.72) 0.23 
RNA at start of cART     
RNA ≤100 000 [Reference]  [Reference]  
RNA 100 000-1 000 000 0.86 (0.75-0.98) 0.03 0.89 (0.76-1.06) 0.18 
RNA >1 000 000  0.63 (0.44-0.90) 0.01 0.70 (0.46-1.07) 0.10 
cART Type     
3TC/d4T + PI   0.83 (0.51-1.37) 0.46 
3TC/d4T + Boosted-PI   0.82 (0.56-1.20) 0.30 
3TC/d4T + NNRTI   0.81 (0.54-1.21) 0.30 
3TC/AZT + PI   0.50 (0.34-0.74) 0.0004 
3TC/AZT + Boosted-PI   0.76 (0.59-0.98) 0.03 
3TC/AZT + NNRTI   1.14 (0.87-1.50) 0.36 
TDF/FTC or TDF/3TC + Boosted-PI   0.77 (0.62-0.95) 0.02 
TDF/FTC or TDF/3TC + NNRTI   [Reference]  
Appendix C – Additional results for Chapter 2 
226 
Table 7. Adjusted hazard ratio (95% confidence intervals) of switching from second-line to third-line due to 
toxicity.   
 
Variables Model 1: Calendar time Model 2: Calendar time and 
regimen type 
 Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 1.64 (1.39-1.94) 0.17 0.58 (0.44-1.00) 0.20 
2001-2005 1.23 (1.09-1.39) 0.04 0.82 (0.67-1.02) 0.07 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 1.04 (1.01-1.07) <.0001 1.02 (0.99-1.06) 0.21 
Sex  0.001   
Male [Reference]  [Reference]  
Female 1.49 (1.23-1.79)  1.44 (1.15-1.82) 0.002 
Region of Origin     
Netherlands [Reference] 0.01 [Reference]  
European 0.92 (0.73-1.15)  0.87 (0.65-1.15) 0.31 
Sub-Saharan Africa 0.77 (0.63-0.95)  0.85 (0.67-1.09) 0.20 
Other 0.79 (0.67-0.94) <.0001 0.85 (0.69-1.04) 0.11 
Route of transmission     
Heterosexual 0.83 (0.70-0.99)  0.82 (0.67-1.02) 0.07 
MSM [Reference] 0.48 [Reference]  
Injecting Drug Use 0.73 (0.46-1.15) 0.01 0.59 (0.32-1.12) 0.11 
Other 0.86 (0.67-1.09) 0.007 0.97 (0.73-1.30) 0.85 
Clinical     
CD4 cell count at start of cART  0.04   
CD4 ≤200  1.48 (1.24-1.77)  1.25 (1.00-1.55) 0.05 
CD4 201-350  1.17 (0.99-1.39) 0.17 1.08 (0.87-1.33) 0.50 
CD4 351-500  [Reference] 0.20 [Reference]  
CD4 >500 1.15 (0.97-1.35)  1.19 (0.98-1.45) 0.08 
RNA at start of cART     
RNA ≤100 000 [Reference] <.0001 [Reference]  
RNA 100 000-1 000 000 1.07 (0.85-1.36) 0.07 1.08 (0.80-1.46) 0.62 
RNA >1 000 000  1.99 (1.15-3.45)  0.79 (0.25-2.48) 0.69 
cART Type     
3TC/d4T + PI   5.03 (3.39-7.48)* <.0001 
3TC/d4T + Boosted-PI   7.49 (5.45-10.28)* <.0001 
3TC/d4T + NNRTI   4.51 (3.25-6.24)* <.0001 
3TC/AZT + PI   2.78 (1.80-4.29)* <.0001 
3TC/AZT + Boosted-PI   3.60 (2.81-4.62)* <.0001 
3TC/AZT + NNRTI   1.74 (1.34-2.27)* <.0001 
TDF/FTC or TDF/3TC + Boosted-PI   1.79 (1.42-2.24)* <.0001 
TDF/FTC or TDF/3TC + NNRTI   [Reference]  
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Table 8. Adjusted hazard ratio (95% confidence intervals) of switching from third-line to fourth-line due to 
toxicity.   
 
Variables Model 1: Calendar time Model 2: Calendar time and 
regimen type 
 Hazard Ratio (95% 
CI) 
P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 1.90 (1.56-2.30) <.0001 1.06 (0.76-1.46) 0.74 
2001-2005 1.35 (1.17-1.56) <.0001 0.99 (0.78-1.25) 0.92 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 1.05 (1.01-1.08) 0.01 1.05 (1.01-1.09) 0.03 
Sex     
Male [Reference]  [Reference]  
Female 1.28 (1.04-1.58) 0.02 1.40 (1.08-1.81) 0.01 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 1.20 (0.94-1.54) 0.14 0.93 (0.67-1.28) 0.65 
Sub-Saharan Africa 0.79 (0.63-1.00) 0.05 0.74 (0.56-0.98) 0.04 
Other 0.90 (0.74-1.08) 0.26 0.87 (0.69-1.09) 0.22 
Route of transmission     
Heterosexual 0.96 (0.79-1.16) 0.67 0.89 (0.70-1.13) 0.34 
MSM [Reference]  [Reference]  
Injecting Drug Use 0.69 (0.44-1.09) 0.11 0.62 (0.35-1.11) 0.11 
Other 0.83 (0.63-1.09) 0.18 0.88 (0.64-1.22) 0.44 
Clinical     
CD4 cell count at start of cART     
CD4 ≤200  1.04 (1.04-1.28) 0.72 1.00 (0.77-1.29) 0.97 
CD4 201-350  1.07 (0.89-1.30) 0.46 1.05 (0.83-1.33) 0.67 
CD4 351-500  [Reference]  [Reference]  
CD4 >500 0.83 (0.69-1.00) 0.05 0.95 (0.75-1.20) 0.66 
RNA at start of cART     
RNA ≤100 000 [Reference]  [Reference]  
RNA 100 000-1 000 000 1.48 (1.19-1.83) 0.0004 1.33 (1.02-1.72) 0.03 
RNA >1 000 000  1.82 (1.00-3.34) 0.05 1.33 (0.62-2.85) 0.46 
cART Type     
3TC/d4T + PI   2.44 (1.44-4.14)* 0.0009 
3TC/d4T + Boosted-PI   4.60 (3.15-6.72)* <.0001 
3TC/d4T + NNRTI   3.27 (2.27-4.71)* <.0001 
3TC/AZT + PI   1.96 (1.27-3.02)* 0.002 
3TC/AZT + Boosted-PI   2.36 (1.76-3.17)* <.0001 
3TC/AZT + NNRTI   1.71 (1.27-2.30)* 0.0004 
TDF/FTC or TDF/3TC + Boosted-PI   2.00 (1.57-2.55)* <.0001 
TDF/FTC or TDF/3TC + NNRTI   [Reference]  
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Table 9 Adjusted hazard ratio (95% confidence intervals) of switching from second-line to third-line due to 
virological failure.   
 
Variables Model 1: Calendar time Model 2: Calendar time and 
regimen type 
 Hazard Ratio (95% 
CI) 
P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 2.17 (1.47-3.21) 0.0001 1.49 (0.71-3.13) 0.30 
2001-2005 1.57 (1.18-2.09) 0.002 1.36 (0.79-2.35 ) 0.27 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 0.91 (0.84-0.98) 0.008 0.87 (0.78-0.96) 0.006 
Sex     
Male [Reference]  [Reference]  
Female 0.97 (0.64-1.47) 0.87 0.89 (0.50-1.57) 0.69 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 0.98 (0.57-1.68) 0.93 0.42 (0.15-1.15) 0.09 
Sub-Saharan Africa 1.38 (0.90-2..11) 0.14 1.31 (0.75-2.30) 0.34 
Other 1.08 (0.75-1.56) 0.67 1.10 (0.68-1.78) 0.70 
Route of transmission     
Heterosexual 0.90 (0.62-1.33) 0.60 0.99 (0.59-1.63) 0.95 
MSM [Reference]  [Reference]  
Injecting Drug Use 0.61 (0.19-1.93) 0.40 0.95 (0.23-3.94) 0.94 
Other 0.84 (0.49-1.45) 0.53 1.26 (0.65-2.46) 0.50 
Clinical     
CD4 cell count at start of cART     
CD4 ≤200  1.69 (1.15-2.49) 0.008 1.61 (0.93-2.77) 0.09 
CD4 201-350  1.20 (0.82-1.76) 0.35 1.20 (0.70-2.06) 0.52 
CD4 351-500  [Reference]  [Reference]  
CD4 >500 0.68 (0.45-1.02) 0.06 0.97 (0.57-1.66) 0.92 
RNA at start of cART     
RNA ≤100 000 [Reference]  [Reference]  
RNA 100 000-1 000 000 1.54 (0.98-2.42) 0.06 1.54 (0.81-2.93) 0.18 
RNA >1 000 000  2.84 (0.90-8.94) 0.07 3.22 (0.76-13.54) 0.11 
cART Type     
3TC/d4T + PI   2.94 (1.13-7.61)* 0.03 
3TC/d4T + Boosted-PI   1.44 (0.45-4.54)* 0.54 
3TC/d4T + NNRTI   1.64 (0.66-4.07)* 0.29 
3TC/AZT + PI   2.69 (1.09-6.59)* 0.03 
3TC/AZT + Boosted-PI   2.42 (1.27-4.63)* 0.01 
3TC/AZT + NNRTI   1.42 (0.75-2.71)* 0.29 
TDF/FTC or TDF/3TC + Boosted-PI   1.59 (0.86-2.96)* 0.14 
TDF/FTC or TDF/3TC + NNRTI   [Reference]  
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Table 10 Adjusted hazard ratio (95% confidence intervals) of switching from third-line to fourth-line due to 
virological failure.   
 
Variables Model 1: Calendar time Model 2: Calendar time and 
regimen type 
 Hazard Ratio (95% 
CI) 
P-value Hazard Ratio (95% CI) P-value 
Calendar period     
1996-2000 1.57 (1.03-2.38) 0.04 1.03 (0.51-2.08) 0.95 
2001-2005 1.37 (1.04-1.81) 0.03 1.19 (0.73-1.92) 0.49 
2006-2010 [Reference]  [Reference]  
Demographic     
Age      
5-year increased from 18 years old 0.93 (0.87-1.00) 0.06 0.96 (0.88-1.06) 0.42 
Sex     
Male [Reference]  [Reference]  
Female 0.90 (0.61-1.34) 0.62 0.74 (0.45-1.23) 0.25 
Region of Origin     
Netherlands [Reference]  [Reference]  
European 1.01 (0.56-1.79) 0.99 1.03 (0.47-2.28) 0.94 
Sub-Saharan Africa 1.42 (0.94-2.16) 0.10 1.87 (1.10-3.19) 0.02 
Other 1.26 (0.89-1.79) 0.19 1.50 (0.95-2.38) 0.08 
Route of transmission     
Heterosexual 0.87 (0.59-1.28) 0.49 0.98 (0.60-1.59) 0.92 
MSM [Reference]  [Reference]  
Injecting Drug Use 0.78 (0.34-1.78) 0.55 0.68 (0.21-2.19) 0.52 
Other 1.05 (0.66-1.70) 0.83 0.90 (0.47-1.72) 0.74 
Clinical     
CD4 cell count at start of cART     
CD4 ≤200  1.81 (1.26-2.60) 0.001 1.62 (1.01-2.62) 0.05 
CD4 201-350  0.97 (0.66-1.42) 0.87 0.98 (0.60-1.58) 0.92 
CD4 351-500  [Reference]  [Reference]  
CD4 >500 0.39 (0.25-0.60) <.0001 0.42 (0.24-0.77) 0.004 
RNA at start of cART     
RNA ≤100 000 [Reference]  [Reference]  
RNA 100 000-1 000 000 1.46 (1.01-2.12) 0.04 1.76 (1.11-2.79) 0.02 
RNA >1 000 000  1.66 (0.61-4.57) 0.32 3.07 (1.07-8.78) 0.04 
cART Type     
3TC/d4T + PI   2.79 (1.10-7.10)* 0.03 
3TC/d4T + Boosted-PI   1.56 (0.63-3.89)* 0.34 
3TC/d4T + NNRTI   1.18 (0.50-2.77)* 0.71 
3TC/AZT + PI   3.26 (1.61-6.60)* 0.001 
3TC/AZT + Boosted-PI   1.10 (0.57-2.13)* 0.78 
3TC/AZT + NNRTI   1.56 (0.88-2.74)* 0.13 
TDF/FTC or TDF/3TC + Boosted-PI   0.90 (0.50-1.65)* 0.74 
TDF/FTC or TDF/3TC + NNRTI   [Reference]  
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Appendix D – Additional results of Chapter 4 for minimum and maximum 
incidence rate 
 
 
Figure 1A.  Future age distribution of HIV-patients in the Netherlands assuming minimum incidence rate.   
 
 
Figure 1 B.  Future age distribution of HIV-patients in the Netherlands assuming maximum incidence rate. 
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Figure 2A.  Projection of number of people per age category assuming minimum incidence rate. 
 
 
Figure 2B.  Projection of number of people per age category assuming maximum incidence rate.    
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Figure 3A. Changes in the number of cause-specific deaths between 2010 and 2030 amongst HIV-patients in 
clinical care in the Netherlands assuming minimum incidence rate.   
 
 
Figure 3B. Changes in the number of cause-specific deaths between 2010 and 2030 amongst HIV-patients in 
clinical care in the Netherlands assuming maximum incidence rate.   
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Figure 4A.  Stacked bar graph of the burden of co-morbidities in HIV-patients between 2010 and 2030 as 
projected by the model, assuming minimum incidence rate.   
 
 
Figure 4B.  Stacked bar graph of the future burden of co-morbidities in HIV-patients between 2010 and 2030 as 
projected by the model, assuming maximum incidence rate.   
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A.      B.  
C.     
Figure 5A. Diagrams representing the changes in the relative number of patients with specific co-morbidities 
types and overlap in co-morbidity types in A. 2010, B. 2020, and C. 2030 assuming minimum incidence rate.  The 
area is representative of the number of HIV-patients with co-morbidities.   
 
 
A.      B.  
C.  
Figure 5B. Diagrams representing the changes in the relative number of patients with specific co-morbidities types 
and overlap in co-morbidity types in A. 2010, B. 2020, and C. 2030 assuming maximum incidence rate.  The area 
is representative of the number of HIV-patients with co-morbidities.   
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Figure 6A. Stacked bar graph of the future burden of co-medication in HIV-patients between 2010 and 2030 as 
projected by the model assuming minimum incidence rate.   
 
 
Figure 6B. Stacked bar graph of the future burden of co- medication in HIV-patients between 2010 and 2030 as 
projected by the model assuming maximum incidence rate.   
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A.      B.  
C.      
Figure 7A.  Changes in prevalence of co-medication assuming minimum incidence rate between A. 2010, B. 2020, 
and C. 2030 as projected by the model.  Figure represents cross-sectional number of patients on the different types 
of co-medications based on a 1,000 patients, with the black area indicating patients on treatment and the white 
area indicating the patients not on treatment.   
 
A.      B.  
C.   
Figure 7B.  Changes in prevalence of co-medication assuming maximum incidence rate between A. 2010, B. 2020, 
and C. 2030 as projected by the model.  Figure represents cross-sectional number of patients on the different types 
of co-medications based on a 1,000 patients, with the black area indicating patients on treatment and the white 
area indicating the patients not on treatment.   
 
Appendix D – Additional results for Chapter 4 
237 
       
Figure 8A. Stacked bar graph of the number of HIV-patients with potential interactions between their co-
medication and NRTIs assuming minimum incidence rate.   
 
      
Figure 8B. Stacked bar graph of the number of HIV-patients with potential interactions between their co-
medication and NRTIs assuming maximum incidence rate. 
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Figure 9A. Stacked bar graph of the number of HIV-patients with potential interactions between their co-
medication and NNRTIs assuming minimum incidence rate.   
 
      
Figure 9B. Stacked bar graph of the number of HIV-patients with potential interactions between their co-
medication and NNRTIs assuming maximum incidence rate.   
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Figure 10A. Stacked bar graph of the number of HIV-patients with potential interactions between their co-
medication and PIs assuming minimum incidence rate.   
 
         
Figure 10B. Stacked bar graph of the number of HIV-patients with potential interactions between their co-
medication and PIs assuming maximum incidence rate. 
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Figure 11A. Stacked bar graph of the number of HIV-patients with potential interactions between their co-
medication and Entry, Fusion and Integrase inhibitor assuming minimum incidence rate.   
 
      
Figure 11B. Stacked bar graph of the number of HIV-patients with potential interactions between their co-
medication and Entry, Fusion and Integrase assuming maximum incidence rate.    
Appendix D – Additional results for Chapter 4 
241 
 
A.      B.  
C.  
Figure 12A.  Impact of increasing prevalence of polypharmacy on drug-drug interactions with recommended 
cART regimens assuming minimum incidence rate in A. 2010, B. 2020, and C. 2030.  Recommended regimens are 
a backbone of TDF/FTC or ABC/3TC combined with either EFV, nevirapine, raltegravir or ritonavir-boosted 
atzanavir, darunavir or lopinavir as listed by the current Europe AIDS Clinical Guidelines.   
 
A.      B.  
C.  
Figure 12B.  Impact of increasing prevalence of polypharmacy on drug-drug interactions with recommended 
cART regimens assuming maximum incidence rate in A. 2010, B. 2020, and C. 2030.  Recommended regimens are 
a backbone of TDF/FTC or ABC/3TC combined with either EFV, nevirapine, raltegravir or ritonavir-boosted 
atzanavir, darunavir or lopinavir as listed by the current Europe AIDS Clinical Guidelines.   
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Glossary 
 
Acquired Immunodeficiency Syndrome (AIDS): The advanced stage of the illness caused by the 
infection with the human immunodeficiency virus (HIV).  The U.S. Centres for Disease Control 
defines AIDS as occurring in HIV-infected individuals with a CD4 count below 200 cells/mm
3 
or 
those with certain HIV-related conditions and symptoms.   
 
Antiretroviral drugs (ARVs): ARVs are drugs used to treat HIV-infection.  ARVs work by stopping 
or suppressing the reproduction or activity of HIV.   
 
AIDS Therapy Evaluation in the Netherlands (ATHENA): This large study was established in 
1997 with the aim of evaluating AIDS therapy in the Netherlands. In 2001, ATHENA was converted 
into a permanent facility, the Stichting HIV Monitoring (SHM), the Dutch HIV monitoring 
foundation.  The SHM was officially appointed by the Dutch Minister of Health, Welfare and Sports 
in 2002 as the national executive foundation for the monitoring of HIV-infected adults in follow-up in 
all the 26 HIV treatment centres in the Netherlands and HIV-infected children and adolescents in four 
institutes that are recognized paediatric HIV treatment centres.  The mission of all the centres is to 
further contribute to the knowledge and understanding of the epidemiology, course of infection and 
clinical outcome of HIV-infected patients.   
 
 
Combination antiretroviral therapy (cART): The combination of three of more ARVs from at least 
two different drug classes for the treatment of HIV.  Combination therapy was first introduced in 
1996 and has had a major effect on mortality in HIV-infected patients.   
 
CD4: A glycoprotein found on the surface of human immune cells called T-lymphocytes.  HIV uses 
CD4 to enter the human host immune cell.   
 
CD4 count: Commonly used surrogate marker for measuring the state of an HIV-infected patients’ 
immune system.  The normal range for CD4 counts is 800 to 1,500 cells/mm
3
.  The CD4 count is 
decreased by HIV and low CD4 counts can result in opportunistic infections.  Another important 
marker for assessing HIV-infection is viral load (see Viral load).   
 
Confidence intervals (CIs): In statistics, CIs are used to give an estimated range of values that are so 
defined that there is a 95% probability that the true value is included in the range.   
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D:A:D Study Group: The Data collection on Adverse events of anti-HIV Drugs (D:A:D) Study is a 
prospective multi-cohort study that focuses on the study of adverse events and long-term toxicity of 
cART.   
 
DALYs: Disability adjusted life years refers to the sum of years lost due to premature death or of 
productive years lost due to disability.  DALYs take a value between 0 and 1, where 0 refers to perfect 
health and 1 to death.   
 
Diabetes mellitus: a disorder of the metabolism resulting in a high amount of glucose levels in the 
blood.  In this thesis, diabetes mellitus is referred to as diabetes. Diabetes was defined according to 
the criteria established by the European AIDS Clinical Society 2011 guidelines.   
 
Drug classes: ARV drugs are classified into various classes according to their mode of action.  The 
three main categories are NRTIs, NNRTIs, and PIs.  In recent years there have been newer classes, 
including Fusion inhibitors, Entry inhibitors, and HIV integrase strand transfer inhibitors.   
 
Entry Inhibitors: This group of ARVs is used in combination therapy for the treatment of HIV-
patients.  Entry inhibitors work by preventing the binding of the virion to the host cell receptor.   
 
Fusion inhibitors: This group of ARVs is used in combination therapy for the treatment of HIV-
patients.  Fusion inhibitors work by preventing the conformational change in the receptor thus 
stopping the virion from entering the host cell.   
 
GDP: Gross Domestic Product is an economic value of all finished goods and services produced 
within a country per year.   
 
Hepatitis: refers to a disease characterized by inflammation of the liver.  Hepatitis B and C are 
caused by infection with the hepatitis B and C virus, respectively.  In this thesis, hepatitis B and C 
were defined according to the criteria established by the European AIDS Clinical Society 2011 
guidelines.   
 
Hepatotoxicity: Toxicity of the liver.   
 
Human Immunodeficiency virus (HIV): Is a retrovirus that causes the progressive failure of the 
immune system, leading to life-threatening opportunistic infections and cancers.   
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Injecting Drug Users (IDU): Person who injects drugs or PWID which is generally the preferred 
term.   
 
Integrase inhibitors: This group of ARVs is used in combination therapy for the treatment of HIV-
patients.  This class works by interfering with the catalytic activity of HIV-1 integrase, inhibiting  the 
integrase enzyme, preventing the integration of the linear viral DNA into the host cell genome, and 
thus preventing the formation of the provirus and propagation of viral infection.    
 
Lactic Acidosis: refers to a physiological condition that is characterized by a low pH in the blood and 
body tissues and a build-up of lactate.  This is an adverse effect of certain ARVs.   
 
Lipoatrophy: localized loss of fat tissue 
 
Men who have sex with men (MSM): Used to describe ‘males who have sex with males’, regardless 
of whether or not they have sex with women or their personal or social identity is gay or bisexual.   
 
Myocardial infarction: heart attack.  Myocardial infarction was defined according to the criteria 
established by the European AIDS Clinical Society 2011 guidelines.   
 
Non-AIDS-defining malignancy: is the terminology given to malignancies that are not related to the 
AIDS-stage of HIV-infection, where malignancy refers to presence of a malignant (with a tendency to 
invade normal tissue or to recur after removal) tumour/cancer.  AIDS-defining malignancies include 
Kaposi’s sarcoma, Burkitt’s lymphoma, and lymphoma.  In this thesis non-AIDS-defining malignancy 
is referred to as malignancy, and excluded precancerous stages of anal or cervical cancer, basal-cell 
carcinoma, and squamous-cell carcinoma of the skin.  In this thesis non-AIDS-defining malignancies 
were defined according to the criteria established by the European AIDS Clinical Society 2011 
guidelines.   
 
Non-Nucleoside reverse transcriptase inhibitor (NNRTI): This group of ARVs is used in 
combination therapy for the treatment of HIV-patients.  NNRTI drugs work by binding directly to the 
active site of reverse transcriptase, thus blocking the DNA polymerase active site.  This binding 
causes a disruption of the enzyme's catalytic site, resulting in the termination of DNA chain 
elongation.   
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Nucleoside reverse transcriptase inhibitor (NRTI): This group of ARVs is used in combination 
therapy for the treatment of HIV-patients, and currently serves as the backbone of the treatment.  This 
group of ARV drugs works by competitively interrupting the conversion of HIV RNA to DNA by 
incorporation into the viral DNA and causing termination of DNA chain growth.   
 
Osteoporosis: a medical condition in which bones become brittle and fragile from loss of tissue.  
Commonly, it is the result of hormonal changes or deficiency in calcium or vitamin D.   
 
Pharmacodynamics: is the relationship between the drug concentration at the site of action and the 
resulting effect, including both therapeutic effects and side effects.   
 
Pharmacokinetics: is defined as the time course from absorption to metabolism and excretion of a 
drug.   
 
Polypharmacy: Note, there are several definitions of polypharmacy, including; 1) the use of six or 
more medications, and 2) the use of potentially inappropriate drugs for which the medication does not 
match the diagnosis.  However, in the context of this thesis, polypharmacy refers to the use of two or 
more medications.   
 
Protease inhibitor (PI): This group of ARVs used in combination therapy for the treatment of HIV-
patients.  PIs work by selectively binding the catalytic site of virus-specific protease enzymes, 
preventing the cleavage of the viral poly-protein and formation of a mature viral particle.   
 
Renal insufficiency: or chronic kidney disease was defined as an estimated glomerular filtration rate 
(eGFR) (referring to the flow rate of liquid through the kidney) below 60 ml/min using the Cockcroft-
Gault equation, confirmed after 3 months or longer.  In this thesis renal insufficiency was defined 
according to the criteria established by the European AIDS Clinical Society 2011 guidelines.   
 
SMART Study: The Strategies for Management on Anti-Retroviral Therapy (SMART) study was a 
community programme evaluating the impact of intermittent treatment interruption on rate of 
progression and toxicity.   
 
Stichting HIV Monitoring (SHM): see AIDS Therapy Evaluation in the Netherlands.   
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Stroke: refers to a medical emergency caused by a disturbance in the blood supply to the brain, which 
can result in the inability to move one or more limbs on one side of the body, understand or formulate 
speech, or to see one side of the visual field.  In this thesis, stroke was defined according to the criteria 
established by the European AIDS Clinical Society 2011 guidelines.   
 
STIVORO: was a Dutch organisation that was established in 1974 and dismantled on 31
st
 December 
2013 by the Dutch Health Ministry.  It was a world-renowned tobacco control centre in the 
Netherlands.  The name originally stood as an abbreviation for ‘Smoking and Health Foundation’ and 
later for ‘Smoke-Free Future’.   
 
Toxicity: Refers to the side effects of ARV drugs.  These can range in severity, and can lead to the 
need to switch a patient’s regimen 
 
Viral load: The number of virions in a sample of blood plasma.  It is used as an indicator for disease 
progression in HIV-infected patients, as a proxy of the burden of infection in patients.   
 
Virological failure: In the ATHENA cohort virological failure is defined as having two subsequent 
viral load tests above detectable level after initial viral load suppression.  It is used as an indicator that 
treatment of HIV-infection with CART is failing.   
 
